<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antibiotics for the treatment of COVID‐19 - Popp, M - 2021 | Cochrane Library</title> <meta content="Antibiotics for the treatment of COVID‐19 - Popp, M - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antibiotics for the treatment of COVID‐19 - Popp, M - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015025" name="dc.identifier" scheme="DOI"/> <meta content="Antibiotics for the treatment of COVID‐19" name="citation_title"/> <meta content="Maria Popp" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="Miriam Stegemann" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Manuel Riemer" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="Maria-Inti Metzendorf" name="citation_author"/> <meta content="Institute of General Practice, Medical Faculty of the Heinrich-Heine-University Düsseldorf" name="citation_author_institution"/> <meta content="Carolina S Romero" name="citation_author"/> <meta content="General University Hospital Valencia" name="citation_author_institution"/> <meta content="Agata Mikolajewska" name="citation_author"/> <meta content="Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin" name="citation_author_institution"/> <meta content="Peter Kranke" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="Patrick Meybohm" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="Nicole Skoetz" name="citation_author"/> <meta content="Faculty of Medicine and University Hospital Cologne, University of Cologne" name="citation_author_institution"/> <meta content="Stephanie Weibel" name="citation_author"/> <meta content="University Hospital Wuerzburg" name="citation_author_institution"/> <meta content="weibel_s@ukw.de" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD015025" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015025/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [adverse effects]; Cause of Death; *COVID-19; Respiration, Artificial; SARS-CoV-2" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015025&amp;doi=10.1002/14651858.CD015025&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="0TJL4CWK";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015025\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015025\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","ru","pt","ms","hr","fr","zh_HANS","zh_HANT","th","ja","fa","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD015025",title:"Antibiotics for the treatment of COVID\\u201019",firstPublishedDate:"Oct 22, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Haematology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015025&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015025';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015025/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015025/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015025%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015025/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015025/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015025/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015025/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015025" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;riskOfBias2&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Risk of bias&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Risk of Bias&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015025/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015025" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015025/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015025/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>69114 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015025" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015025/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/appendices#CD015025-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2"> Risk of bias </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/supinfo/CD015025StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/supinfo/CD015025StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015025/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015025/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015025/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015025/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD015025/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antibiotics for the treatment of COVID‐19</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0004">Maria Popp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0005">Miriam Stegemann</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0006">Manuel Riemer</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0007">Maria-Inti Metzendorf</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0008">Carolina S Romero</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0009">Agata Mikolajewska</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0010">Peter Kranke</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0011">Patrick Meybohm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0012">Nicole Skoetz</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015025/information#CD015025-cr-0013"><i class="icon corresponding-author fa fa-envelope"></i>Stephanie Weibel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015025/information/en#CD015025-sec-0122">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015025/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015025">https://doi.org/10.1002/14651858.CD015025</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015025-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015025-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015025-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015025-abs-0019">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015025-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015025-abs-0005">Português</a> </li> <li class="section-language"> <a class="" href="full/th#CD015025-abs-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015025-abs-0013">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015025-abs-0001" lang="en"> <section id="CD015025-sec-0001"> <h3 class="title" id="CD015025-sec-0001">Background</h3> <p>The effect of antibiotics with potential antiviral and anti‐inflammatory properties are being investigated in clinical trials as treatment for COVID‐19. The use of antibiotics follows the intention‐to‐treat the viral disease and not primarily to treat bacterial co‐infections of individuals with COVID‐19. A thorough understanding of the current evidence regarding effectiveness and safety of antibiotics as anti‐viral treatments for COVID‐19 based on randomised controlled trials (RCTs) is required. </p> </section> <section id="CD015025-sec-0002"> <h3 class="title" id="CD015025-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of antibiotics compared to each other, no treatment, standard of care alone, placebo, or any other active intervention with proven efficacy for treatment of COVID‐19 outpatients and inpatients.  </p> </section> <section id="CD015025-sec-0003"> <h3 class="title" id="CD015025-sec-0003">Search methods</h3> <p>We searched the Cochrane COVID‐19 Study Register (including MEDLINE, Embase, ClinicalTrials.gov, WHO ICTRP, medRxiv, CENTRAL), Web of Science and WHO COVID‐19 Global literature on coronavirus disease to identify completed and ongoing studies to 14 June 2021. </p> </section> <section id="CD015025-sec-0004"> <h3 class="title" id="CD015025-sec-0004">Selection criteria</h3> <p>RCTs were included that compared antibiotics with each other, no treatment, standard of care alone, placebo, or another proven intervention, for treatment of people with confirmed COVID‐19, irrespective of disease severity, treated in the in‐ or outpatient settings. </p> <p>Co‐interventions had to be the same in both study arms. We excluded studies comparing antibiotics to other pharmacological interventions with unproven efficacy. </p> </section> <section id="CD015025-sec-0005"> <h3 class="title" id="CD015025-sec-0005">Data collection and analysis</h3> <p>We assessed risk of bias of primary outcomes using the Cochrane risk of bias tool (ROB 2) for RCTs. We used GRADE to rate the certainty of evidence for the following primary outcomes: 1. to treat inpatients with moderate to severe COVID‐19: mortality, clinical worsening defined as new need for intubation or death, clinical improvement defined as being discharged alive, quality of life, adverse and serious adverse events, and cardiac arrhythmias; 2. to treat outpatients with asymptomatic or mild COVID‐19: mortality, clinical worsening defined as hospital admission or death, clinical improvement defined as symptom resolution, quality of life, adverse and serious adverse events, and cardiac arrhythmias. </p> </section> <section id="CD015025-sec-0006"> <h3 class="title" id="CD015025-sec-0006">Main results</h3> <p>We included 11 studies with 11,281 participants with an average age of 54 years investigating antibiotics compared to placebo, standard of care alone or another antibiotic. No study was found comparing antibiotics to an intervention with proven efficacy. All studies investigated azithromycin, two studies investigated other antibiotics compared to azithromycin. Seven studies investigated inpatients with moderate to severe COVID‐19 and four investigated mild COVID‐19 cases in outpatient settings. Eight studies had an open‐label design, two were blinded with a placebo control, and one did not report on blinding. We identified 19 ongoing and 15 studies awaiting classification pending publication of results or clarification of inconsistencies. </p> <p>Of the 30 study results contributing to primary outcomes by included studies, 17 were assessed as overall low risk and 13 as some concerns of bias. Only studies investigating azithromycin reported data eligible for the prioritised primary outcomes. Azithromycin doses and treatment duration varied among included studies.  </p> <p><b>Azithromycin for the treatment of COVID‐19 compared to placebo or standard of care alone in inpatients</b> </p> <p>We are very certain that azithromycin has little or no effect on all‐cause mortality at day 28 compared to standard of care alone (risk ratio (RR) 0.98; 95% confidence interval (CI) 0.90 to 1.06; 8600 participants; 4 studies; high‐certainty evidence). Azithromycin probably has little or no effect on clinical worsening or death at day 28 (RR 0.95; 95% CI 0.87 to 1.03; 7311 participants; 1 study; moderate‐certainty evidence), on clinical improvement at day 28 (RR 0.96; 95% CI 0.84 to 1.11; 8172 participants; 3 studies; moderate‐certainty evidence), on serious adverse events during the study period (RR 1.11; 95% CI 0.89 to 1.40; 794 participants; 4 studies; moderate‐certainty evidence), and cardiac arrhythmias during the study period (RR 0.92; 95% CI 0.73 to 1.15; 7865 participants; 4 studies; moderate‐certainty evidence) compared to placebo or standard of care alone. Azithromycin may increase any adverse events slightly during the study period (RR 1.20; 95% CI 0.92 to 1.57; 355 participants; 3 studies; low‐certainty evidence) compared to standard of care alone. No study reported quality of life up to 28 days. </p> <p><b>Azithromycin for the treatment of COVID‐19 compared to placebo or standard of care alone in outpatients</b> </p> <p>Azithromycin may have little or no effect compared to placebo or standard of care alone on all‐cause mortality at day 28 (RR 1.00 ; 95% CI 0.06 to 15.69; 876 participants; 3 studies; low‐certainty evidence), on admission to hospital or death within 28 days (RR 0.94 ; 95% CI 0.57 to 1.56; 876 participants; 3 studies; low‐certainty evidence), and on symptom resolution at day 14 (RR 1.03; 95% CI 0.95 to 1.12; 138 participants; 1 study; low‐certainty evidence). We are uncertain whether azithromycin increases or reduces serious adverse events compared to placebo or standard of care alone (0 participants experienced serious adverse events; 454 participants; 2 studies; very low‐certainty evidence). No study reported on adverse events, cardiac arrhythmias during the study period or quality of life up to 28 days. </p> <p><b>Azithromycin for the treatment of COVID‐19 compared to any other antibiotics in inpatients and outpatients</b> </p> <p>One study compared azithromycin to lincomycin in inpatients, but did not report any primary outcome. </p> <p>Another study compared azithromycin to clarithromycin in outpatients, but did not report any relevant outcome for this review. </p> </section> <section id="CD015025-sec-0007"> <h3 class="title" id="CD015025-sec-0007">Authors' conclusions</h3> <p>We are certain that risk of death in hospitalised COVID‐19 patients is not reduced by treatment with azithromycin after 28 days. Further, based on moderate‐certainty evidence, patients in the inpatient setting with moderate and severe disease probably do not benefit from azithromycin used as potential antiviral and anti‐inflammatory treatment for COVID‐19 regarding clinical worsening or improvement. For the outpatient setting, there is currently low‐certainty evidence that azithromycin may have no beneficial effect for COVID‐19 individuals. There is no evidence from RCTs available for other antibiotics as antiviral and anti‐inflammatory treatment of COVID‐19. </p> <p>With accordance to the living approach of this review, we will continually update our search and include eligible trials to fill this evidence gap. However, in relation to the evidence for azithromycin and in the context of antimicrobial resistance, antibiotics should not be used for treatment of COVID‐19 outside well‐designed RCTs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015025-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015025-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD015025-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD015025-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015025-abs-0020">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015025-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD015025-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD015025-abs-0018">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015025-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD015025-abs-0021">Polski</a> </li> <li class="section-language"> <a class="" href="full/pt#CD015025-abs-0006">Português</a> </li> <li class="section-language"> <a class="" href="full/ru#CD015025-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD015025-abs-0017">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015025-abs-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015025-abs-0015">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015025-abs-0002" lang="en"> <h3>Are antibiotics an effective treatment for COVID‐19 and do they cause unwanted effects?</h3> <p><b>Key messages</b> </p> <p>• The antibiotic azithromycin is not an effective treatment for COVID‐19.</p> <p>• We don’t know whether antibiotics other than azithromycin are effective treatments for COVID‐19 because there is not enough research. </p> <p>• We found 19 ongoing studies that are investigating antibiotics for COVID‐19. We will update this review if their results change our conclusions. </p> <p><b>What are antibiotics?</b> </p> <p>Antibiotics are cheap and common medicines used to treat bacterial infections. However, recent laboratory studies found that some antibiotics slowed the reproduction of some viruses, including SARS‐CoV‐2, the virus that causes COVID‐19. In laboratory tests, one antibiotic, azithromycin, reduced viral activity and inflammation, and so it has been studied as a potential treatment for COVID‐19. We need good evidence before giving antibiotics for COVID‐19 because overuse or misuse of antibiotics can lead to ‘antimicrobial resistance’, where organisms that cause infection change, so that antibiotics stop working.  </p> <p><b>What did we want to find out?</b> </p> <p>We wanted to know if antibiotics reduce death, severity of disease, and length of infection in people with COVID‐19, if they have an effect on quality of life or cause unwanted effects. We included studies that compared antibiotics to placebo (dummy treatment), no treatment, usual care, another antibiotic, or treatments for COVID‐19 that are known to work to some extent, such as remdesivir or dexamethasone. We excluded treatments that we know do not work for COVID‐19, such as hydroxychloroquine, or have an unknown influence on the disease. </p> <p>We evaluated the effects of antibiotics on people with COVID‐19 on:<br/>• people dying;<br/>• whether people's COVID‐19 symptoms got better or worse;<br/>• unwanted effects;<br/>• heart rhythm problems;<br/>• quality of life.  </p> <p><b>What did we do?</b> </p> <p>We searched for studies that investigated antibiotics to treat people with COVID‐19 in hospital or as outpatients. </p> <p>We compared and summarised the results of the studies and rated our confidence in the evidence, based on common criteria such as study methods and sizes. </p> <p><b>What did we find?</b> </p> <p>We found 11 studies with 11,281 people that investigated antibiotics to treat COVID‐19. All 11 studies investigated azithromycin. Nine studies (10,807 people) compared azithromycin to no treatment, placebo or usual care alone. Two studies compared azithromycin to another antibiotic: lincomycin (1 study, 24 people) and clarithromycin (1 study, 450 people), however, they did not report data that we could use in this review, so our results apply to azithromycin only. </p> <p>Seven studies included people with moderate to severe COVID‐19 in hospital and four studies included outpatients with mild COVID‐19. The studies used different doses of azithromycin and different durations of treatment. </p> <p>We found 19 ongoing studies. We have not classified 15 completed studies because we are waiting for more information from the authors, or they have not yet been published.  </p> <p><b>Main results</b> </p> <p><b>Inpatients with moderate to severe COVID‐19</b> </p> <p>Azithromycin compared to usual care alone, does not lead to more or fewer deaths in the 28 days after treatment (4 studies, 8600 people). </p> <p>Compared to usual care alone or placebo, azithromycin probably does not:<br/>• worsen (1 study, 7311 people) or <br/>• improve patients’ condition (3 studies, 8172 people);<br/>• increase or decrease serious unwanted events (4 studies, 794 people), and heart rhythm problems (4 studies, 7865 people). </p> <p>Azithromycin may increase non‐serious unwanted effects slightly compared to usual care alone (3 studies, 355 people). </p> <p>No studies looked at quality of life.</p> <p><b>Outpatients with mild COVID‐19</b> </p> <p>Compared to usual care alone or placebo azithromycin may make little or no difference to: <br/>• people dying in the 28 days after treatment (3 studies, 876 people); </p> <p>• whether the people's disease worsened in the 28 days after treatment (3 studies, 876 people) or<br/>• whether people's COVID‐19 symptoms got better in the 14 days after treatment (1 study, 138 people). </p> <p>We don't know whether azithromycin compared to usual care alone or placebo increases or decreases serious unwanted effects (2 studies, 454 participants).  </p> <p>No studies reported non‐serious unwanted events, heart rhythm problems, or quality of life. </p> <p><b>What are the limitations of the evidence?</b> </p> <p>We are very confident in the evidence on azithromycin for COVID‐19 inpatients. However, we are less confident in the evidence on azithromycin in outpatients, mainly because there were few studies that also had some flaws, therefore we could not draw reliable conclusions. We found relevant evidence on only one antibiotic, azithromycin, so we do not know the effects of other antibiotics for treating COVID‐19. We will continue to search for new studies to fill this evidence gap. Our evidence does not suggest azithromycin is an effective treatment for COVID‐19, especially given the danger of antimicrobial resistance. Azithromycin or any other antibiotic should not be used to treat COVID‐19 outside well‐designed studies. </p> <p><b>How up to date is this evidence?</b> </p> <p>The evidence is up to date to 14 June 2021. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015025-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015025-sec-0112"></div> <h3 class="title" id="CD015025-sec-0113">Implications for practice</h3> <section id="CD015025-sec-0113"> <p>Based on the current moderate‐ to high‐certainty evidence, we are certain that patients in the inpatient setting with moderate and severe disease do not benefit from azithromycin used as antiviral or anti‐inflammatory treatment for COVID‐19. For the outpatient setting, there is currently low‐certainty evidence that azithromycin has no beneficial effect for COVID‐19 individuals. However, results from inpatients studies may be to some extent transferable to the outpatient setting as inpatient COVID‐19 participants had only minor need for respiratory support, and thus the study populations were fairly similar. </p> <p>As the emergence and spread of antimicrobial resistance has been considered as a global threat already before the pandemic, and the ongoing COVID‐19 pandemic may further contribute, a prudent use of antibiotics is of utmost importance. Macrolide use during the pandemic is being discussed as a relevant contributor to the spread of antimicrobial resistance (<a href="./references#CD015025-bbs2-0178" title="World Health Organization. Antimicrobial resistance. who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed 7 July 2021).">WHO 2020d</a>). In this context, the currently reliable evidence does not support the use of azithromycin for COVID‐19 treatment outside well‐designed randomized trials.  </p> <p>There is no evidence available from the study pool supporting or opposing the use of other antibiotics for treatment of COVID‐19. With accordance to the living approach of this review, we will continually update our search and include eligible trials to fill this evidence gap. However, in relation to the evidence for azithromycin and in the context of antimicrobial resistance, other antibiotics should also not be used for treatment of COVID‐19 outside well‐designed randomized trials. </p> <p>Given this review's focus, we cannot draw any conclusions on the use of antibiotics as prophylaxis or preemptive therapy of co‐bacterial infections in patients also infected with SARS‐CoV‐2. </p> </section> <h3 class="title" id="CD015025-sec-0114">Implications for research</h3> <section id="CD015025-sec-0114"> <p>For azithromycin, we do not expect further studies on its efficacy and safety against SARS‐CoV‐2 to change the conclusion of this review since the certainty of the evidence for futility regarding mortality, the most significant outcome during this pandemic, is already high. </p> <p>However, if researchers plan future trials with outpatients for whom the current certainty of evidence is very low to low, we would suggest considering a more differentiated approach investigating azithromycin administered to patients only very early after symptom onset. Any potential antiviral and anti‐inflammatory effect could have a greater influence on the disease at that early stage of viral replication. </p> <p>There is still a lack of evidence regarding the efficacy and safety of other antibiotics than azithromycin used for antiviral and anti‐inflammatory treatment in people with COVID‐19 in the in‐ and outpatient setting. To support the use of suggested substances such as doxycycline or clarithromycin outside clinical studies, high‐quality RCTs preferably with a double‐blinded, placebo‐controlled design and sufficient power are required.  </p> <p>Our review question did not focus on antibiotic prophylaxis or preemptive therapy of bacterial infections in patients also infected with SARS‐CoV‐2. However, this is an evidence gap that needs to be addressed in the light of the global emergence of antimicrobial resistance as a major public health and development threat. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015025-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015025-sec-0008"></div> <div class="table" id="CD015025-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with moderate to severe disease (WHO scale 4 to 9)  </p> <p><b>Setting:</b> inpatient  </p> <p><b>Intervention:</b> azithromycin<b> </b> </p> <p><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo or standard of care<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>223 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>219 per 1000 </b> </p> <p>(201 to 236)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.90 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8600</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin has little or no effect on all‐cause mortality at day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>261 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b> 248 per 1000</b> </p> <p>(227 to 269)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> (0.87 to 1.03) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7311 </p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on worsening of clinical status or death at day 28 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement of clinical status: participants discharged alive at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>672 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>645 per 1000 </b> </p> <p>(564 to 746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b> </p> <p>(0.84 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8172</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on improvement of clinical status at day 28 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at longest follow‐up available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>214 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>238 per 1000 </b> </p> <p>(190 to 300)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.11</b> </p> <p>(0.89 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>794</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on serious adverse events during the study period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b> </p> <p>(306 to 523)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.20</b> </p> <p>(0.92 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>e</sup><br/><i> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may increase any adverse events slightly during the study period</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrhythmias during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b> 41 per 1000 </b> </p> <p>(33 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7865</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on cardiac arrhythmias during the study period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No change of result in sensitivity analysis (RR 1.04; 95% CI 0.82 to 1.31; 837 participants; 3 studies) excluding studies with mixed populations (negative or unknown RT‐PCR). Therefore, no downgrading of evidence for indirectness.<br/><sup>b</sup>Downgrade by one level for serious indirectness due to the effect estimate based on only one study with a mixed population (8.5% participants with negative or unknown RT‐PCR).<br/><sup>c</sup>Downgrade by one level for serious heterogeneity (I<sup>2</sup> = 49%). No change of result in sensitivity analysis (RR 0.89; 95% CI 0.65 to 1.21; 402 participants; 2 studies) excluding studies with mixed populations (negative or unknown RT‐PCR). Therefore, no downgrading of evidence for indirectness.<br/><sup>d</sup>Downgrade by one level for serious risk of bias due to an as‐treated analysis in the study with the highest weight (97.0%). The certainty of evidence was not downgraded due to indirectness, even if the imprecision of the effect estimate had increased in the sensitivity analysis excluding the study with a mixed population (RR 0.98; 95% CI 0.26 to 3.60; 355 participants; 3 studies), as the same study was already the reason for downgrading due to risk of bias.<br/><sup>e</sup>Downgrade by one level for serious risk of bias due to non‐blinded outcome assessment in the study with the highest weight (87.7%), and one level for serious imprecision due to few small studies.<br/><sup>f</sup>Downgrade by one level for serious indirectness due to the effect estimate based mainly (weight 99.1%) on two studies with mixed populations (8.5% and 11% participants with negative or unknown RT‐PCR). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD015025-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild disease (WHO scale 1 to 3)  </p> <p><b>Setting:</b> outpatient  </p> <p><b>Intervention:</b> azithromycin<b> </b> </p> <p><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo or standard of care<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 1000 </b> </p> <p>(0 to 31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b> </p> <p>(0.06 to 15.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on all‐cause mortality at day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> <p>(38 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b> </p> <p>(0.57 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on admission to hospital or death within 28 days </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All initial symptoms resolved (asymptomatic) at day 14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>927 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>955 per 1000 </b> </p> <p>(881 to 1038)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.03</b> </p> <p>(0.95 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 138</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on symptom resolution (all initial symptoms resolved) at day 14 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at duration to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at longest follow‐up available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at any adverse events during the study period.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Two studies assessed serious adverse events during the study period, but none of the participants in either group were affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖</p> <p>Very low<sup>d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether azithromycin increases or reduces serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrhythmias during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at cardiac arrhythmias during the study period</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in that study contributing events to the analysis; and by one level for serious imprecision due to a wide confidence interval and few events.<br/><sup>b</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in one study and lack of registering the outcome in another study; and by one level for serious imprecision due to a wide confidence interval.<br/><sup>c</sup>Downgrade by two levels for very serious imprecision due to the effect estimate based on one small study.<br/><sup>d</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in one study and lack of registering the outcome in the other study; and by two levels for very serious imprecision due to zero events in both studies. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015025-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015025-sec-0009"></div> <p>This work is part of a series of Cochrane Reviews investigating treatments and therapies for coronavirus disease 2019 (COVID‐19). Reviews of this series share information in the background section and methodology based on the first published reviews about monoclonal antibodies (Kreuzberger 2021b), convalescent plasma (<a href="./references#CD015025-bbs2-0115" title="ChaiKL , ValkSJ , PiechottaV , KimberC , MonsefI , DoreeC , et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013600. [DOI: 10.1002/14651858.CD013600.pub3]">Chai 2020</a>), and ivermectin (<a href="./references#CD015025-bbs2-0154" title="PoppM , StegemannM , Metzendorf M-I, GouldS , KrankeP , Meybohm P et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021</a>) from the German research project “CEOsys” (COVID‐19 Evidence‐Ecosystem). </p> <section id="CD015025-sec-0010"> <h3 class="title" id="CD015025-sec-0010">Description of the condition</h3> <p>COVID‐19 is a rapidly spreading infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2; <a href="./references#CD015025-bbs2-0175" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 2 July 2021).">WHO 2020a</a>). On March 22, 2020 the World Health Organization (WHO) declared the current COVID‐19 outbreak a pandemic. Severity of this disease can be classified according to a standardised scale established by the WHO which is also used throughout this review (<a href="./references#CD015025-bbs2-0143" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>). COVID‐19 is unprecedented in comparison to previous coronavirus outbreaks, such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), with 813 and 858 deaths, respectively (<a href="./references#CD015025-bbs2-0172" title="World Health Organization. Cumulative number of reported probable cases of SARS. www.who.int/csr/sars/country/2003_07_11/en (accessed 22 March 2021).">WHO 2003</a>; <a href="./references#CD015025-bbs2-0173" title="World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). www.who.int/emergencies/mers-cov/en (accessed 22 March 2021).">WHO 2019a</a>). Despite intensive international efforts to contain its spread, as of July 2021, COVID‐19 has resulted in more than 180 million confirmed cases and over 3.9 million deaths worldwide (<a href="./references#CD015025-bbs2-0179" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 2 July 2021).">WHO 2021a</a>). In the same time, the emergence of variants of SARS‐CoV‐2, with potential for altered transmission or disease characteristics and vaccine and therapeutics effectiveness could impact established and proven disease control methods (<a href="./references#CD015025-bbs2-0180" title="World Health Organization Available from. SARS-CoV-2 Variants. https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/ (accessed 5 April 2021).">WHO 2021b</a>). </p> <p>Vaccination has been shown to be highly effective at reducing severe illness and death from COVID‐19. More than 2.95 billion doses of COVID‐19 vaccines have been administered at the global level, as of July 2021 (<a href="./references#CD015025-bbs2-0179" title="World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. covid19.who.int (accessed 2 July 2021).">WHO 2021a</a>). Additional vaccine candidates are in development (<a href="./references#CD015025-bbs2-0177" title="World Health Organization. Draft landscape of COVID-19 candidate vaccines. www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (accessed 22 March 2021).">WHO 2020c</a>). However, the majority of vaccines have been administered ina  few high‐income countries. The majority of the world's population still remains susceptible to SARS‐CoV‐2 infection and is at risk of developing COVID‐19. Moreover, the duration and degree of protection against the disease, but also against infection and transmission is still not well‐defined, and vaccine hesitancy poses direct and indirect threats to health (<a href="./references#CD015025-bbs2-0127" title="GrubaughND , HanageWP , RasmussenAL . Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell2020;182(4):794-5. [DOI: 10.1016/j.cell.2020.06.040]">Grubaugh 2020</a>). Besides unequal access to vaccines, evidence is available indicating a significant impact of certain circulating variants of SARS‐CoV‐2 on immunity that is likely to have an impact on the epidemiological situation. </p> <p>Specific risk factors for severe disease, hospitalisation and mortality have been identified: older age, certain underlying medical conditions, such as cancer, chronic kidney disease, chronic lung disease including chronic obstructive pulmonary disease (COPD), moderate‐to‐severe asthma, interstitial lung disease, cystic fibrosis, and pulmonary hypertension, dementia or other neurological conditions, diabetes mellitus, Down syndrome, heart conditions, HIV infection, immunocompromised state, liver disease, overweight and obesity, Sickle cell disease or thalassemia, smoking, solid organ or blood stem cell transplant, stroke or cerebrovascular disease, substance use disorders, and pregnancy can increase the risk for severe disease (<a href="./references#CD015025-bbs2-0132" title="HuangC , WangY , LiX , RenL , ZhaoJ , HuY , et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet2020;395(10223):497-506. [DOI: 10.1016/S0140-6736(20)30183-5]">Huang 2020</a>; <a href="./references#CD015025-bbs2-0140" title="LiangW , GuanW , ChenR , WangW , LiJ , XuK , et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology2020;21(3):335-7. [DOI: 10.1016/S1470-2045(20)30096-6]">Liang 2020</a>; <a href="./references#CD015025-bbs2-0175" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 2 July 2021).">WHO 2020a</a>; <a href="./references#CD015025-bbs2-0181" title="WilliamsonE , WalkerAJ , BhaskaranKJ , BaconS , BatesC , MortonCE , et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature2020;584:430-6. [DOI: 10.1038/s41586-020-2521-4]">Williamson 2020</a>). Reported COVID‐19 case fatality ratios varied widely between countries and reporting periods (from 0% to more than 25%, <a href="./references#CD015025-bbs2-0134" title="Johns Hopkins University &amp; Medicine Coronavirus Resource Center. Mortality analyses. https://coronavirus.jhu.edu/data/mortality (accessed at 22 March 2021).">Johns Hopkins University &amp; Medicine</a>). However, these numbers may be misleading as they tend to overestimate the infection fatality ratio due to varying testing frequency, lag in reporting dates, incomplete capturing of all cases, and variations in case definitions since the beginning of the pandemic (<a href="./references#CD015025-bbs2-0176" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 5 April 2021).">WHO 2020b</a>).  </p> <p>The median incubation period is estimated to be between five and six days and 97.5% of symptomatic cases develop symptoms within 11.5 days of exposure (<a href="./references#CD015025-bbs2-0137" title="LauerSA , GrantzKH , BiQ , JonesFK , ZhengQ , MeredithHR , et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of Internal Medicine2020;172(9):577–82. [DOI: 10.7326/M20-0504]">Lauer 2020</a>). Sore throat, cough, fever, headache, fatigue, and myalgia (muscle pain)or arthralgia (joint pain) are the most commonly reported symptoms (<a href="./references#CD015025-bbs2-0168" title="StruyfT , DeeksJJ , DinnesJ , TakwoingiY , DavenportC , LeeflangMM , et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database of Systematic Reviews2020, Issue 7. Art. No: CD013665. [DOI: 10.1002/14651858.CD013665]">Struyf 2020</a>). Other symptoms include dyspnoea, chills, nausea or vomiting, diarrhoea and nasal congestion (<a href="./references#CD015025-bbs2-0175" title="World Health Organization. Report of the WHO‐China Joint Mission on coronavirus disease 2019 (COVID‐19). www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report (accessed 2 July 2021).">WHO 2020a</a>). The majority of infected people develops mild symptoms, not requiring hospitalisation or remains completely asymptomatic (approximately 80% to 90%), depending on the time of the investigation, the cohort investigated and the virus variant (<a href="./references#CD015025-bbs2-0116" title="Chen T,  Wu D,  Chen H,  Yan W,  Yang D,  ChenG , et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ2020;368:m1091. [DOI: 10.1136/bmj.m1091]">Chen 2020</a>; <a href="./references#CD015025-bbs2-0125" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015025-bbs2-0150" title="PanA , Liu L, WangC ,  GuoH ,  HaoX , WangQ , et al. Association of public health interventions with the epidemiology of the COVID-19 outbreak in Wuhan, China. JAMA2020;323(19):1915-23. [DOI: 10.1001/jama.2020.6130]">Pan 2020</a>; <a href="./references#CD015025-bbs2-0182" title="WuZ , McGoogan JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>). The reported frequency of asymptomatic courses also varies greatly and ranges between 6% and 96% (<a href="./references#CD015025-bbs2-0113" title="Buitrago-GarciaD , Egli-GanyD , CounotteMJ , HossmannS , ImeriH , Ipekci AzizM , et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLOS Medicine2020;17(9):e1003346-e1003346. [DOI: 10.1371/journal.pmed.1003346]">Buitrago‐Garcia 2020</a>; <a href="./references#CD015025-bbs2-0125" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015025-bbs2-0149" title="OranDP , TopolEJ . Prevalence of asymptomatic SARS-CoV-2 infection: A narrative review. Annals of Internal Medicine  2020;173(5):362-7. [DOI: 10.7326/M20-3012]">Oran 2020</a>). A smaller proportion is affected by severe (approximately 11% to 20%) or critical (approximately 1% to 5%) disease with hospitalisation and intensive care unit (ICU) admittance due to respiratory failure, septic shock or multiple organ dysfunction syndrome (<a href="./references#CD015025-bbs2-0125" title="FunkT , PharrisA , SpiteriG , BundleN , MelidouA , CarrM , et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Eurosurveillance2021;26(16):2100348. [DOI: 10.2807/1560-7917.ES.2021.26.16.2100348]">Funk 2021</a>; <a href="./references#CD015025-bbs2-0182" title="WuZ , McGoogan JM . Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA2020;323(13):1239-42. [DOI: 10.1001/jama.2020.2648]">Wu 2020</a>).  In light of the extent of the COVID‐19 pandemic with its pressure on health systems, especially in the face of evolving virus variants with potential increased transmissibility and altered disease characteristics, the ongoing scarcity of effective treatments, and the low global vaccination coverage, there is an urgent need for effective and safe therapies to save lives and to reduce the burden on healthcare systems. </p> </section> <section id="CD015025-sec-0011"> <h3 class="title" id="CD015025-sec-0011">Description of the intervention</h3> <p> During the current COVID‐19 pandemic, several antimicrobials have been investigated as treatment options for COVID‐19. International clinical trials are evaluating the effect of repurposed drugs including certain antibiotics. The effect of antibiotics with potential antiviral and anti‐inflammatory properties such as azithromycin are being investigated as treatment for a viral, and not treatment or prophylaxis of primary bacterial superinfections.  </p> <p>Most randomised trials and observational studies which evaluated the efficacy and safety of antibiotics studied macrolides such as azithromycin and clarithromycin. Macrolides are widely available and their safety profile is well‐established. The antibacterial mechanism of action involves binding to the bacterial ribosome leading to inhibition of bacterial protein synthesis. The most common adverse reactions encountered with macrolides include gastrointestinal discomfort such as nausea, diarrhoea and abdominal pain.  A potential adverse reaction is a clinically relevant QT‐prolongation predisposing to cardiac arrhythmias. Especially when azithromycin is combined with other drugs known to prolong QT, like hydroxychloroquine.<br/>. Established dosing regimens range from 250 mg to 500 mg per day, administered orally or intravenously (<a href="./references#CD015025-bbs2-0124" title="US Food and Drug Administration. FDA Professional Drug Information. drugs.com/professionals.html (accessed 11 June 2021).">FDA 2021</a>). Dosing of clarithromycin in bacterial infections is 500  mg to 1000 mg per day, administered orally or intravenously. Besides their frequent use in acute bacterial infections, including community‐acquired respiratory tract infections, macrolides are sometimes used for their anti‐inflammatory, immunomodulatory effects in chronic inflammatory diseases (<a href="./references#CD015025-bbs2-0128" title="HansenMP , ScottAM , McCulloughA , ThorningS , AronsonJK , BellerEM ,  . Adverse events in people taking macrolide antibiotics versus placebo for any indication. Cochrane Database of Systematic Reviews2019, Issue 1. Art. No: CD011825. [DOI: 10.1002/14651858.CD011825.pub2]">Hansen 2019</a>). Macrolides belong to antibiotic classes that have higher resistance potential than others. The WHO advice is to prioritise these medicines as key targets of stewardship program and monitoring to reduce antimicrobial resistance (AMR) (<a href="./references#CD015025-bbs2-0174" title="World Health Organization. The 2019 WHO AWaRe classification of antibiotics for evaluation and monitoring of use. . Geneva: World Health Organization; 2019 November. Report No.: WHO/EMP/IAU/2019.11.">WHO 2019b</a>). Macrolide use during the pandemic is being discussed as a relevant contributor to the spread of AMR which is an ongoing problem that has implications for global health and the world economy (<a href="./references#CD015025-bbs2-0178" title="World Health Organization. Antimicrobial resistance. who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed 7 July 2021).">WHO 2020d</a>). </p> <p>Another antibiotic studied as treatment for COVID‐19 is the broad‐spectrum antibiotic doxycycline, a long‐acting tetracycline. Tetracyclines exhibit bacteriostatic properties and also inhibit the bacterial protein synthesis. The wide range of activity includes gram‐positive bacteria, gram‐negative bacteria, intracellular organisms, and protozoan parasites. Doxycycline is an important antimalarial agent (<a href="./references#CD015025-bbs2-0136" title="KrakauerT , BuckleyM . Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrobial Agents and Chemotherapy2003;47(11):3630–3. [DOI: 10.1128/AAC.47.11.3630-3633.2003]">Krakauer 2003</a>). Tetracyclines are generally well‐tolerated. The most common adverse reactions include gastrointestinal side effects and increased photosensitivity occurring in sun‐exposed areas. Established dosing regimens range from 100 mg to 200 mg per day orally or intravenously (<a href="./references#CD015025-bbs2-0124" title="US Food and Drug Administration. FDA Professional Drug Information. drugs.com/professionals.html (accessed 11 June 2021).">FDA 2021</a>). It is commonly used in many areas of the world. </p> <p>Finally, lincosamides are also being studied in the context of COVID‐19. Lincomycin is pharmaceutically similar to clindamycin, but has no therapeutic advantages over clindamycin, and is rarely used in infections caused by susceptible bacterial strains in penicillin‐allergic patients. Dose regimens of 600 mg two to three times daily by intravenous or intramuscular route, or lower oral dosing are considered acceptable (<a href="./references#CD015025-bbs2-0122" title="Wishart Research Group. Lincomycin. Available at go.drugbank.com/drugs/DB01627.">DrugBank Online</a>; <a href="./references#CD015025-bbs2-0124" title="US Food and Drug Administration. FDA Professional Drug Information. drugs.com/professionals.html (accessed 11 June 2021).">FDA 2021</a>). Lincosamides have a similar mechanism of action as macrolides. Lincomycin has largely been superseded by its semisynthetic derivative clindamycin due to higher efficacy. In the EU lincomycin is approved for veterinary use only. However, it is still used in human medicine in the US, Canada and Russia amongst others (<a href="./references#CD015025-bbs2-0122" title="Wishart Research Group. Lincomycin. Available at go.drugbank.com/drugs/DB01627.">DrugBank Online</a>; <a href="./references#CD015025-bbs2-0123" title="European Medicines Agency  [Lincomycin — Summary Report]. Available at ema.europa.eu/en/documents/mrl-report/lincomycin-summary-report-1-committee-veterinary-medicinal-products_en.pdf1998.">EMA 1998</a>). </p> </section> <section id="CD015025-sec-0012"> <h3 class="title" id="CD015025-sec-0012">How the intervention might work</h3> <p>There are several rationales for using antibiotics in the context of COVID‐19. The most intuitive is using antibiotics to treat secondary bacterial infections or bacterial co‐infections which antibiotics could effectively treat. However, this review focuses on using antibiotics as repurposed treatment options with direct activity against the SARS‐CoV‐2 virus and a reduction of the pro‐inflammatory immune response through anti‐inflammatory properties.  </p> <p>Macrolides have been shown to have in‐vitro antiviral activity against a range of viruses and have been reported to inhibit SARS‐CoV‐2 replication in vitro. Their anti‐inflammatory and immunomodulatory activity triggered their use in patients with COVID‐19. Especially azithromycin is being used in patients with chronic pulmonary inflammatory conditions to decrease inflammation and exacerbation frequency, e.g. panbronchiolitis, chronic obstructive pulmonary disease or cystic fibrosis. The beneficial effect is proposed to be based on down‐regulating inflammatory mediators like interleukin 6 (IL‐6), interleukin 1beta (IL‐1ß) and tumour necrosis factor (TNF) (<a href="./references#CD015025-bbs2-0151" title="Pani A, Lauriola M,  Romandini A,  Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. International Journal of Antimicrobial Agents2020;56(2):106053. [DOI: 10.1016/j.ijantimicag.2020.106053]">Pani 2020</a>; <a href="./references#CD015025-bbs2-0161" title="ShinkaiM , HenkeMO , RubinBK . Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacology and Therapeutics2008;117(11):393-405. [DOI: 10.1016/j.pharmthera.2007.11.001]">Shinkai 2008</a>). Further, in vitro activity inhibiting virus replication was observed for influenza H1N1, Ebola and Zika virus (<a href="./references#CD015025-bbs2-0110" title="Al-HoraniRA , KarS , AliterKF . Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. International Journal of Molecular Sciences2020;21(15):2114. [DOI: 10.3390/ijms21155224]">Al‐Horani 2020</a>). The precise mechanism is unknown, but theories include the drug's capacity of creating an acidic environment that blocks endocytosis, release of viral content after endocytosis or interfering with the SARS‐CoV‐2 spike protein mediated cell entry, all mechanisms would ultimately limit virus replication (<a href="./references#CD015025-bbs2-0110" title="Al-HoraniRA , KarS , AliterKF . Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. International Journal of Molecular Sciences2020;21(15):2114. [DOI: 10.3390/ijms21155224]">Al‐Horani 2020</a>). Similarly, clarithromycin is suggested to potentially inhibit virus replication and correct the immune dysregulation in critically ill patients (<a href="./references#CD015025-bbs2-0110" title="Al-HoraniRA , KarS , AliterKF . Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. International Journal of Molecular Sciences2020;21(15):2114. [DOI: 10.3390/ijms21155224]">Al‐Horani 2020</a>; <a href="./references#CD015025-bbs2-0161" title="ShinkaiM , HenkeMO , RubinBK . Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacology and Therapeutics2008;117(11):393-405. [DOI: 10.1016/j.pharmthera.2007.11.001]">Shinkai 2008</a>). </p> <p>Doxycycline is being tested for its benefit in COVID‐19 patients as well. On the one hand, it has also been suggested to suppress pro‐inflammatory cytokine production, especially IL‐6. On the other hand, it inhibits certain enzymes' activity that normally help the coronavirus entering and replicating in host cells (<a href="./references#CD015025-bbs2-0110" title="Al-HoraniRA , KarS , AliterKF . Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. International Journal of Molecular Sciences2020;21(15):2114. [DOI: 10.3390/ijms21155224]">Al‐Horani 2020</a>; <a href="./references#CD015025-bbs2-0136" title="KrakauerT , BuckleyM . Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrobial Agents and Chemotherapy2003;47(11):3630–3. [DOI: 10.1128/AAC.47.11.3630-3633.2003]">Krakauer 2003</a>).  </p> <p>For lincosamides, especially lincomycin, less research is available on activity outside its antibacterial effect. However, it is suggested impeding hyperinflammation by blocking neutrophil chemotaxis and down‐regulating cytokines (<a href="./references#CD015025-bbs2-0165" title="SpížekJ , ŘezankaT . Lincomycin, clindamycin and their applications. Applied Microbiology and Biotechnology2004;64:455–64. [DOI: 10.1007/s00253-003-1545-7]">Spížek 2004</a>). </p> </section> <section id="CD015025-sec-0013"> <h3 class="title" id="CD015025-sec-0013">Why it is important to do this review</h3> <p>There is a need for evidence‐based information to guide clinical decision‐making for COVID‐19 patients. Current treatment consists of supportive care with oxygen therapy in cases with moderate disease, and with respiratory support as mechanical ventilation, and extracorporeal membrane oxygenation in cases with severe disease (<a href="./references#CD015025-bbs2-0114" title="Centers for Disease Control and Prevention. COVIDView - a weekly surveillance summary of U.S. COVID-19 activity (Key updates for week 43). www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (accessed 22 March 2021).">CDC 2020</a>; <a href="./references#CD015025-bbs2-0176" title="World Health Organization. Estimating mortality from COVID-19 - scientific brief. www.who.int/publications/i/item/WHO-2019-nCoV-Sci-Brief-Mortality-2020.1 (accessed 5 April 2021).">WHO 2020b</a>). Overall, data from randomised controlled trials (RCTs) do not demonstrate a clear, major clinical benefit with most drugs evaluated so far. Data from RCTs at this stage support the role of corticosteroids for severe COVID‐19 and clinical guidelines recommend their use (<a href="./references#CD015025-bbs2-0147" title="National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19: supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. covid19evidence.net.au/#living-guidelines (accessed 19 July 2021).">National COVID‐19 Clinical Evidence Taskforce 2021</a>; <a href="./references#CD015025-bbs2-0162" title="SiemieniukR , RochwergB , AgoritsasT , LamontagneF , Leo YS , MacdonaldH , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;370:m3379:1-14. [DOI: 10.1136/bmj.m3379]">Siemieniuk 2020</a>). Further, tocilizumab is recommended for certain patient groups, while other drugs, such as hydroxychloroquine, are not recommended for the treatment of COVID‐19 (<a href="./references#CD015025-bbs2-0147" title="National COVID-19 Clinical Evidence Taskforce. Caring for people with COVID-19: supporting Australia’s healthcare professionals with continually updated, evidence-based clinical guidelines. covid19evidence.net.au/#living-guidelines (accessed 19 July 2021).">National COVID‐19 Clinical Evidence Taskforce 2021</a>; <a href="./references#CD015025-bbs2-0162" title="SiemieniukR , RochwergB , AgoritsasT , LamontagneF , Leo YS , MacdonaldH , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;370:m3379:1-14. [DOI: 10.1136/bmj.m3379]">Siemieniuk 2020</a>). Furthermore, evidence on the efficacy of anti‐SARS‐CoV‐2 monoclonal antibodies as treatments for COVID‐19 patients is being generated (Kreuzberger 2021b). Management strategies for most patient subgroups are still to be identified. </p> <p>The idea of drug repurposing follows the desire and need to rapidly find an effective treatment against COVID‐19 as the drug candidates are mostly well‐investigated in other clinical scenarios and thus adverse effects are well‐known. However, it has to be kept in mind that every drug has side effects and possible negative consequences. Safety and potential collateral damage have to be elucidated just as much as the potential efficacy. Antibiotic use was already excessive before 2020 resulting in increased antimicrobial resistance (AMR) rates worldwide (<a href="./references#CD015025-bbs2-0157" title="RussellCD , FairfieldCJ , DrakeTM , TurtleL , SeatonRA , Wootton, DG, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2 June 2021 [Epub ahead of print]. [DOI: 10.1016/S2666-5247(21)00090-2]">Russell 2021</a>). The WHO has declared that AMR is one of the top 10 global public health threats facing humanity (<a href="./references#CD015025-bbs2-0178" title="World Health Organization. Antimicrobial resistance. who.int/news-room/fact-sheets/detail/antimicrobial-resistance (accessed 7 July 2021).">WHO 2020d</a>). As long as the current body of evidence regarding the efficacy of antibiotics as antiviral treatment option for COVID‐19 is not completely mapped, the uncontrolled use of antibiotics in COVID‐19 patients could enhance this problem even more. </p> <p>Extensive work in the field of systematic reviews for interventions to treat COVID‐19 has already been undertaken, including treatment with antibiotics (<a href="./references#CD015025-bbs2-0135" title="KamelAM , MonemMSA , SharafNA , MagdyN , FaridSR . Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Reviews in Medical Virology 2 June 2021 [Epub ahead of print]. [DOI: 10.1002/rmv.2258]">Kamel 2021</a>; <a href="./references#CD015025-bbs2-0142" title="MangkuligunaG , Glenardi, SusantoN , PramonoLA . Efficacy and safety of azithromycin for the treatment of COVID-19: a systematic review and meta-analysis. 20 May 2021 [Epub ahead of print]. [DOI: 10.4046/trd.2021.0075]">Mangkuliguna 2021</a>; <a href="./references#CD015025-bbs2-0160" title="SharmaS , SinghA , BanerjeeT . Antibacterial agents used in COVID-19: A systematic review and meta-analysis. Environmental Sustainability 7 June 2021 [Epub ahead of print]. [DOI: 10.1007/s42398-021-00194-6]">Sharma 2021</a>)<a href="https://link.springer.com/article/10.1007/s42398-021-00194-6)." target="_blank">.</a> However, none fulfilled all quality standards for evidence syntheses such as risk of bias assessment and the GRADE approach. </p> <p>Therefore, we aim to provide a complete evidence profile based on current Cochrane standards for antibiotics with regard to efficacy and safety as treatment of COVID‐19. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015025-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015025-sec-0014"></div> <p>To assess the efficacy and safety of antibiotics compared to each other, standard of care alone, placebo, or any other active intervention with proven efficacy for treatment of COVID‐19 outpatients and inpatients. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015025-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015025-sec-0015"></div> <section id="CD015025-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015025-sec-0017"> <h4 class="title">Types of studies</h4> <p>The main description of methods is based on the standard template of the Cochrane Haematology review group and is in line with a series of Cochrane Reviews investigating treatments and therapies for COVID‐19 (e.g. Kreuzberger 2021b; <a href="./references#CD015025-bbs2-0167" title="Stroehlein  JK, Wallqvist  J, Iannizzi  C, Mikolajewska  A, Metzendorf  M-I, Benstoem  C, et al. Vitamin D supplementation for the treatment of COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>; <a href="./references#CD015025-bbs2-0154" title="PoppM , StegemannM , Metzendorf M-I, GouldS , KrankeP , Meybohm P et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021</a>). The original review protocol for this review was registered with PROSPERO on January 25, 2021 (<a href="./references#CD015025-bbs2-0183" title="WeibelS , PoppM , MeybohmP , KrankeP , StegemannM , MikolajewskaA , et al. Efficacy and safety of antibiotics for treatment of hospitalised COVID-19 patients (part of German Ecosystem CEO-Sys). www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021233062 (first received 24 January 2021).">CRD42021233062</a>). As this review and the other reviews of the Cochrane Review series are living systematic reviews during the COVID‐19 pandemic, specific adaptions related to the research question, including participants, interventions, comparators, outcomes, and methods were necessary. Relevant protocol changes are transparently reported in the section <a href="#CD015025-sec-0126">Differences between protocol and review</a>.  </p> <p>To assess the efficacy and safety of antibiotics for the treatment of people with COVID‐19, we included randomised controlled trials (RCTs), as this study design, if performed appropriately, provides the best evidence for experimental therapies in highly controlled therapeutic settings. We used the methods recommended in the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD015025-bbs2-0129" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020a</a>). Non‐standard RCT designs, such as cluster‐randomised and cross‐over trials, were not eligible for the review. These designs are not appropriate in this context, since the underlying cause of COVID‐19 is an infection with the SARS‐CoV‐2 virus and the medical condition evolves over time. </p> <p>We excluded controlled non‐randomised studies of intervention and observational studies. We also excluded animal studies, pharmacokinetic studies, and in vitro studies. </p> <p>We included the following formats, if sufficient information was available on study design, characteristics of participants, interventions and outcomes. </p> <p> <ul id="CD015025-list-0001"> <li> <p>Full‐text journal publications</p> </li> <li> <p>Preprint articles</p> </li> <li> <p>Abstract publications</p> </li> <li> <p>Results published in trial registries</p> </li> <li> <p>Additional personal communication with investigators, if results were available in any of the above listed format </p> </li> </ul> </p> <p>We included preprints and conference abstracts to have a complete overview of the ongoing research activity, especially for tracking newly emerging studies about antibiotics as antiviral and anti‐inflammatory treatments for COVID‐19. We did not apply any limitation with respect to the length of follow‐up or language of the publication. </p> </section> <section id="CD015025-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included studies investigating adults with a confirmed diagnosis of COVID‐19 (reverse transcription polymerase chain reaction (RT‐PCR) or antigen testing) irrespective of age, gender, ethnicity, disease severity or setting. If studies included participants with a confirmed or suspected COVID‐19 diagnosis, we used only the data for the patient population with confirmed COVID‐19 diagnosis. In cases, where data were not reported separately for patients with confirmed or suspected COVID‐19 diagnosis, we included the mixed population. The participants' status of included studies including the type of COVID‐19 diagnosis is reported in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a>. If mixed population studies contributed data to meta‐analyses, we excluded these studies in sensitivity analyses (<a href="#CD015025-sec-0042">Sensitivity analysis</a>) to test the robustness of the results.  </p> <p>We excluded studies that evaluated antibiotic treatment for other coronavirus diseases such as SARS or MERS, or other viral diseases, such as influenza. If studies enrolled populations with or exposed to mixed viral diseases, we had planned to only include studies if trial authors provided subgroup data for SARS‐CoV‐2 infection. </p> </section> <section id="CD015025-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Any antibiotic given with antiviral and anti‐inflammatory intent was eligible as an intervention for this review, e.g. azithromycin, lincomycin, doxycycline, and clarithromycin. All doses and regimens were eligible. We categorised dose categories into usual dose as recommended for other infectious diseases (<a href="./references#CD015025-bbs2-0124" title="US Food and Drug Administration. FDA Professional Drug Information. drugs.com/professionals.html (accessed 11 June 2021).">FDA 2021</a>), low dose (&lt; usual dose), and high dose (&gt; usual dose) for the used antibiotics as following. </p> <p> <ul id="CD015025-list-0002"> <li> <p>Azithromycin usual dose:</p> <ul id="CD015025-list-0003"> <li> <p>oral route: 250 to 500 mg once daily; low dose &lt; 250 mg; and high dose: &gt; 500 mg;</p> </li> <li> <p>intravenous route: 500 mg daily; low dose &lt; 500 mg; and high dose &gt; 500 mg.</p> </li> </ul> </li> <li> <p>Clarithromycin usual dose: 250 mg twice daily by the oral or intravenous route; low dose &lt; 500 mg daily; and high dose &gt; 500 mg daily. </p> </li> <li> <p>Doxycycline usual dose: 200 mg daily followed by 100 mg daily by the oral route or intravenous route; low dose &lt; 200 mg and 100 mg daily, respectively; and high dose &gt; 200 mg and 100 mg daily, respectively; </p> </li> <li> <p>Lincomycin usual dose: 600 mg twice daily by the intravenous or intramuscular route; low dose &lt; 1200 mg; and high dose &gt; 1200 mg. Oral use is not recommended by the FDA any more. </p> </li> </ul> </p> <p>We compared antibiotics with each other, standard of care alone, or placebo. Placebo and standard of care alone were treated as the same control group, as well as standard of care at different institutions and time points during the pandemic. Standard of care (co‐interventions) had to be comparable between intervention and control groups. We have planned to compare any antibiotic with any other active pharmacological comparator with proven efficacy for the treatment of COVID‐19. While for this review version this considers mainly dexamethasone and remdesivir, more interventions with proven efficacy might become available for future updates. For dexamethasone, it has been shown that mortality from COVID‐19 was lower among people who were randomised to receive dexamethasone than among those who received the usual standard of care (<a href="./references#CD015025-bbs2-0162" title="SiemieniukR , RochwergB , AgoritsasT , LamontagneF , Leo YS , MacdonaldH , et al. A living WHO guideline on drugs for Covid-19. BMJ2020;370:m3379:1-14. [DOI: 10.1136/bmj.m3379]">Siemieniuk 2020</a>; <a href="./references#CD015025-bbs2-0155" title="Recovery Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine2021;384:693-704. [DOI: 10.1056/NEJMoa2021436]">RECOVERY 2021</a>). Remdesivir showed some benefit for people hospitalised with COVID‐19, though to a lesser extent (<a href="./references#CD015025-bbs2-0112" title="BeigelJH , TomashekKM , DoddLE , MehtaAK , ZingmanBS , KalilAC , et al. Remdesivir for the treatment of COVID-19 — final report. New England Journal of Medicine2020;383:1813-26. [DOI: 10.1056/NEJMoa2007764]">Beigel 2020</a>). For patients that qualify for e.g. dexamethasone therapy or for another intervention that proves to be beneficial in the future, it would be unethical to further conduct trials that use placebo only. In contrary, studies using comparators without proven efficacy, e.g. hydroxychloroquine, may confound the assessment of the efficacy or safety of antibiotics and were excluded. Although those kinds of interventions were possibly used at a certain point of time during the pandemic with the best intentions, their use was never supported by actual evidence, and they have potential side effects as well (<a href="./references#CD015025-bbs2-0163" title="Singh B , Ryan H , Kredo T , Chaplin M, FletcherT . Chloroquine or hydroxychloroquine for prevention and treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 2. Art. No: CD013587. [DOI: 10.1002/14651858.CD013587.pub2]">Singh 2021</a>). From those comparisons no reliable evidence can be obtained, therefore, active comparators without proven efficacy were not eligible for this review. For the current review, we found no study using an active comparator with proven efficacy. </p> <p>We excluded studies evaluating antibiotics in combination with other active treatments, if the same treatment was not used in the control group. We also excluded studies investigating the efficacy and safety to prevent COVID‐19. </p> <p>We created the following comparisons.</p> <p> <ul id="CD015025-list-0004"> <li> <p>Any antibiotic versus placebo/standard of care alone.</p> </li> <li> <p>Any antibiotic versus other antibiotic.</p> </li> <li> <p>Any antibiotic vs active pharmacological intervention for the treatment of COVID‐19 with proven efficacy (no studies were available for the current review version). </p> </li> </ul> </p> </section> <section id="CD015025-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We evaluated core outcomes in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients (<a href="./references#CD015025-bbs2-0118" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 22 March 2021).">COMET 2020</a>; <a href="./references#CD015025-bbs2-0143" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the German guideline panel for inpatient therapy of people with COVID‐19. The current outcome set differed between previous protocols and reviews and the current review. Changes to the outcomes were necessary due to the risk of competing events associated with the original outcome set. All differences are reported in the section <a href="#CD015025-sec-0126">Differences between protocol and review</a>. </p> <p>We defined outcome sets with primary and secondary outcomes for two populations\;</p> <p> <ul id="CD015025-list-0005"> <li> <p>hospitalised individuals with moderate to severe COVID‐19; and</p> </li> <li> <p>ambulatory managed individuals with asymptomatic or mild COVID‐19.</p> </li> </ul> </p> <p>Primary outcomes were used to inform the summary of findings tables.</p> <section id="CD015025-sec-0021"> <h5 class="title">Inpatients with moderate to severe COVID‐19 </h5> <p> <ul id="CD015025-list-0006"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and at hospital discharge.</p> </li> <li> <p>Clinical status at day 28, day 60, and up to the longest follow‐up, including:</p> <ul id="CD015025-list-0007"> <li> <p>Worsening of clinical status:</p> <ul id="CD015025-list-0008"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death. </p> </li> </ul> </li> <li> <p>Improvement of clinical status:</p> <ul id="CD015025-list-0009"> <li> <p>participants discharged alive. Participants should be discharged without clinical deterioration or death. </p> </li> </ul> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days; up to 28 days, and longest follow‐up available. </p> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any event. </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any event. </p> </li> <li> <p>Cardiac arrhythmias during the study period; cardiac arrhythmias included any event that was classified as such by the individual study definition. We reported on the incidence of QT prolongation narratively. </p> </li> </ul> </p> </section> <section id="CD015025-sec-0022"> <h5 class="title">Outpatients with asymptomatic or mild COVID‐19 </h5> <p> <ul id="CD015025-list-0010"> <li> <p>All‐cause mortality at day 28, day 60, time‐to‐event, and up to the longest follow‐up</p> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD015025-list-0011"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14, day 28, and up to the longest follow‐up; </p> </li> <li> <p>duration to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life, including fatigue and neurological status, assessed with standardised scales (e.g. WHOQOL‐100) at up to 7 days, up to 28 days, and longest follow‐up available. </p> </li> <li> <p>Serious adverse events during the study period, defined as number of participants with any event. </p> </li> <li> <p>Adverse events (any grade) during the study period, defined as number of participants with any event. </p> </li> <li> <p>Cardiac arrhythmias during the study period; cardiac arrhythmias included any event that was classified as such by the individual study definition. We reported on the incidence of QT prolongation narratively. </p> </li> </ul> </p> </section> <section id="CD015025-sec-0023"> <h5 class="title">Timing of outcome measurement</h5> <p>We collected information on outcomes from all time points reported in the publications. If only a few studies contributed data to an outcome, we pooled different time points, provided the studies had produced valid data and pooling was clinically reasonable.  </p> <p>In case of time‐to‐event analysis, e.g. for time to death, we included the outcome measure based on the longest follow‐up time and measured from randomisation.  </p> <p>We included serious adverse events and adverse events occurring during the study period, including adverse events during active treatment and long‐term adverse events as well. If sufficient data were available, we grouped the measurement time points of eligible outcomes, for example, adverse events and serious adverse events, into those measured directly after treatment (up to 7 days after treatment), medium‐term outcomes (up to 14 days after treatment) and longer‐term outcomes (more than 28 days after treatment). </p> </section> <section id="CD015025-sec-0024"> <h5 class="title">Inpatients with moderate to severe COVID‐19</h5> <section id="CD015025-sec-0025"> <h6 class="title">Additional outcomes for efficacy of antibiotics (not included in summary of findings table) </h6> <p> <ul id="CD015025-list-0012"> <li> <p>Clinical status at day 28, day 60, and up to the longest follow‐up, including:</p> <ul id="CD015025-list-0013"> <li> <p>Worsening of clinical status:</p> <ul id="CD015025-list-0014"> <li> <p>new need for invasive mechanical ventilation;</p> </li> <li> <p>new need for non‐invasive mechanical ventilation or high flow;</p> </li> <li> <p>new need for oxygen by mask or nasal prongs.</p> </li> </ul> </li> <li> <p>Improvement of clinical status:</p> <ul id="CD015025-list-0015"> <li> <p>weaning or liberation from invasive mechanical ventilation in surviving patients;</p> </li> <li> <p>Ventilator‐free days;</p> </li> <li> <p>duration to liberation from invasive mechanical ventilation;</p> </li> <li> <p>liberation from supplemental oxygen in surviving patients;</p> </li> <li> <p>duration to liberation from supplemental oxygen.</p> </li> </ul> </li> </ul> </li> <li> <p>Need for dialysis at up to 28 days.</p> </li> <li> <p>Admission to the intensive care unit (ICU) at day 28.</p> </li> <li> <p>Duration of hospitalisation.</p> </li> <li> <p>Viral clearance, assessed with reverse transcription polymerase chain reaction (RT‐PCR) test for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days </p> </li> <li> <p>Hospital‐acquired infections at up to 28 days.</p> </li> </ul> </p> </section> </section> <section id="CD015025-sec-0026"> <h5 class="title">Outpatients with asymptomatic or mild COVID‐19 (outpatients)</h5> <section id="CD015025-sec-0027"> <h6 class="title">Additional outcomes for efficacy of antibiotics (not included in summary of findings table) </h6> <p> <ul id="CD015025-list-0016"> <li> <p>Clinical status at day 28 and up to the longest follow‐up:</p> <ul id="CD015025-list-0017"> <li> <p>worsening of clinical status (moderate to severe COVID‐19 symptoms):</p> <ul id="CD015025-list-0018"> <li> <p>need for invasive mechanical ventilation;</p> </li> <li> <p>need for non‐invasive mechanical ventilation or high flow;</p> </li> <li> <p>need for hospitalisation with need for oxygen by mask or nasal prongs;</p> </li> <li> <p>need for hospitalisation without oxygen therapy.</p> </li> </ul> </li> </ul> </li> <li> <p>Viral clearance, assessed with RT‐PCR for SARS‐CoV‐2 at baseline, up to 3, 7, and 14 days. </p> </li> <li> <p>Hospital‐acquired infections at up to 28 days.</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD015025-sec-0028"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD015025-sec-0029"> <h4 class="title">Electronic searches</h4> <p>On 14 June 2021 our Information Specialist (MIM) conducted systematic searches in the following sources from the inception of each database to 14 June 2021 (date of last search for all databases) and did not place restrictions on the language of publication: </p> <p> <ul id="CD015025-list-0019"> <li> <p>Cochrane COVID‐19 Study Register (CCSR) (<a href="http://www.covid-19.cochrane.org" target="_blank">www.covid-19.cochrane.org</a>), comprising: </p> <ul id="CD015025-list-0020"> <li> <p>MEDLINE (PubMed), daily updates;</p> </li> <li> <p>Embase, weekly updates;</p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>), daily updates, </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>), weekly updates, </p> </li> <li> <p>medRxiv (<a href="http://www.medrxiv.org" target="_blank">www.medrxiv.org</a>), weekly updates; </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), monthly updates.</p> </li> </ul> </li> <li> <p>Web of Science Core Collection:</p> <ul id="CD015025-list-0021"> <li> <p>Science Citation Index Expanded;</p> </li> <li> <p>Emerging Sources Citation Index.</p> </li> </ul> </li> <li> <p>WHO COVID‐19 Global literature on coronavirus disease (<a href="https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/" target="_blank">https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/</a>). </p> </li> </ul> </p> <p>For detailed search strategies, see <a href="./appendices#CD015025-sec-0118">Appendix 1</a>. </p> </section> <section id="CD015025-sec-0030"> <h4 class="title">Searching other resources</h4> <p>We searched for other potentially eligible studies or ancillary publications by searching the reference lists of included studies, systematic reviews and meta‐analyses. In addition, we contacted the investigators of included studies to obtain additional information on the retrieved studies. </p> <p>We searched for grey literature, which we defined as searching study registries such as ClinicalTrials.gov and WHO ICTRP contained in the CCSR, as well as searching preprint servers and grey literature indexes contained in CCSR and WHO COVID‐10 Global Literature database. Once we established our set of included studies, we searched for preprints via Europe PMC, to check if any preprints for included studies were published since our database search. </p> </section> </section> <section id="CD015025-sec-0031"> <h3 class="title" id="CD015025-sec-0031">Data collection and analysis</h3> <section id="CD015025-sec-0032"> <h4 class="title">Selection of studies</h4> <p>In accordance with the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD015025-bbs2-0138" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf MI , et al. Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Lefebvre 2020</a>), two review authors (MP, MR) independently screened the results of the search strategies for eligibility for this review by reading the titles and abstracts using Covidence (<a href="./references#CD015025-bbs2-0119" title="Covidence. Melbourne, Australia: Veritas Health Innovation, (accessed 14 June 2021). Available at covidence.org.">Covidence</a>). We then retrieved full‐text articles and assessed eligibility of the remaining records against pre‐defined eligibility criteria in duplicate. Discrepancies were resolved by discussion within the group of review authors. We included studies in the review irrespective of whether measured outcome data were reported in a ‘usable’ way. We collated multiple reports of the same study, so that the study, rather than the report, was the unit of interest in the review. </p> <p>We documented the study selection process in a flow diagram, as recommended in the PRISMA statement (<a href="./references#CD015025-bbs2-0146" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097]">Moher 2009</a>), and show the total numbers of retrieved references and the numbers of included, ongoing, excluded studies as well as awaiting classification. We listed all studies that we excluded after full‐text assessment and the reasons for their exclusion in the 'Characteristics of excluded studies' section, same procedure was conducted for the studies awaiting classification.  </p> </section> <section id="CD015025-sec-0033"> <h4 class="title">Data extraction and management</h4> <p>We conducted data extraction according to the guidelines proposed by Cochrane (<a href="./references#CD015025-bbs2-0139" title="LiT , HigginsJP , DeeksJJ . Chapter 5: Collecting data. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Li 2020</a>). Two out of three review authors (MP, MR, SW) extracted data independently and in duplicate, using a customised data extraction form developed in Microsoft Excel (<a href="./references#CD015025-bbs2-0145" title="Mircosoft Excel. Microsoft Corporation. Microsoft Corporation, 2018.">Microsoft 2018</a>). We solved disagreements by discussion. If no agreement was obtained, a third review author was involved to resolve the disagreement.   </p> <p>Two review authors (MP, SW) independently assessed eligible studies in the process of study selection (as described above) for methodological quality and risk of bias. If the review authors were unable to reach a consensus, a third review author was consulted.  </p> <p>We extracted the following information, if reported.</p> <p> <ul id="CD015025-list-0022"> <li> <p>General information: author, title, source, country, language, type of publication, publication date. </p> </li> <li> <p>Study characteristics: setting and dates, inclusion/exclusion criteria, number of study arms, comparability of groups, treatment cross‐overs, length of follow‐up, funding. </p> </li> <li> <p>Participant characteristics: number of participants randomized/received intervention/analysed, COVID‐19 diagnostics, severity of disease, age, gender, co‐morbidities (e.g. diabetes, immunosuppression), concurrent interventions, time since symptom onset. </p> </li> <li> <p>Intervention: type of antibiotic, dose, frequency, duration and route of administration.</p> </li> <li> <p>Control intervention: type of control, frequency, duration and route of administration.</p> </li> <li> <p>Outcomes: as specified under <a href="#CD015025-sec-0020">Types of outcome measures</a>. </p> </li> </ul> </p> </section> <section id="CD015025-sec-0034"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the risk of bias 2.0 (RoB 2) tool to analyse the risk of bias of study results contributing information to our primary outcomes (<a href="./references#CD015025-bbs2-0166" title="SterneJA , SavovicJ , PageMJ , ElbersRG , BlencoweN , BoutronI , et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ2019;366:l4898. [DOI: 10.1136/bmj.l4898]">Sterne 2019</a>). Of interest for this review was the effect of the assignment to the intervention (the intention‐to‐treat (ITT) effect), thus, we performed all assessments with RoB 2 on this effect. The outcomes that we assessed are the primary outcomes specified for inclusion in the summary of findings tables. </p> <p>Two review authors (MP, SW) independently assessed the risk of bias for each outcome. In case of discrepancies among their judgements and inability to reach consensus, we consulted the third review author to reach a final decision. We assessed the following types of bias as outlined in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015025-bbs2-0130" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020b</a>). </p> <p> <ul id="CD015025-list-0023"> <li> <p>Bias arising from the randomisation process.</p> </li> <li> <p>Bias due to deviations from the intended interventions.</p> </li> <li> <p>Bias due to missing outcome data.</p> </li> <li> <p>Bias in measurement of the outcome.</p> </li> <li> <p>Bias in selection of the reported result.</p> </li> </ul> </p> <p>To address these types of bias we used the signalling questions recommended in RoB 2 and make a judgement using the following options. </p> <p> <ul id="CD015025-list-0024"> <li> <p>'Yes': if there is firm evidence that the question is fulfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably yes': a judgement has been made that the question is fulfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No': if there is firm evidence that the question is unfilled in the study (i.e. the study is at low or high risk of bias for the given the direction of the question). </p> </li> <li> <p>'Probably no': a judgement has been made that the question is unfilled in the study (i.e. the study is at low or high risk of bias given the direction of the question). </p> </li> <li> <p>'No information': if the study report does not provide sufficient information to allow any judgement. </p> </li> </ul> </p> <p>We used the algorithms proposed by RoB 2 to assign each domain one of the following levels of bias. </p> <p> <ul id="CD015025-list-0025"> <li> <p>Low risk of bias</p> </li> <li> <p>Some concerns</p> </li> <li> <p>High risk of bias</p> </li> </ul> </p> <p>Subsequently, we derived an overall risk of bias rating for each pre‐specified outcome in each study in accordance with the following suggestions. </p> <p> <ul id="CD015025-list-0026"> <li> <p>'Low risk of bias': we judge the trial to be at low risk of bias for all domains for this result. </p> </li> <li> <p>'Some concerns': we judge the trial to raise some concerns in at least one domain for this result, but not to be at high risk of bias for any domain. </p> </li> <li> <p>'High risk of bias': we judge the trial to be at high risk of bias in at least one domain for the result, or we judge the trial to have some concerns for multiple domains in a way that substantially lowers confidence in the results. </p> </li> </ul> </p> <p>We used the RoB 2 version 2019. We used the RoB 2 Excel tool to implement RoB 2 (available on the website <a href="https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2" target="_blank">www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2</a>), and stored and presented our detailed RoB 2 assessments in the analyses section. </p> </section> <section id="CD015025-sec-0035"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we recorded the number of events and total number of participants in both treatment and control groups. We reported the pooled risk ratio (RR) with a 95% confidence intervals (CIs) (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>).   </p> <p>For continuous outcomes, we recorded the mean, standard deviation and total number of participants in both treatment and control groups. Where continuous outcomes used the same scale, we performed analyses using the mean difference (MD) with 95% CIs (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). For continuous outcomes measured with different scales, we planned to perform analyses using the standardised mean difference (SMD) (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). For interpreting SMDs, we planned to re‐express SMDs in the original units of a particular scale with the most clinical relevance and impact. For the current review, all outcomes were measured on comparable scales. </p> <p>If available, we extracted and report hazard ratios (HRs) for time‐to‐event outcomes (e.g. time to hospital discharge). If HRs were not available, we would have made every effort to estimate the HR as accurately as possible from available data using the methods proposed by Parmar and Tierney (<a href="./references#CD015025-bbs2-0152" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [DOI: 10.1002/(sici)1097-0258(19981230)17:24&lt;2815::aid-sim110&gt;3.0.co;2-8]">Parmar 1998</a>; <a href="./references#CD015025-bbs2-0170" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16]">Tierney 2007</a>). Had sufficient studies provided HRs, we planned to use HRs rather than RRs or MDs in a meta‐analysis, as they provide more information.  </p> </section> <section id="CD015025-sec-0036"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis for this review is the individually‐randomised‐participant. </p> <p>In studies with multiple intervention groups, we followed the recommendations in Chapter 6 of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD015025-bbs2-0131" title="HigginsJP , TiangingL , DeeksJJ ,  editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020c</a>). Studies with multiple treatment groups of the same intervention (i.e. dose, route of administration) were combined if study arms were sufficiently homogeneous. If arms could not be pooled, which was not the case for the current review, we had planned to compare each arm with the common comparator separately. For pairwise meta‐analysis, we had planned to split the ‘shared’ group into two or more groups with smaller sample size, and include two or more (reasonably independent) comparisons. For this purpose, in case of dichotomous outcomes, both the number of events and the total number of participants would have been divided, and for continuous outcomes, the total number of participants would have been divided with unchanged means and standard deviations (SDs). </p> </section> <section id="CD015025-sec-0037"> <h4 class="title">Dealing with missing data</h4> <p>There are many potential sources of missing data in a systematic review or meta‐analysis, which can affect the level of studies, outcomes, summary data, individuals, or study‐level characteristics (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). Incomplete data can introduce bias into the meta‐analysis, if they are not missing at random. We addressed all sources of missing data. Missing studies may be the result of reporting bias, and we addressed this as described in the <a href="#CD015025-sec-0039">Assessment of reporting biases</a> section. Missing outcomes and summary data may be the result of selective reporting bias; missing individuals may be the result of attrition from the study or lack of intention‐to‐treat analysis. We addressed these sources of missing data using the RoB 2 tool (<a href="#CD015025-sec-0034">Assessment of risk of bias in included studies</a>). If data were incompletely reported, we contacted the study authors to request additional information. </p> </section> <section id="CD015025-sec-0038"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the descriptive statistics reported in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a> to assess whether the studies within each pairwise comparison are homogenous enough, with respect to study and intervention details and population baseline characteristics, that the assumption of homogeneity might be plausible. In case of excessive clinical heterogeneity, we did not pool the findings of included studies.<br/>We measured statistical heterogeneity using the Chi<sup>2</sup> test and the I<sup>2</sup> statistic (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>), and the 95% prediction interval (PI) for random‐effects meta‐analysis (<a href="./references#CD015025-bbs2-0133" title="IntHout J , Ioannidis JP , Rovers MM, GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: 27406637]">IntHout 2016</a>). The prediction interval helps in the clinical interpretation of heterogeneity by estimating what true treatment effects can be expected in future settings (<a href="./references#CD015025-bbs2-0133" title="IntHout J , Ioannidis JP , Rovers MM, GoemanJJ . Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open2016;12(6):e010247. [DOI: 10.1136/bmjopen-2015-010247] [PMID: 27406637]">IntHout 2016</a>). We restricted calculation of a 95% PI to meta‐analyses with four or more studies (≥ 200 participants), since the interval would be imprecise when a summary estimate is based on only a few small studies. We used the open‐source statistical software R package meta to calculate 95% PIs (<a href="./references#CD015025-bbs2-0144" title="Meta: General Package for Meta-Analysis. SchwarzerG . Available at https://cran.r-project.org/web/packages/meta/meta.pdf, 2021.">Meta</a>). We declared statistical heterogeneity if the P value was less than 0.1 for the Chi<sup>2</sup> statistic, or the I<sup>2</sup> statistic was equal to or greater than 40% (40% to 60%: moderate heterogeneity; 50% to 90%: substantial heterogeneity; 75% to 100%: considerable heterogeneity, <a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>), or the range of the 95% PI revealed a different clinical interpretation of the effect estimate compared to the 95% CI. </p> </section> <section id="CD015025-sec-0039"> <h4 class="title">Assessment of reporting biases</h4> <p>We sought to identify all research that meets our predefined eligibility criteria. Missing studies can introduce bias to the analysis. We searched for completed non‐published trials in trials registers, contacted authors to seek assurance that the results will be made available, and classified them as 'awaiting classification' until the results are reported. We reported the number of completed non‐published trials.<br/>We  planned to investigate risk of reporting bias (publication bias) in pairwise meta‐analyses using contour‐enhanced funnel plots, when there were 10 or more relevant studies pooled in a meta‐analysis. In the current review, there are no meta‐analyses including 10 or more studies. For future review updates, if funnel plot asymmetry is suggested by a visual assessment, we plan to perform exploratory analyses (e.g. Rücker’s arcsine test for dichotomous data and Egger’s linear regression test for continuous data) to further investigate funnel plot asymmetry. A P value of less than 0.1 will be considered as the level of statistical significance. In future review updates, we will analyse reporting bias using the open‐source statistical software R package meta (<a href="./references#CD015025-bbs2-0144" title="Meta: General Package for Meta-Analysis. SchwarzerG . Available at https://cran.r-project.org/web/packages/meta/meta.pdf, 2021.">Meta</a>). </p> </section> <section id="CD015025-sec-0040"> <h4 class="title">Data synthesis</h4> <p>We analysed trials including different severities of disease separately, grouping them into asymptomatic to mild, and moderate to severely ill, as these are different populations in different settings, resulting in different outcome sets (see <a href="#CD015025-sec-0020">Types of outcome measures</a>). We analysed trials with the following participant populations separately, as follows. </p> <p> <ul id="CD015025-list-0027"> <li> <p>Inpatients moderate to severe COVID‐19.</p> </li> <li> <p>Outpatients with asymptomatic or mild COVID‐19.</p> </li> </ul> </p> <p>For these populations, we created the following comparisons.</p> <p> <ul id="CD015025-list-0028"> <li> <p>Any antibiotic versus placebo/standard of care alone.</p> </li> <li> <p>Any antibiotic versus other antibiotic.</p> </li> <li> <p>Any antibiotic vs active pharmacological intervention for the treatment of COVID‐19 with proven efficacy (no studies available for the current review version). </p> </li> </ul> </p> <p>Placebo and standard of care alone were treated as the same intervention, as well as standard of care at different institutions and time points during the pandemic.  </p> <p>We performed meta‐analyses according to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions (<a href="./references#CD015025-bbs2-0121" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventionsversion 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Deeks 2020</a>). If clinical and methodological characteristics of individual studies were sufficiently homogeneous, we pooled the data in meta‐analysis. We used the RevMan Web software for meta‐analyses (<a href="./references#CD015025-bbs2-0156" title="Review Manager Web (RevMan Web). Version 2.3.0. The Cochrane Collaboration, 2020.">RevMan Web 2020</a>). One review author entered the data into the software, and a second review author checked the data for accuracy. When meta‐analysis was feasible, we used the random‐effects model as we assume that the intervention effects are related but are not the same for the included studies. For dichotomous outcomes, we performed meta‐analyses using the Mantel‐Haenszel method under a random‐effects model to calculate the summary (combined) intervention effect estimate as a weighted average of the intervention effects estimated in the individual studies. For continuous outcomes, we used the inverse‐variance method.  </p> <p>We planned to present descriptive statistics only, if we deemed meta‐analysis inappropriate for a certain outcome because of heterogeneity or because of serious study limitations leading to considerably high risk of bias (e.g competing risk of death not taken into account in outcome measurement). This was not the case for the current review version. </p> <p>If meta‐analysis was possible, we assessed the effects of potential biases in sensitivity analyses (see <a href="#CD015025-sec-0042">Sensitivity analysis</a>) and considered investigating heterogeneity in subgroup analyses (see <a href="#CD015025-sec-0041">Subgroup analysis and investigation of heterogeneity</a>). Subgroup analyses were not possible due to the low number of studies per outcome. For future review updates, if we could not find a cause for the heterogeneity, we had planned to not perform a meta‐analysis, but to comment on the results as a narrative with the results from all studies presented in tables. </p> <p>Forest plots were used to visualise for meta‐analyses of primary outcomes only, including risk of bias assessment. Secondary outcomes without risk of bias assessment were reported in additional tables. </p> </section> <section id="CD015025-sec-0041"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Subgroup analyses were restricted to the primary outcomes.</p> <p>For hospitalised individuals with moderate to severe COVID‐19, we performed a subgroup analysis independent of heterogeneity and number of studies for the following characteristic, because we considered it essential to test the intervention for its impact in different stages of the disease. </p> <p> <ul id="CD015025-list-0029"> <li> <p>Severity of condition at baseline: moderate (WHO 4 to 5) versus severe disease (WHO 6 to 9) as defined by the WHO Clinical Progression Scale. Studies providing data only for a mixed population including moderate and severe participants where included in the subgroup 'moderate to severe disease (WHO 4 to 9)'. Details of the patients' status at baseline were provided in the footnotes of the forest plots. </p> </li> </ul> </p> <p>We investigated heterogeneity by visual inspection of the forest plot. Details of the intervention, comparator, and the population were reported for each study in the footnotes of the forest plot.  </p> <p>In future review updates, we will perform subgroup analyses to investigate heterogeneity for the following characteristics. </p> <p> <ul id="CD015025-list-0030"> <li> <p>Dose of antibiotic (usual dose versus low dose versus high dose);</p> </li> <li> <p>Route of administration (oral versus intravenous versus inhalational)</p> </li> <li> <p>Age (children versus adults).</p> </li> </ul> </p> <p>We had planned to explore heterogeneity by subgroup analysis to calculate RR or MD in conjunction with the corresponding CI for each subgroup, if sufficient studies had been available (at least 10 studies per outcome). In the current review, there are not enough studies available. In future review updates, we will perform subgroup analyses, if statistical heterogeneity is present (P &lt; 0.1 for the Chi<sup>2</sup> test of heterogeneity, I<sup>2</sup> ≥ 50%, or a different clinical conclusion of 95% CI versus 95% PI). We planned to use the tests for interaction to test for differences between subgroup results. </p> </section> <section id="CD015025-sec-0042"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses of the following characteristics for our primary outcomes. </p> <p> <ul id="CD015025-list-0031"> <li> <p>Risk of bias assessment (only studies with a low risk of bias or some concerns).</p> </li> <li> <p>Comparison of preprint articles versus peer‐reviewed articles (only studies published as journal articles). </p> </li> <li> <p>Confirmed versus mixed (suspected and confirmed) COVID‐19 diagnosis (only studies/participants with confirmed COVID‐19 diagnosis). </p> </li> </ul> </p> </section> <section id="CD015025-sec-0043"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <section id="CD015025-sec-0044"> <h5 class="title">Summary of findings</h5> <p>We created separate summary of findings tables for the different patient populations and for the different comparisons with regard to the intervention and comparator, respectively. For the current review version, there was no study with active comparator available. We evaluated the certainty of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach for interventions evaluated in RCTs. </p> <p>We used the MAGICapp software to create summary of findings tables (<a href="./references#CD015025-bbs2-0141" title="MAGICapp. Brønnøysund (NOR): Norwegian MAGIC Evidence Ecosystem Foundation (powered by UserVoice Inc.), 2020.">MAGICapp</a>). For time‐to‐event outcomes, we planned to calculate absolute effects at specific time points, as recommended in the GRADE guidance 27 (<a href="./references#CD015025-bbs2-0164" title="SkoetzN , GoldkuhleM , Van DalenEC , AklEA , TrivellaM , MustafaRA , et al. GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and evidence profiles. Journal of Clinical Epidemiology2020;118:124-31. [DOI: 10.1016/j.jclinepi.2019.10.015]">Skoetz 2020</a>). For the current review there were no time‐to‐event data available. According to Chapter 14 of the updated Cochrane Handbook for Systematic Reviews of Interventions, the “most critical and/or important health outcomes, both desirable and undesirable, limited to seven or fewer outcomes” should be included in the summary of findings table(s) (<a href="./references#CD015025-bbs2-0159" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>). We included outcomes prioritised according to the Core Outcome Set for intervention studies (<a href="./references#CD015025-bbs2-0118" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 22 March 2021).">COMET 2020</a>), and patient‐relevance. Those are the primary outcomes of this review. </p> <section id="CD015025-sec-0045"> <h6 class="title">Inpatients with moderate to severe COVID‐19</h6> <p> <ul id="CD015025-list-0032"> <li> <p>All‐cause mortality​​​​​​; all‐cause mortality at hospital discharge most favourable; if not reported all‐cause mortality day 60, followed by day 28, or time‐to‐event estimate, will be included in summary of findings table. </p> </li> <li> <p>Worsening of clinical status at day 28:</p> <ul id="CD015025-list-0033"> <li> <p>participants with clinical deterioration (new need for invasive mechanical ventilation) or death. </p> </li> </ul> </li> <li> <p>Improvement of clinical status at day 28:</p> <ul id="CD015025-list-0034"> <li> <p>participants discharged alive.</p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>Serious adverse events during the study period.</p> </li> <li> <p>Any adverse events during the study period.</p> </li> <li> <p>Cardiac arrhythmias during the study period.</p> </li> </ul> </p> </section> <section id="CD015025-sec-0046"> <h6 class="title">Outpatients with asymptomatic or mild COVID‐19</h6> <p> <ul id="CD015025-list-0035"> <li> <p>All‐cause mortality​​​​​​; all‐cause mortality at longest follow‐up and &gt; 60 days most favourable; if not reported all‐cause mortality day 60, followed by day 28, or time‐to‐event estimate, will be included in the summary of findings table. </p> </li> <li> <p>Admission to hospital or death within 28 days</p> </li> <li> <p>Symptom resolution:</p> <ul id="CD015025-list-0036"> <li> <p>all initial symptoms resolved (asymptomatic) at day 14;</p> </li> <li> <p>duration to symptom resolution.</p> </li> </ul> </li> <li> <p>Quality of life at longest follow‐up available.</p> </li> <li> <p>Serious adverse events during the study period.</p> </li> <li> <p>Any adverse events during the study period.</p> </li> <li> <p>Cardiac arrhythmias during the study period.</p> </li> </ul> </p> </section> </section> <section id="CD015025-sec-0047"> <h5 class="title">Assessment of the certainty in the evidence</h5> <p>We used the GRADE approach to assess the certainty in the evidence for the outcomes listed in the previous section. </p> <p>The GRADE approach uses five domains (risk of bias, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty in the body of evidence for each prioritised outcome.  </p> <p>We downgraded our certainty of evidence for:</p> <p> <ul id="CD015025-list-0037"> <li> <p>serious (‐1) or very serious (‐ 2) risk of bias;</p> </li> <li> <p>serious (‐1) or very serious (‐ 2) inconsistency;</p> </li> <li> <p>serious (‐1) or very serious (‐ 2) uncertainty about directness;</p> </li> <li> <p>serious (‐1) or very serious (‐ 2) imprecise or sparse data;</p> </li> <li> <p>serious (‐1) or very serious (‐ 2) probability of reporting bias.</p> </li> </ul> </p> <p>The GRADE system used the following criteria for assigning grade of evidence.</p> <p> <ul id="CD015025-list-0038"> <li> <p>High: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>We followed the current GRADE guidance for these assessments in its entirety as recommended in the Cochrane Handbook for Systematic Reviews of Interventions, Chapter 14 (<a href="./references#CD015025-bbs2-0159" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>). </p> <p>We used the overall risk of bias judgement, derived from the RoB 2 Excel tool, to inform our decision on downgrading for risk of bias. We phrased the findings and certainty in the evidence as suggested in the informative statement guidance (<a href="./references#CD015025-bbs2-0158" title="SantessoN , GlentonC , DahmP , GarnerP , Akl A, AlperB , et al. GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions. Journal of Clinical Epidemiology2020;119:126-35. [DOI: 10.1016/j.jclinepi.2019.10.014]">Santesso 2020</a>). </p> </section> <section id="CD015025-sec-0048"> <h5 class="title">Methods for future updates</h5> <section id="CD015025-sec-0049"> <h6 class="title">Living systematic review considerations</h6> <p>Our information specialist (MIM) will provide us with new search records each week, which two review authors will screen, extract, evaluate, and integrate following the guidance for Cochrane living systematic reviews (<a href="./references#CD015025-bbs2-0117" title="Guidance for the production and publication of Cochrane living systematic reviews: Cochrane Reviews in living mode.. Available from community.cochrane.org/review-production/production-resources/living-systematic-reviews (accessed 22 March 2021).">Cochrane LSR</a>). </p> <p>We will manually check platform trials that were previously identified and listed as 'studies awaiting classification' for additional treatment arms. </p> <p>We will wait until the accumulating evidence changes our conclusions of the implications of research and practice before republishing the review. We will consider one or more of the following components to inform this decision. </p> <p> <ul id="CD015025-list-0039"> <li> <p>The findings of one or more prioritised outcomes</p> </li> <li> <p>The credibility (e.g. GRADE rating) of one or more prioritised outcomes</p> </li> <li> <p>New settings, populations, interventions, comparisons or outcomes studied.</p> </li> </ul> </p> <p>In case of emerging policy relevance because of global controversies around the intervention, we will consider republishing an updated review even though our conclusions remain unchanged. We will review the review scope and methods approximately monthly, or more frequently if appropriate, in light of potential changes in COVID‐19 research (for example, when additional comparisons, interventions, subgroups or outcomes, or new review methods become available). </p> </section> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015025-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015025-sec-0050"></div> <section id="CD015025-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD015025-sec-0052"> <h4 class="title">Results of the search</h4> <p>The literature search resulted in 3733 records. Three records were additionally identified via han search of reference lists, resulting in overall 3736 records. After removing duplicates, 1781 records remained. During title and abstract screening 1633 records were judged as irrelevant. We proceeded to full text screening with 148 records, considering published full texts or if these were not available, trial register entries. 77 records related to 64 studies were excluded after full‐text assessment. Three studies were cancelled before starting patient recruitment. 25 studies investigated a combined treatment including an antibiotic plus another intervention, nine studies used an active comparator without proven efficacy, and one study analysed a wrong study population including patients in recovery phase after surviving COVID‐19. Furthermore, 10 studies were not RCTs and 16 studies turned out to focus on another intervention than antibiotics. We identified 19 ongoing studies with 24 records and 15 studies with 21 records awaiting assessment. Finally, we included 11 studies with 26 records in our qualitative synthesis, with 10 studies being eligible for meta‐analyses, of which nine studies contributed data to the primary outcomes of this review. The search process is visualised in <a href="#CD015025-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD015025-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD015025-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> </section> <section id="CD015025-sec-0053"> <h4 class="title">Designs of the studies and publication status</h4> <p>The characteristics of including studies are available in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a> section. </p> <p>We included 11 studies describing 11,281 adult participants randomised to study arms relevant for the review question (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Eight studies had an open‐label design (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>), two studies were placebo‐controlled and double‐ (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) or quadruple‐blinded (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>), and one study did not sufficiently report on its blinding method (<a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). Seven studies were performed as multi‐centre studies in Brazil (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>), UK (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>), USA (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>), and Qatar (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>).<br/>The remaining four studies were performed as single‐centre studies in Egypt (<a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>), Iran (<a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>), Turkey (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>), and the USA (<a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). Two studies were prematurely terminated due to poor recruitment and enrolled 11 and 20 participants, respectively (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). The smallest regularly completed study was <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a> with 24 randomised participants, and <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> was the largest trial with a sample size of 7763 participants. The remaining studies ranged in sizes between 111 (<a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>) and 1415 participants (<a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). </p> <p>Two studies were published as preprint articles by the end of July 2021 (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>), the two prematurely terminated trials posted their results in the trial registry (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). The remaining seven studies were available as publications in indexed journals. </p> <p>Except for one study with a retrospective trial registry entry (<a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>) and another one with neither any publicly available protocol nor registry entry (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>), all included studies registered a study protocol prospectively. </p> <p>All studies reported information on the responsible ethics committee. However, five publications did not provide any approval reference number (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>).  </p> <p>Four studies were partially or fully funded by pharmaceutical companies producing or distributing azithromycin, including EMS Pharma (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>), Novartis Pharmaceuticals (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>), Pfizer Inc. (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>) and six studies were solely funded by departmental or governmental resources as well as non‐profit organisations (<a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). One study did not report its funding source (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>). </p> </section> <section id="CD015025-sec-0054"> <h4 class="title">Participants</h4> <p>Four of the 11 eligible studies used antibiotics for treating mild COVID‐19 cases in outpatient settings (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). Of those outpatient trials, only one also included asymptomatic participants (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>), while the other three investigated ambulatory treatment exclusively in participants presenting COVID‐19 symptoms. </p> <p>The majority of the seven studies conducted in the inpatient settings included moderately ill participants according to WHO 4 to 5 (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Only <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> and <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> included participants with moderate to severe COVID‐19 according to WHO scale 4 to 7. </p> <p>Five trials included participants with suspected or test‐confirmed SARS‐CoV‐2 infection (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). The exact rates of negative or unknown RT‐PCR test results are recorded in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a> section for each study. For <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>, <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a> and <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>, data for all outcomes of interest for our meta‐analyses were reported separately for RT‐PCR confirmed SARS‐CoV‐2 infections, either in the publication or via personal communication with the study authors. <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported efficacy outcomes for the SARS‐CoV‐2 positive subgroup, however the study's safety outcomes were only reported for the overall population which included 11% of participants with negative RT‐PCR result. The largest eligible study reported data for all outcomes for the overall population only, which included 8.5% of participants with a negative or unknown RT‐PCR result (<a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). The authors of  <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> nor <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> did not provide a subset of outcome data for confirmed diagnosis upon request. </p> <p>Except for <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a> who gave very little information on eligibility criteria, all included studies listed pre‐existing QT‐prolongation or electrocardiogram (ECG) abnormalities observed prior to the trial initiation as exclusion criteria to secure patient safety in the face of macrolides’ known proarrhythmic potential. </p> <p>The overall population mean age of the included studies was 54 years. <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> included the youngest participants with a population mean age of 41 years. <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> included the oldest participants with a population mean age of 65 years. The mean proportion of males in all included studies was 64%. The lowest proportion of males was included in <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a> with 43% males, while <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> included the highest proportion with 98% males.<br/>Co‐morbidities and relevant risk factors such as obesity, diabetes, respiratory diseases and hypertension were partially reported by the included studies and listed in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a>. In one study, existing co‐morbidities were excluded and partially specified in the inclusion and exclusion criteria (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). Five studies did not report data on risk factors in their publications or study reports (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). </p> </section> <section id="CD015025-sec-0055"> <h4 class="title">Interventions and comparators</h4> <p>All 11 included studies investigated azithromycin. All outpatient studies administered azithromycin orally, while four of the seven inpatient studies additionally allowed nasogastric (<a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>) or nasogastric and intravenous application (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>;  <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). The first day's dosage was consistently defined as 500 mg. Further doses and duration of treatment varied between studies. After day one, most studies exceeded usual dosage of azithromycin for bacterial infections which is defined as 250 mg per day on days 2 to 5. <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>, <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>, <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a> and <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> used exactly that regimen, while the remaining seven studies proceeded with 500 mg daily. The shortest duration was 500 mg per day for three days in <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>, whereas the longest time period was 500 mg per day for 14 days (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>). With five days <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a> ranged in between those time periods, as well as <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> and <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a> with seven days and <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> and <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> with 10 days of treatment duration. </p> <p>Apart from two studies that used azithromycin‐placebo tablets (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>), the antibiotic was compared with standard of care alone. Hydroxychloroquine was used as part of the standard of care treatment in all study arms of six included studies (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Three studies did not include hydroxychloroquine, but other active treatments such as corticosteroids (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>); although <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a> indicated similar proceedings (‘standard of care according to the NICE guideline’), no details of utilised substances were provided. Standard of care varied between the included studies, but was comparable between the study arms of the individual studies. </p> <p><a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a> compared azithromycin with lincomycin, another antibiotic, which was administered orally 600 mg twice daily for 5 days. The second study investigating another antibiotic than azithromycin was <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>. This study had three arms investigating azithromycin or clarithromycin (500 mg twice daily for 7 days) compared to supportive care only. </p> <p>No studies were identified that compared antibiotics with an active comparator with proven efficacy. </p> </section> <section id="CD015025-sec-0056"> <h4 class="title">Outcome measures</h4> <p>Neither of the studies comparing azithromycin to another antibiotic reported our defined primary outcomes. <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a> focused on duration of individual symptoms and time to PCR negativity, but did not report any relevant outcomes for this review. <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a> provided data on PCR‐negativity at day 6 only, which was eligible for our secondary outcome viral clearance up to seven days. Ten studies where included in the meta‐analysis, from which only nine studies contributed data to the primary outcomes of this review. </p> <p>All‐cause mortality at 28 days was reported by four studies in inpatients settings (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>) and three studies in outpatient settings (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>).  </p> <p>One study in the inpatient setting reported data assessing clinical worsening by participants with new need for invasive mechanical ventilation or death at day 28 (<a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). Three studies in outpatient settings reported data for ‘admission to hospital or death within 28 days’, the equivalent outcome for ambulant patients (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). </p> <p>Improvement of clinical status was reported by three studies in the inpatient setting as ‘patients discharged without respiratory deterioration or death at 28 days’ (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). In the outpatient setting, two studies reported improvement of clinical status as participants with all initial symptoms resolved at 28 days (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>), additionally <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> reported this outcome for day 14 as well.  </p> <p>Four studies in the inpatient setting reported the number of participants with serious adverse events during the study period, which ranged from 15 to 60 days (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). Two studies reported this safety outcome in the outpatient setting including study durations of 21 and 28 days (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). Regarding adverse events of any grade, three studies provided data for inpatients during the study period, which was followed up for a maximum of 60 days overall for this outcome (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). No study reported usable data this outcome for outpatients. </p> <p>Five studies investigating hospitalised patients reported the number of participants with ‘cardiac arrhythmias during the study period’ employing slightly varying though equally relevant definitions (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). </p> <p>None of the included studies reported data for the primary outcome ‘duration to symptom resolution’ and ‘cardiac arrhythmias during the study period’ in the outpatient setting. Neither of the eligible inpatient nor outpatient studies reported data on quality of life or any efficacy outcome at day 60. </p> <p>We defined a set of secondary outcomes for both healthcare settings which are not presented in the summary of findings tables. If data were available for those outcomes, we report the effect estimates in the <a href="#CD015025-sec-0065">Effects of interventions</a> section and list further details of the meta‐analyses in <a href="#CD015025-tbl-0003">Table 1</a> and <a href="#CD015025-tbl-0004">Table 2</a>. </p> <div class="table" id="CD015025-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measures of heterogeneity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New need for invasive mechanical ventilation at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65 </b><br/>(0.16 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7422</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 0.64; Chi² = 1.57, df = 1 (P = 0.21); I² = 36%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventilator‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.10</b><br/>(‐1.16 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New need for non‐invasive mechanical ventilation or high flow at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.78 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4073</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weaning or liberation from invasive mechanical ventilation in surviving patients at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.11</b><br/>(0.85 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liberation from supplemental oxygen in surviving patients at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b><br/>(0.67 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for dialysis at up to 28 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.03</b><br/>(0.85 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8052</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 0.00; Chi² = 1.27, df = 1 (P = 0.26); I² = 21%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to the intensive care unit (ICU) at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.28 </b><br/>(0.06 to 1.29 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.61</b> <br/>(‐2.58 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 1.61; Chi² = 5.37, df = 2 (P = 0.07); I² = 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.50</b><br/>(0.35 to 6.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospital‐acquired infections at up to 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16 </b><br/>(0.90 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>MD:</b> mean difference <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD015025-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measures of heterogeneity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for invasive mechanical ventilation at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61 </b><br/>(0.11 to 3.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for hospitalisation with need for oxygen by mask or nasal prongs at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b><br/>(0.29 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>406</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83 </b><br/>(0.44 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD015025-sec-0057"> <h4 class="title">Ongoing studies</h4> <p>The characteristics of ongoing studies are available in the <a href="./references#CD015025-sec-0132" title="">Characteristics of ongoing studies</a> section. </p> <p>We classified a total of 19 studies as ongoing. 12 studies which are still active, either currently recruiting or not yet recruiting, and compare azithromycin with standard of care alone (<a href="./references#CD015025-bbs2-0091" title="AkramJ , AzharS , ShahzadM , LatifW , KhanKS . Pakistan Randomized and Observational Trial to Evaluate Coronavirus Treatment (PROTECT) of hydroxychloroquine, oseltamivir and azithromycin to treat newly diagnosed patients with COVID-19 infection who have no comorbidities like diabetes mellitus: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21(1):702. [DOI: 10.1186/s13063-020-04616-4]NCT04338698. Hydroxychloroquine, oseltamivir and azithromycin for the trreatment of COVID-19 Infection: an RCT (PROTECT). clinicaltrials.gov/ct2/show/NCT04338698 (first received 8 April 2020). ">Akram 2020</a>; <a href="./references#CD015025-bbs2-0093" title="CTRI/2020/04/024904. Treatment of COVID19: a randomised controlled trial. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=43130&amp;EncHid=&amp;modid=&amp;compid=%27,%2743130det%27 (first received 28 April 2020). ">CTRI/2020/04/024904</a>; <a href="./references#CD015025-bbs2-0095" title="EUCTR-2020-001527-14/NL. COVID-19: addition of azithromycin to chloroquine treatment. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001527-14/NL (first received 6 April 2020). ">EUCTR‐2020‐001527‐14/NL</a>;  <a href="./references#CD015025-bbs2-0096" title="NCT04328272. Effectiveness of hydroxychloroquine in Covid-19 patients. clinicaltrials.gov/ct2/show/study/NCT04328272 (first received 31 March 2020). ">NCT04328272</a>; <a href="./references#CD015025-bbs2-0098" title="NCT04336332. Randomized comparison of combination azithromycin and hydroxychloroquine vs. hydroxychloroquine alone for the treatment of confirmed COVID-19. clinicaltrials.gov/ct2/show/NCT04336332 (first received 7 April 2020). ">NCT04336332</a>; <a href="./references#CD015025-bbs2-0100" title="NCT04344444. Treatment in patients With suspected or confirmed COVID-19 with early moderate or severe disease (RCT). clinicaltrials.gov/ct2/show/NCT04344444 (first received 14 April 2020). ">NCT04344444</a>; <a href="./references#CD015025-bbs2-0101" title="NCT04359316. Azithromycin in hospitalized COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04359316 (first received 24 April 2020). ">NCT04359316</a>; <a href="./references#CD015025-bbs2-0102" title="EUCTR-2020-001303-16/FR. Efficacy of hydroxychloroquine, telmisartan and azithromycin on survival in elderly hospitalized patients with VIDOC-19: a randomized, multi-centre, adaptive, blinded study. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001303-16/FR (first received 29 March 2020). NCT04359953. Efficacy of hydroxychloroquine, telmisartan and azithromycin on the survival of hospitalized elderly patients with COVID-19 (COVID-Aging). clinicaltrials.gov/ct2/show/study/NCT04359953 (first received 24 April 2020). ">NCT04359953</a>; <a href="./references#CD015025-bbs2-0103" title="NCT04363060. Azithromycin+amoxicillin/clavulanate vs amoxicillin/clavulanate in COVID19 patients with pneumonia in non-intensive unit (AziA). clinicaltrials.gov/ct2/show/NCT04363060 (first received 27 April 2020). ">NCT04363060</a>; <a href="./references#CD015025-bbs2-0105" title="NCT04371107. Proactive care of ambulatory COVID19 patients (AMBU-COVID). clinicaltrials.gov/ct2/show/NCT04371107 (first received 1 May 2020). ">NCT04371107</a>; <a href="./references#CD015025-bbs2-0107" title="NCT04405921. Hydroxychloroquine, azithromycin in the treatment of Covid-19 (PACTT). clinicaltrials.gov/ct2/show/NCT04405921 (first received 28 May 2020). ">NCT04405921</a>), except for one trial using placebo (<a href="./references#CD015025-bbs2-0097" title="NCT04332107. Azithromycin for COVID-19 Treatment In Outpatients Nationwide (ACTION). clinicaltrials.gov/ct2/show/NCT04332107 (first 2 April 2020). ">NCT04332107</a>). Those studies evaluate primarily inpatients with between 40 and 2271 participants, completion date according to the trial registries lies in the past (2020) for five studies, another five studies should be finished during the course of 2021, and another two studies did not give information on a planned completion date. </p> <p>The large platform trial REMAP‐CAP, evaluating 71,00 participants, plans to investigate a range of different antibiotics and indicates its overall completion date for 2023 (<a href="./references#CD015025-bbs2-0092" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , vanBentum-PuijkW , et al. The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]EUCTR-2015-002340-14. Adaptive trial in severe pneumonia (REMAP-CAP) - Version 23.0. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14 (first received 13 July 2020). ISRCTN67000769. An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19. isrctn.com/ISRCTN67000769 (first received 9 July 2020). NCT02735707. Randomized, Embedded, Multifactorial Adaptive Platform trial for community- Acquired Pneumonia (REMAP-CAP) with sub-platform REMAP-COVID. clinicaltrials.gov/ct2/show/NCT02735707 (protocol for sub-platform REMAP-COVID first received 25 March 2020). ">Angus 2020</a>). </p> <p>Four trials evaluating between 94 and 330 participants investigate other antibiotics than azithromycin with the last one to be finished in 2022. Two trials in the outpatient setting compare doxycycline with placebo or standard of care alone, one study is not yet recruiting (<a href="./references#CD015025-bbs2-0106" title="NCT04371952. DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19). clinicaltrials.gov/ct2/show/NCT04371952 (first received 1 May 2020). ">NCT04371952</a>), and the other study is currently still recruiting (<a href="./references#CD015025-bbs2-0109" title="NCT04729140. An outpatientc linical trial using ivermectin and doxycycline in COVID-19 positive patients at high risk to prevent COVID-19 related hospitalization. clinicaltrials.gov/ct2/show/NCT04729140 (first received 28 January 2021). ">NCT04729140</a>). Another two trials use cotrimoxazol as antibiotic intervention in an inpatient setting, one recruiting (<a href="./references#CD015025-bbs2-0094" title="CTRI/2020/10/028297. Cotrimoxazole in hospitalised patients with moderate to early-severe COVID-19 infection. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=48268&amp;EncHid=&amp;modid=&amp;compid=%27,%2748268det%27 (first received 8 October 2020). ">CTRI/2020/10/028297</a>) and the other not yet recruiting (<a href="./references#CD015025-bbs2-0108" title="NCT04470531. Role of co-trimoxazole in severe COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04470531 (first received 14 July 2020). ">NCT04470531</a>). </p> <p>Two trials evaluating azithromycin in 300 and 500 participants have been suspended, from the information in their registry entry it remains unclear if they will be terminated or resume patient recruitment (<a href="./references#CD015025-bbs2-0104" title="NCT04363203. VA Remote and Equitable Access to COVID-19 Healthcare delivery (VA-REACH TRIAL). clinicaltrials.gov/ct2/show/NCT04363203 (first received 27 April 2020). ">NCT04363203</a>; <a href="./references#CD015025-bbs2-0099" title="NCT04341727. Hydroxychloroquine, hydroxychloroquine, azithromycin in the treatment of SARS CoV-2 Infection (WU352). clinicaltrials.gov/ct2/show/NCT04341727 (first received 10 April 2020). ">NCT04341727</a>). </p> </section> <section id="CD015025-sec-0058"> <h4 class="title">Studies awaiting classification</h4> <p>The characteristics of studies awaiting classification are available in the <a href="./references#CD015025-sec-0131" title="">Characteristics of studies awaiting classification</a> section. </p> <p>Fifteen studies are awaiting classification until either publication of results, a protocol update or clarification of details by the study authors. If eligible eventually, they will be considered in the next review update (<a href="./references#CD015025-bbs2-0076" title="DuskaF , WaldaufP , HalacovaM , ZvonicekV , BalaJ , BalikM , et al. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU. Trials2020;21(1):631. [DOI: 10.1186/s13063-020-04566-x]EUCTR-2020-001456-18/CZ. Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19)-Randomised Controlled Trial, phase III. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001456-18/CZ (first received 8 April 2020). NCT04339816. Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial (AZIQUINE-ICU). clinicaltrials.gov/ct2/show/NCT04339816 (first received 9 April 2020). ">Duska 2020</a>; <a href="./references#CD015025-bbs2-0077" title="2020-001156-18/ES. Efficacy of different treatments in patients infected with COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES (first received 3 April 2020). ">EUCTR‐2020‐001156‐18/ES</a>; <a href="./references#CD015025-bbs2-0078" title="2020-001606-33/ES. Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES (fist received 7 April 2020). ">EUCTR‐2020‐001606‐33/ES</a>; <a href="./references#CD015025-bbs2-0079" title="EUCTR-2020-001265-36/IE. A trial to compare standard of care (SOC) alone with SOC plus hydroxychloroquine or SOC with a combination of hydroxycholorquine and azithromysin in the treatment of coronovirus. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001265-36/IE (first received 7 April 2020). FeeneyE , WallaceD , CotterA , TinagoW , McCarthyC , KeaneD , et al. The COVIRL-001 trial: a multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):430. [DOI: 10.1186/s13063-020-04407-x]">Feeney 2020</a>; <a href="./references#CD015025-bbs2-0080" title="EUCTR-2020-001614-38/BE. Covid-19: a randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE (first received 27 March 2020). GyselinckI , LiesenborgsL , LandeloosE , BelmansA , VerbekeG , VerhammeP , et al. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials2021;22(1):126. [DOI: 10.1186/s13063-021-05033-x]">Gyselinck 2021</a>; <a href="./references#CD015025-bbs2-0081" title="IRCT20080901001165N50. Investigating the efficacy and safety of azithromycin inhaled spray in controlling the symptoms of patients with COVID-19. en.irct.ir/trial/47576 (first received 1 May 2020). ">IRCT20080901001165N50</a>; <a href="./references#CD015025-bbs2-0082" title="IRCT20191211045691N2. Evaluation of the efficacy and safety of doxycycline in combination with standard treatment in Covid-19 patients: a clinical trial. irct.ir/trial/51951 (first received 2 November 2020). ">IRCT20191211045691N2</a>; <a href="./references#CD015025-bbs2-0083" title="IRCT20200428047228N2. Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit. en.irct.ir/trial/48096 (first received 10 June 2020). ">IRCT20200428047228N2</a>; <a href="./references#CD015025-bbs2-0084" title="IRCT20200608047686N1. Evaluation of therapeutic effects of metronidazole In inpatients with pneuomonia due to COVID-19. en.irct.ir/trial/48717 (first received 30 June 2020). ">IRCT20200608047686N1</a>; <a href="./references#CD015025-bbs2-0085" title="IRCT20200718048129N1. Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caugh caused by COVID-19 in recovery phase. en.irct.ir/trial/49729 (first received 11 August 2020). ">IRCT20200718048129N1</a>; <a href="./references#CD015025-bbs2-0086" title="EUCTR-2020-001406-27/FR. Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001406-27/FR (first received 3 April 2020). University Hospital Montpellier. Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial). clinicaltrials.gov/ct2/show/NCT04345861 (first received 15 April 2020). ">NCT04345861</a>; <a href="./references#CD015025-bbs2-0087" title="NCT04370782. Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting. clinicaltrials.gov/ct2/show/NCT04370782 (first received 1 May 2020). ">NCT04370782</a>; <a href="./references#CD015025-bbs2-0088" title="Purwati, Budiono, RachmanBE , Yulistiani, MiatmokoA , Nasronudin, et al. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo. Biochemistry Research International2021;2021:6685921. [DOI: 10.1155/2021/6685921]">Purwati 2021</a>; <a href="./references#CD015025-bbs2-0089" title="SayedAM , KhalafAM , AbdelrahimMEA , ElgendyMO . Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. International Journal of Clinical Practice 17 December 2020 [Epub ahead of print]. [DOI: 10.1111/ijcp.13877]">Sayed 2020</a>; <a href="./references#CD015025-bbs2-0090" title="jRCTs071210011. CAM (Clarithromycin) Effectivity for COVID-19 pneumonia which does not require oxygen administration; multicenter, randomized-controlled, open-label, 3-armed parallel group comparison, exploratory trial. https://jrct.niph.go.jp/latest-detail/jRCTs071210011 (first received 13 April 2021). YamamotoK , HosogayaN , SakamotoN , YoshidaH , IshiiH , YateraK , et al. Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study). medrxiv.org/content/10.1101/2021.06.02.21258257v1.full-text (first posted 5 June 2021). [DOI: 10.1101/2021.06.02.21258257]">Yamamoto 2021</a>). Two studies had already been published their results in journal articles. However, despite using the term 'randomised controlled trial', we could not find sufficient details on fulfilment of a genuine randomisation process nor any study protocol that allowed us to classify those studies as RCTs (<a href="./references#CD015025-bbs2-0088" title="Purwati, Budiono, RachmanBE , Yulistiani, MiatmokoA , Nasronudin, et al. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo. Biochemistry Research International2021;2021:6685921. [DOI: 10.1155/2021/6685921]">Purwati 2021</a>; <a href="./references#CD015025-bbs2-0089" title="SayedAM , KhalafAM , AbdelrahimMEA , ElgendyMO . Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. International Journal of Clinical Practice 17 December 2020 [Epub ahead of print]. [DOI: 10.1111/ijcp.13877]">Sayed 2020</a>). Authors were given a chance to clarify and adjust this assessment through personal communication, though we have not received any response at the time of review publication. We identified six completed and three prematurely terminated, but potentially eligible RCTs from trial register entries, but no results are available or have been published yet. Four of those studies investigated oral azithromycin versus placebo or standard of care alone in a total of 317 participants in an inpatient setting (<a href="./references#CD015025-bbs2-0076" title="DuskaF , WaldaufP , HalacovaM , ZvonicekV , BalaJ , BalikM , et al. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU. Trials2020;21(1):631. [DOI: 10.1186/s13063-020-04566-x]EUCTR-2020-001456-18/CZ. Azithromycin added to Hydrochloroquine in Patients Admitted to Intensive Care due to Coronavirus Disease 2019 (COVID-19)-Randomised Controlled Trial, phase III. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001456-18/CZ (first received 8 April 2020). NCT04339816. Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial (AZIQUINE-ICU). clinicaltrials.gov/ct2/show/NCT04339816 (first received 9 April 2020). ">Duska 2020</a>; <a href="./references#CD015025-bbs2-0079" title="EUCTR-2020-001265-36/IE. A trial to compare standard of care (SOC) alone with SOC plus hydroxychloroquine or SOC with a combination of hydroxycholorquine and azithromysin in the treatment of coronovirus. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001265-36/IE (first received 7 April 2020). FeeneyE , WallaceD , CotterA , TinagoW , McCarthyC , KeaneD , et al. The COVIRL-001 trial: a multicentre, prospective, randomised trial comparing standard of care (SOC) alone, SOC plus hydroxychloroquine monotherapy or SOC plus a combination of hydroxychloroquine and azithromycin in the treatment of non- critical, SARS-CoV-2 PCR-positive population not requiring immediate resuscitation or ventilation but who have evidence of clinical decline: a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):430. [DOI: 10.1186/s13063-020-04407-x]">Feeney 2020</a>; <a href="./references#CD015025-bbs2-0083" title="IRCT20200428047228N2. Evaluation of the efficiency of hydroxychloroquine drug regimen in comparison with hydroxychloroquine + azithromycin in hospitalized patients with covid-19 in the intensive care unit. en.irct.ir/trial/48096 (first received 10 June 2020). ">IRCT20200428047228N2</a>; <a href="./references#CD015025-bbs2-0086" title="EUCTR-2020-001406-27/FR. Randomized open label trial assessing efficacy and safety of hydroxychloroquine plus azithromycin versus hydroxychloroquine for hospitalized patients with COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001406-27/FR (first received 3 April 2020). University Hospital Montpellier. Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial). clinicaltrials.gov/ct2/show/NCT04345861 (first received 15 April 2020). ">NCT04345861</a>), one study including 80 patients applied azithromycin via an intranasal spray (<a href="./references#CD015025-bbs2-0081" title="IRCT20080901001165N50. Investigating the efficacy and safety of azithromycin inhaled spray in controlling the symptoms of patients with COVID-19. en.irct.ir/trial/47576 (first received 1 May 2020). ">IRCT20080901001165N50</a>). Another three completed studies investigated various other antibiotics like clarithromycin (<a href="./references#CD015025-bbs2-0085" title="IRCT20200718048129N1. Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caugh caused by COVID-19 in recovery phase. en.irct.ir/trial/49729 (first received 11 August 2020). ">IRCT20200718048129N1</a>; 45 outpatients), doxycycline (<a href="./references#CD015025-bbs2-0082" title="IRCT20191211045691N2. Evaluation of the efficacy and safety of doxycycline in combination with standard treatment in Covid-19 patients: a clinical trial. irct.ir/trial/51951 (first received 2 November 2020). ">IRCT20191211045691N2</a>; 60 inpatients) or metronidazole (<a href="./references#CD015025-bbs2-0084" title="IRCT20200608047686N1. Evaluation of therapeutic effects of metronidazole In inpatients with pneuomonia due to COVID-19. en.irct.ir/trial/48717 (first received 30 June 2020). ">IRCT20200608047686N1</a>; 39 inpatients) versus standard of care alone. One study with completed recruitment compared azithromycin to doxycycline in 18 outpatients (<a href="./references#CD015025-bbs2-0087" title="NCT04370782. Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting. clinicaltrials.gov/ct2/show/NCT04370782 (first received 1 May 2020). ">NCT04370782</a>). Another four studies are not explicit enough in their protocol to make a final decision on eligibility. Those studies have not reported a clear description of the type of control intervention used as comparator or in case of standard of care as control it remained unclear if this was administered in all study arms equally (<a href="./references#CD015025-bbs2-0077" title="2020-001156-18/ES. Efficacy of different treatments in patients infected with COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001156-18/ES (first received 3 April 2020). ">EUCTR‐2020‐001156‐18/ES</a>; <a href="./references#CD015025-bbs2-0078" title="2020-001606-33/ES. Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001606-33/ES (fist received 7 April 2020). ">EUCTR‐2020‐001606‐33/ES</a>; <a href="./references#CD015025-bbs2-0080" title="EUCTR-2020-001614-38/BE. Covid-19: a randomized, open-label, adaptive, proof-of- concept clinical trial of new antiviral drug candidates against SARS-CoV-2. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001243-15/BE (first received 27 March 2020). GyselinckI , LiesenborgsL , LandeloosE , BelmansA , VerbekeG , VerhammeP , et al. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial. Trials2021;22(1):126. [DOI: 10.1186/s13063-021-05033-x]">Gyselinck 2021</a>; <a href="./references#CD015025-bbs2-0090" title="jRCTs071210011. CAM (Clarithromycin) Effectivity for COVID-19 pneumonia which does not require oxygen administration; multicenter, randomized-controlled, open-label, 3-armed parallel group comparison, exploratory trial. https://jrct.niph.go.jp/latest-detail/jRCTs071210011 (first received 13 April 2021). YamamotoK , HosogayaN , SakamotoN , YoshidaH , IshiiH , YateraK , et al. Efficacy of clarithromycin on COVID-19 pneumonia without oxygen administration; protocol for multicenter, open-label, randomized-controlled, 3-armed parallel group comparison, exploratory trial (CAME COVID study). medrxiv.org/content/10.1101/2021.06.02.21258257v1.full-text (first posted 5 June 2021). [DOI: 10.1101/2021.06.02.21258257]">Yamamoto 2021</a>). </p> </section> <section id="CD015025-sec-0059"> <h4 class="title">Excluded studies</h4> <p>The characteristics of excluded studies are available in the <a href="./references#CD015025-sec-0130" title="">Characteristics of excluded studies</a> section. </p> <p>We excluded 64 studies that did not match our inclusion criteria. Three studies were withdrawn before enrolling patients, therefore, we did not expect any interim results to be published in the future (<a href="./references#CD015025-bbs2-0044" title="NCT04365582. Outpatient treatment of COVID-19 in patients with risk factor for poor outcome. clinicaltrials.gov/ct2/show/NCT04365582 (first received 28 April 2020). ">NCT04365582</a>; <a href="./references#CD015025-bbs2-0057" title="NCT04433078. RepurpoSing old drugs TO SuppRess a Modern threat: COVID-19 STORM. clinicaltrials.gov/ct2/show/study/NCT04433078 (first received 16 June 2020). ">NCT04433078</a>; <a href="./references#CD015025-bbs2-0063" title="NCT04575558. HOPE: a trial of Hydroxichloroquine plus azithromycin in high risk COVID-19 (HOPE_BRAZIL). clinicaltrials.gov/ct2/show/NCT04575558 (first received 5 October 2020). ">NCT04575558</a>). Twenty‐five studies evaluated a combination of antibiotics with other treatments that were different between groups (<a href="./references#CD015025-bbs2-0013" title="AhmedS , KarimMM , RossAG , Hossain MS, ClemensJD , SumiyaMK , et al. A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness. International Journal of Infectious Diseases2020;103:214-6. [DOI: https://doi.org/10.1016/j.ijid.2020.11.191]">Ahmed 2020</a>; <a href="./references#CD015025-bbs2-0017" title="ChowdhuryATMM , ShahbazM , KarimR , IslamJ , DanG , HeS . A comparative study on ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients. Eurasian Journal of Medicine and Oncology2021;5(1):63-70. [DOI: 10.14744/ejmo.2021.16263]">Chowdhury 2021</a>; <a href="./references#CD015025-bbs2-0025" title="HashimHA , MauloodMF , RasheedAM , FatakDF , KabahKK , AbdulamirAS . Controlled randomized clinical trial on using Ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq. medrxiv.org/content/10.1101/2020.10.26.20219345v1 (first posted 27 October 2020). [DOI: 10.1101/2020.10.26.20219345]NCT04591600. Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients. clinicaltrials.gov/ct2/show/NCT04591600 (first received 19 October 2020). ">Hashim 2020</a>; <a href="./references#CD015025-bbs2-0026" title="IRCT20200418047121N1. Study of the effectiveness of concomitant use of vitamin C, metformin, azithromycin and doxycycline on improving patients with COVID-19. en.irct.ir/trial/47578 (first received 1 May 2020). ">IRCT20200418047121N1</a>; <a href="./references#CD015025-bbs2-0028" title="jRCT2071200109. FOY-305-03:Thorough QT study of FOY-305 in healthy adult subjects(COVID-19). https://jrct.niph.go.jp/latest-detail/jRCT2071200109 (first received 8 March 2021). ">jRCT2071200109</a>; <a href="./references#CD015025-bbs2-0029" title="Mahmud R , Rahman M , Alam I , Ahmed KG , Humayon Kabir AK , Jakaria Been Sayeed SK, et al. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial. Journal of International Medical Research2021;49(5):1-14. [DOI: 10.1177/03000605211013550]NCT04523831. Clinical Trial of ivermectin plus doxycycline for the treatment of confirmed Covid-19 infection. clinicaltrials.gov/ct2/show/results/NCT04523831 (first received 24 August 2020). ">Mahmud 2021</a>; <a href="./references#CD015025-bbs2-0035" title="NCT04334512. A study of quintuple therapy to treat COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04334512 (first received 6 April 2020). ">NCT04334512</a>; <a href="./references#CD015025-bbs2-0037" title="NCT04341870. Study of immune modulatory Ddugs and other treatments in COVID-19 patients: sarilumab, azithromycin, hydroxychloroquine trial - CORIMUNO-19 - VIRO (CORIMUNO-VIRO). clinicaltrials.gov/ct2/show/NCT04341870 (first received 10 April 2020). ">NCT04341870</a>; <a href="./references#CD015025-bbs2-0039" title="NCT04354597. Hydroxychloroquine and azithromycin as prophylaxis forhHealthcare workers dealing with COVID19 patients (MOPHYDA). clinicaltrials.gov/ct2/show/NCT04354597 (first received 21 April 2020). ">NCT04354597</a>; <a href="./references#CD015025-bbs2-0041" title="NCT04358068. Evaluating the efficacy of hydroxychloroquine and azithromycin to prevent hospitalization or death in persons With COVID-19. clinicaltrials.gov/ct2/show/study/NCT04358068 (first received 22 April 2020). ">NCT04358068</a>; <a href="./references#CD015025-bbs2-0043" title="NCT04365231. Hydroxychloroquine azithromycin COVID-19 pregnancy trial (HASCOPT). clinicaltrials.gov/ct2/show/NCT04365231 (first received 28 April 2020). ">NCT04365231</a>; <a href="./references#CD015025-bbs2-0045" title="NCT04371406. Efficacy of azithromycin-associated hydroxychloroquine therapy given in general practice in early-stage disease in COVID-19 patients (MG-COVID). clinicaltrials.gov/ct2/show/NCT04371406 (first received 1 May 2020). ">NCT04371406</a>; <a href="./references#CD015025-bbs2-0048" title="NCT04374552. Asymptomatic COVID-19 Trial (ACT). clinicaltrials.gov/ct2/show/NCT04374552 (first received 5 May 2020). ">NCT04374552</a>; <a href="./references#CD015025-bbs2-0052" title="NCT04392128. Study evaluating the efficacy of hydroxychloroquine and azithromycine inpatients with COVID-19 and hematological malignancies (HYACINTHE). clinicaltrials.gov/ct2/show/NCT04392128 (first received 18 May 2020). ">NCT04392128</a>; <a href="./references#CD015025-bbs2-0054" title="NCT04399746. Ivermectin-azithromycin-cholecalciferol (IvAzCol) combination therapy for COVID-19. clinicaltrials.gov/ct2/show/NCT04399746 (first received 22 May 2020). ">NCT04399746</a>; <a href="./references#CD015025-bbs2-0056" title="NCT04407130. Efficacy and safety of ivermectin and doxycycline in combination or IVE alone in patients with COVID-19 infection. clinicaltrials.gov/ct2/show/study/NCT04407130 (first received 29 May 2020). ">NCT04407130</a>; <a href="./references#CD015025-bbs2-0060" title="NCT04482686. Trial of combination therapy to treat COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04482686 (first received 22 July 2020). ">NCT04482686</a>; <a href="./references#CD015025-bbs2-0062" title="NCT04551755. Safety and efficacy of ivermectin and doxycycline in treatment of Covid-19. clinicaltrials.gov/ct2/show/NCT04551755 (first received 16 September 2020). ">NCT04551755</a>; <a href="./references#CD015025-bbs2-0066" title="NCT04715295. Safety and efficacy of doxycycline and rivaroxaban in COVID-19 (DOXYCOV). clinicaltrials.gov/ct2/show/NCT04715295 (first received 20 January 2021). ">NCT04715295</a>; <a href="./references#CD015025-bbs2-0068" title="PACTR202005622389003. Hydroxychloroquine, azithromycine and zinc for the treatment of SARS-Cov2 infection in Senegal. COVID-19. https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11053 (first received 28 May 2020). ">PACTR202005622389003</a>; <a href="./references#CD015025-bbs2-0069" title="RBR-3k4wxb. Evaluation of the use of hydroxychlorochine in Chinese flu. ensaiosclinicos.gov.br/rg/RBR-3k4wxb/ (first received 5 May 2020). ">RBR‐3k4wxb</a>; <a href="./references#CD015025-bbs2-0071" title="RBR-7nzwkpg. Effects of treatment with oral anticoagulant associated with antibiotics on clinical, immunological, hospitalization and death parameters in patients with suspected Covid-19 infection and coagulation disorders. ensaiosclinicos.gov.br/trial/10336 (first received 6 January 2021). ">RBR‐7nzwkpg</a>; <a href="./references#CD015025-bbs2-0072" title="RBR-95yjmq. Placebo-controlled clinical trial to evaluate the efficacy and safety of hydroxychloroquine and azithromycin in relation to placebo in the negative viral load of participants with SARS-CoV2 flu syndrome and who do not have an indication for hospitalization. ensaiosclinicos.gov.br/rg/RBR-95yjmq (first received 29 April 2020). ">RBR‐95yjmq</a>; <a href="./references#CD015025-bbs2-0073" title="2020-001198-55/DK. Proactive prophylaxis with azithromycin andhHydroxychloroquine patients hospitalized with COVID. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001198-55/DK (first received 21 March 2020). NCT04322396. Proactive Protection With Azithromycin and hydroxyChloroquine in hospitalized Patients with COVID-19 (ProPAC-COVID). clinicaltrials.gov/ct2/show/NCT04322396 (first received 26 May 2020). SivapalanP , UlrikCS , BojesenRD , LapperreTS , EklofJV , Hakansson KEJ et al. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalised patients with COVID-19 (ProPAC-COVID): a structured summary of a study protocol for a randomised controlled trial. Trials2020;21(1):513. [DOI: 10.1186/s13063-020-04409-9]SivapalanP , UlrikCS , LappereTS , EklofJV , ShakerSB , BodtgerUC , et al. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials 2020;21:867. [DOI: 10.1186/s13063-020-04795-0]SivapalanP , UlrikCS , LapperreTS , BojesenRD , EklofJ , BrowatzkiA . Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19–a randomised double-blinded placebo-controlled trial. European Respiratory Journal (in press). [DOI: 10.1183/13993003.00752-2021]">Sivapalan 2020</a>; <a href="./references#CD015025-bbs2-0074" title="SpoorthiV , SasankS . Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2. International Archives of Integrated Medicine2020;7(10):177-82. [iaimjournal.com/wp-content/uploads/2020/10/iaim_2020_0710_23.pdf]">Spoorthi 2020</a>). Nine studies investigated active comparators without proven efficacy (<a href="./references#CD015025-bbs2-0015" title="BrownSM , PeltanI , KumarN , LeitherL , WebbBJ , StarrN . Hydroxychloroquine versus azithromycin for hospitalized patients with suspected or confirmed COVID-19 (HAHPS). protocol for a pragmatic, open-label, active comparator trial. Annals of the American Thoracic Society2020;17(8):1008-15. [DOI: 10.1513/AnnalsATS.202004-309SD]BrownSM , PeltanI , KumarN , LeitherL , WebbBJ , StarrN . Hydroxychloroquine vs. azithromycin for hospitalized patients with COVID-19 (HAHPS): results of a randomized, active comparator trial. Annals of the American Thoracic Society2020;18(4):590-7. [DOI: https://doi.org/10.1513/AnnalsATS.202008-940OC]">Brown 2020</a>; <a href="./references#CD015025-bbs2-0019" title="CTRI/2020/10/028234. Study to compare the effect of different antiviral medicines in COVID-19 infected sick children. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=47844&amp;EncHid=&amp;modid=&amp;compid=%27,%2747844det%27 (first received 5 October 2020). ">CTRI/2020/10/028234</a>; <a href="./references#CD015025-bbs2-0023" title="EUCTR-2020-001605-23/ES. Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection. https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001605-23/ES (first received 31 May 2020). ">EUCTR‐2020‐001605‐23/ES</a>; <a href="./references#CD015025-bbs2-0027" title="JohnstonC , BrownER , StewartJ , KaritaHCS , KissingerPJ , DwyerJ , et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: a randomized clinical trial. EClinicalMedicine2021;3:100773. [DOI: 10.1016/j.eclinm.2021.100773]NCT04354428. Treatment for COVID-19 in high-risk adult outpatients. clinicaltrials.gov/ct2/show/NCT04354428 (first received 21 April 2020). ">Johnston 2021</a>; <a href="./references#CD015025-bbs2-0031" title="NCT04286503. The clinical study of carrimycin on treatment patients With COVID-19. clinicaltrials.gov/ct2/show/NCT04286503 (first received 27 February 2020). ">NCT04286503</a>; <a href="./references#CD015025-bbs2-0032" title="NCT04329832. Hydroxychloroquine vs. azithromycin for hospitalized patients with suspected or confirmed COVID-19 (HAHPS). clinicaltrials.gov/ct2/show/NCT04329832 (first received 1 April 2020). ">NCT04329832</a>; <a href="./references#CD015025-bbs2-0034" title="NCT04334382. Hydroxychloroquine vs. azithromycin for outpatients in Utah With COVID-19 (HyAzOUT). clinicaltrials.gov/ct2/show/NCT04334382 (first received 6 April 2020). ">NCT04334382</a>; <a href="./references#CD015025-bbs2-0040" title='NCT04355052. Open label study to compare efficacy, safety and tolerability of hydroxychloroquine combined withaAzithromycin Compared tohHydroxychloroquine combined with camostat mesylate and to "no treatment" in SARS CoV 2 Virus (COSTA). clinicaltrials.gov/ct2/show/NCT04355052 (first received 21 April 2020). '>NCT04355052</a>; <a href="./references#CD015025-bbs2-0049" title="NCT04374903. Hydroxychloroquine in combination with azithromycin or sirolimus for treating COVID-19 patients (COVID19-HOPE). clinicaltrials.gov/ct2/show/NCT04374903 (first received 5 May 2020). ">NCT04374903</a>). Sixteen studies investigated a wrong intervention (<a href="./references#CD015025-bbs2-0018" title="CTRI/2020/08/027033. SARS-COV-2 and COVID-19 - A randomized controlled trail (unblinded). ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=46096&amp;EncHid=&amp;modid=&amp;compid=%27,%2746096det%27 (first received 5 August 2020). ">CTRI/2020/08/027033</a>; <a href="./references#CD015025-bbs2-0021" title="EUCTR2020‐001366‐11/ES. An international randomised trial of additional treatments for COVID-19 in hospitalised patients who are all receiving the local standard of care. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001366-11/ES (first received 26 March 2020). ">EUCTR‐2020‐001366‐11/ES</a>; <a href="./references#CD015025-bbs2-0024" title='EUCTR-2020-001971-33/ES. Pragmatic study "CORIVER": Ivermectin as antiviral treatment for patients infected by SARS-COV2 (COVID-19). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001971-33/ES (fist received 22 July 2020). '>EUCTR‐2020‐001971‐33/ES</a>; <a href="./references#CD015025-bbs2-0033" title="2020-001442-19/ES. Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001442-19/ES (first received 3 April 2020). NCT04332094. Clinical trial of the Use of Tocilizumab for treatment of SARS-CoV-2 infection (COVID-19) (TOCOVID). clinicaltrials.gov/ct2/show/NCT04332094 (first received 2 April 2020). ">NCT04332094</a>; <a href="./references#CD015025-bbs2-0038" title="NCT04345419. A real-life experience on treatment of patients with COVID 19. clinicaltrials.gov/ct2/show/NCT04345419 (first received 14 April 2020). ">NCT04345419</a>; <a href="./references#CD015025-bbs2-0042" title="NCT04359095. Effectiveness and safety of medical treatment for SARS-CoV-2 (COVID-19) in Colombia. clinicaltrials.gov/ct2/show/NCT04359095 (first received 24 April 2020). ">NCT04359095</a>; <a href="./references#CD015025-bbs2-0046" title="Chelsea, Westminster N H S Foundation Trust. A randomised controlled trial of early intervention in patients hospItalised with COVID-19: favipiravir verses hydroxycholorquine &amp; azithromycin &amp; zinc verses standard care. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001449-38/GB (first received 17 May 2020). NCT04373733. A randomised controlled trial of early intervention in COVID-19: favipiravir verses hydroxycholorquine &amp; azithromycin &amp; zinc verses standard care (PIONEER). clinicaltrials.gov/ct2/show/NCT04373733 (first received 4 May 2020). ">NCT04373733</a>; <a href="./references#CD015025-bbs2-0047" title="NCT04374019. Novel agents for treatment of high-risk COVID-19 positive patients. clinicaltrials.gov/ct2/show/NCT04374019 (first received 5 May 2020). ">NCT04374019</a>; <a href="./references#CD015025-bbs2-0050" title="NCT04382846. Novel regimens in COVID-19 treatment. clinicaltrials.gov/ct2/show/NCT04382846 (first received 11 May 2020). ">NCT04382846</a>; <a href="./references#CD015025-bbs2-0051" title="NCT04390594. Efficacy and safety evaluation of treatment regimens in adult COVID-19 patients in Senegal (SEN-CoV-Fadj). clinicaltrials.gov/ct2/show/NCT04390594 (first received 15 May 2020). ">NCT04390594</a>; <a href="./references#CD015025-bbs2-0053" title="ACTRN12620000557932. International ALLIANCE study of therapies to prevent progression of COVID-19, a randomized trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12620000557932 (first 8 May 2020). NCT04395768. International ALLIANCE Study of therapies to prevent progression of COVID-19. clinicaltrials.gov/ct2/show/study/NCT04395768 (first received 20 May 2020). ">NCT04395768</a>; <a href="./references#CD015025-bbs2-0055" title="NCT04403555. Ivermectin and doxycycline in COVID-19 treatment. clinicaltrials.gov/ct2/show/NCT04403555 (first received 27 May 2020). ">NCT04403555</a>; <a href="./references#CD015025-bbs2-0059" title="NCT04459702. A study of combination therapies to treat COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04459702 (first received 7 July 2020). ">NCT04459702</a>; <a href="./references#CD015025-bbs2-0061" title="NCT04492501. Investigational treatments for COVID-19 in tertiary care hospital of Pakistan. clinicaltrials.gov/ct2/show/NCT04492501 (first received 30 July 2020). ">NCT04492501</a>; <a href="./references#CD015025-bbs2-0064" title="NCT04621461. Hydroxychloroquine, azithromycin and zinc for the treatment of COVID-19 in theoOutpatient setting. clinicaltrials.gov/ct2/show/NCT04621461 (first received 9 November 2020). ">NCT04621461</a>; <a href="./references#CD015025-bbs2-0070" title="RBR-3rywwg. A clinical, randomized study to evaluate the efficacy and safety of Naproxen compared to placebo in combination with azithromycin or levofloxacin in patients with Severe Acute Respiratory Syndrome during the Covid-19 pandemic. ensaiosclinicos.gov.br/rg/RBR-3rywwg (first received 10 July 2020). ">RBR‐3rywwg</a>), one study analysed a wrong study population including patients post COVID‐19 (<a href="./references#CD015025-bbs2-0020" title="CTRI/2020/11/029305. Clarithromycin in post Covid 19 parenchymal organizing pneumonia. http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=48195&amp;EncHid=&amp;userName=CTRI/2020/11/029305 (first received 23 November 2020). ">CTRI/2020/11/029305</a>), and 10 studies were non‐RCTs (<a href="./references#CD015025-bbs2-0012" title="AbbasHM , Al-JumailiAA , NassirKF , Al-ObaidyMW , Al JubouriAM , DakhilBD , et al. Assessment of COVID-19 treatment containing both hydroxychloroquine and azithromycin: a natural clinical trial. International Journal of Clinical Practice2021;75(4):e13856. [DOI: https://doi.org/10.1111/ijcp.13856]">Abbas 2021</a>; <a href="./references#CD015025-bbs2-0014" title="BernardiniA , CiconteG , NegroG , RondineR , MecarocciV , VivaT , et al. Assessing QT interval in COVID-19 patients: safety of hydroxychloroquine-azithromycin combination regimen. International Journal of Cardiology2021;324:242-8. [DOI: https://doi.org/10.1016/j.ijcard.2020.09.038]">Bernardini 2021</a>; <a href="./references#CD015025-bbs2-0016" title="CadegianiFA , GorenA , WambierCG , McCoyJ . Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly reduced symptoms compared to known outcomes in untreated patients. https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1 (first posted 4 November 2020). [DOI: 10.1101/2020.10.31.20223883v1]">Cadegiani 2020</a>; <a href="./references#CD015025-bbs2-0022" title="EUCTR-2020-001466-11/GR. Prevention of severe respiratory failure in Covid-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001466-11/GR (first received 14 April 2020). ">EUCTR‐2020‐001466‐11/GR</a>; <a href="./references#CD015025-bbs2-0030" title="MoschiniL , LoffiM , RegazzoniV , Di TanoG , GherbesiE , Danzi GB . Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. Heart and Vessels2021;36:115-20. [DOI: 10.1007/s00380-020-01671-4]">Moschini 2021</a>; <a href="./references#CD015025-bbs2-0036" title="NCT04339426. Atovaquone and azithromycin combination for confirmed COVID-19 infection. clinicaltrials.gov/ct2/show/NCT04339426 (first received 9 April 2020). ">NCT04339426</a>;<a href="./references#CD015025-bbs2-0058" title="NCT04458948. Open label non-comparative trial of the combination of hydroxychloroquine and azithromycin in the treatment of hospitalized patients. clinicaltrials.gov/ct2/show/NCT04458948 (first received 7 July 2020). ">NCT04458948</a>; <a href="./references#CD015025-bbs2-0065" title="NCT04699097. The effect of azithromycin use on conduction system of heart in COVID-19 positive children. clinicaltrials.gov/ct2/show/NCT04699097 (first received 7 January 2021). ">NCT04699097</a>; <a href="./references#CD015025-bbs2-0067" title="OkourM , Al-KofahiM , AustinD . Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. Journal of Pharmacokinetics and Pharmacodynamics2020;47:187-8. [DOI: 10.1007/s10928-020-09689-x]">Okour 2020</a>; <a href="./references#CD015025-bbs2-0075" title="2020-001882-36/GR. Clarithromycin in COVID-19. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001882-36/GR (first received 30 April 2020). NCT04398004. Anti-inflammatory clarithromycin for improving COVID-19 Infection Early (ACHIEVE). clinicaltrials.gov/ct2/show/NCT04398004 (first received 21 May 2020). TsiakosK , TsakirisA , TsibrisG , VoutsinasP , PanagopoulosP , KosmidouM , et al. Oral clarithromycin in COVID-19 of moderate severity: the ACHIEVE open-label trial using concurrent matched comparators. medrxiv.org/content/10.1101/2020.12.22.20248753v1 (first posted 26 October 2020). [DOI: 10.1101/2020.12.22.20248753]">Tsiakos 2020</a>) . </p> </section> </section> <section id="CD015025-sec-0060"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed methodological quality and risk of bias for nine RCTs contributing results to our primary outcomes using the RoB 2 tool (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>)<i>.</i> We did not judge risk of bias for two studies (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a> reported results only eligible for our secondary outcomes, and <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a> has not reported any outcome of interest for this review. In total, the nine studies contributed 30 study results to 11 outcomes, six outcomes for hospitalised COVID‐19 individuals and five outcomes for outpatients, that were finally assessed using RoB 2. The RoB 2 judgements for all study results per outcomes and for all domains are available in an interactive risk of bias table (<a href="./references#CD015025-bbs2-0169" title="WeibelS , PoppM . Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1). Zenodo2021. [DOI: 10.5281/zenodo.5568845]">Supplementary File_Antibiotics_Risk of Bias</a>) and are briefly summarised below. The complete set of data is available in the supplementary file (<a href="./references#CD015025-bbs2-0169" title="WeibelS , PoppM . Supplementary File_Antibiotics_Risk of Bias Excel Tool (Version 1). Zenodo2021. [DOI: 10.5281/zenodo.5568845]">Supplementary File_Antibiotics_Risk of Bias</a>). </p> <section id="CD015025-sec-0061"> <h4 class="title">Overall risk of bias by study</h4> <p>About half of the 30 study results (56.7%) were assessed as overall low risk of bias and the remaining study results (43.3%) were assessed as some concerns for the overall risk of bias. None of the 30 study results was assessed as overall high risk of bias.  </p> </section> <section id="CD015025-sec-0062"> <h4 class="title">Overall risk of bias by outcome</h4> <p>The following section summarises the risk of bias per outcome for all primary outcomes included in the summary of findings tables (<a href="./full#CD015025-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015025-tbl-0002">summary of findings Table 2</a>). </p> <section id="CD015025-sec-0063"> <h5 class="title">Azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19 </h5> <p>We have no concerns regarding risk of bias across studies for the outcomes ‘all‐cause mortality at day 28’, ‘participants with clinical deterioration or death at day 28’, ‘participants discharged alive at day 28’, and ‘cardiac arrhythmias during the study period’. For these outcomes ‘low risk of bias studies’ dominated the effect estimates with more than 90% of the weight in the meta‐analyses. Key concerns across studies and per outcome were identified for the following outcomes: ‘serious adverse events during the study period’ due to an as‐treated analysis in one study with 97.0% of the weight in the meta‐analysis (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>); ‘adverse events (any grade) during the study period’ due to non‐blinded outcome assessment in the study with the 87.7% weight (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>). </p> </section> <section id="CD015025-sec-0064"> <h5 class="title">Azithromycin compared to placebo or standard of care alone for outpatients with asymptomatic or mild COVID‐19  </h5> <p>We have no concerns regarding risk of bias across studies for the outcome ‘all initial symptoms resolved at day 14’. For this outcome, one ‘low risk of bias study’ contributed data to the result. Key concerns across studies and per outcome were identified for the following outcomes: ‘all‐cause mortality at day 28’ due to possible trial context related deviations from the intended interventions in that study contributing events to the analysis; ‘admission to hospital or death within 28 days’ due to possible trial context related deviations from the intended interventions in one study (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>) and lack of registering the outcome in another study (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) contributing together more than 50% weight to the meta‐analysis; and ‘serious adverse events during the study period’ due to possible trial context related deviations from the intended interventions in one of two studies (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>) and lack of registering the outcome in the other study (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). </p> </section> </section> </section> <section id="CD015025-sec-0065"> <h3 class="title" id="CD015025-sec-0065">Effects of interventions</h3> <p>See: <a href="./full#CD015025-tbl-0001"><b>Summary of findings 1</b> Azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</a>; <a href="./full#CD015025-tbl-0002"><b>Summary of findings 2</b> Azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</a> </p> <p>We included11 studies in the qualitative synthesis of this review (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Ten studies were included in the meta‐analyses (quantitative synthesis), as one outpatient study did not report any relevant outcome for our meta‐analyses (<a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). Apart from two studies that used an azithromycin‐placebo (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>), or another antibiotic (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>), respectively, azithromycin was compared with standard of care alone in the remaining studies. No studies were identified that compared antibiotics with an active comparator with proven efficacy. </p> <p>Five studies investigated azithromycin for treating COVID‐19 in the inpatient setting and contributed data to primary outcomes of our meta‐analyses. Two of these studies investigated participants with a mixed population regarding disease severity, corresponding to WHO scale 4 to 7 (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). All other studies investigated participants with COVID‐19 severity according to WHO scale 4 to 5. Therefore, planned subgroup analyses for severity at baseline were performed, considering the subgroups moderate COVID‐19 and moderate to severe COVID‐19, and were reported in the <a href="./references#CD015025-sec-0116" title="">Data and analyses</a>. Since for none of the outcomes any clinically relevant subgroup difference was detectable, we do not report results of the subgroup analyses repeatedly in the following. We performed sensitivity analyses excluding non peer‐reviewed articles (e.g. preprint articles, results in trial registry) and of studies with confirmed COVID‐19 diagnosis only. Sensitivity analyses regarding risk of bias were not required since none of the eligible outcomes were assessed as high risk of bias. The main findings for the inpatient setting are summarised in the  <a href="./full#CD015025-tbl-0001">summary of findings Table 1</a>.  </p> <p>Three studies investigated azithromycin for treating COVID‐19 in the outpatient setting and contributed data to meta‐analyses (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). We performed sensitivity analyses including peer‐reviewed articles only. The main findings for the outpatient setting are summarised in the <a href="./full#CD015025-tbl-0002">summary of findings Table 2</a>.  </p> <p>For both settings, we assessed heterogeneity by calculating 95% prediction interval (PIs) for each outcome if at least four studies contributed to the result. In the current review, there are not enough studies available to perform the planned subgroup analyses to investigate heterogeneity for study characteristics regarding different dosage, route of administration and participants' age in either setting. </p> <section id="CD015025-sec-0066"> <h4 class="title">Azithromycin compared to placebo or standard of care alone for inpatients individuals with moderate to severe COVID‐19  </h4> <section id="CD015025-sec-0067"> <h5 class="title">Primary outcomes</h5> <section id="CD015025-sec-0068"> <h6 class="title">All‐cause mortality at day 28</h6> <p>Four studies with peer‐reviewed publications reported on all‐cause mortality at day 28 comparing azithromycin with standard of care alone (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Azithromycin has little or no effect on all‐cause mortality at day 28 (RR 0.98; 95% CI 0.90 to 1.06; 8600 participants; 4 studies; <a href="./references#CD015025-fig-0002" title="">Analysis 1.1</a>). The 95% prediction interval ranges from 0.85 to 1.12. Certainty of the evidence for this outcome was high. We did not downgrade for risk of bias, although one study had some concerns, since the weight of the respective study was only 0.1% of the overall effect estimate (<a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). While <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> and <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a> included RT‐PCR confirmed moderate COVID‐19, <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> and <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> investigated moderately to severely ill participants, with the latter also including 8.5% participants with negative RT‐PCR. Excluding those patients in a sensitivity analysis did not result in a different conclusion (RR 1.04; 95% CI 0.82 to 1.31; 837 participants; 3 studies). </p> <p>Two more studies reported on all‐cause mortality at time points that were not eligible for our meta‐analysis. <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a> completed follow up after 15 days which was too short and <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a> with a follow‐up of 46 days was considered clinically not useful for pooling in the 28‐day analysis of mortality. This study on moderately ill RT‐PCR confirmed COVID‐19 patients, recorded three and one death in the azithromycin and standard of care group, respectively, with a total of five participants per group. The result was posted as registry entry only. </p> </section> <section id="CD015025-sec-0069"> <h6 class="title">Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 </h6> <p><a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> provided data for worsening of clinical status assessed as new need for invasive mechanical ventilation or death at day 28 in an inpatient population with mixed RT‐PCR test results (8.5% participants with negative or unknown RT‐PCR) and moderate to severe disease. Azithromycin probably has little or no effect on worsening of clinical status or death at day 28 (RR 0.95; 95% CI 0.87 to 1.03; 7311 participants; 1 study; <a href="./references#CD015025-fig-0003" title="">Analysis 1.2</a>). We downgraded the certainty of the evidence by one level for serious indirectness due to the effect estimate based on only one study with a mixed population regarding COVID‐19 diagnosis. The study was published in a peer‐reviewed journal. </p> <p>Other studies included in this review reported related endpoints that were not eligible for pooling.  </p> <p><a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported the number of participants on invasive mechanical ventilation at day 29. However, the study included participants on all kinds of respiratory support at baseline. Therefore, these data cannot be classified as ‘new need for respiratory support’ or generally worsening of clinical status. <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> reported this outcome for 15 days, which was too short and not clinically useful to pool with the eligible time point. <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a> reported new need for invasive mechanical ventilation and death within 30 days separately, therefore we could not judge if patients would be counted twice when combining the data. <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a> reported outcome data similarly which in addition to a follow‐up period of 46 days was not eligible for our meta‐analysis. </p> </section> <section id="CD015025-sec-0070"> <h6 class="title">Improvement of clinical status: participants discharged alive at day 28</h6> <p>Three studies reported improvement of clinical status as participants being discharged alive at day 28 comparing azithromycin to standard of care alone (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>) or placebo (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>) in RT‐PCR confirmed moderate to severe COVID‐19 participants. Azithromycin probably has little or no effect on improvement of clinical status at day 28 (RR 0.96; 95% CI 0.84 to 1.11; 8172 participants; 3 studies; <a href="./references#CD015025-fig-0004" title="">Analysis 1.3</a>). We downgraded the certainty of the evidence by one level for serious heterogeneity (I<sup>2</sup> = 49%). The sensitivity analysis excluding one study with a mixed population (<a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; 8.5% participants with negative or unknown RT‐PCR) did not change the conclusion (RR 0.89; 95% CI 0.65 to 1.21; 409 participants; 2 studies). The sensitivity analysis excluding the results posted as a registry entry (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>) and only including peer‐reviewed publications was almost identical to the original analysis (RR 0.92; 95% CI 0.72 to 1.18; 8158 participants; 2 studies) (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). </p> <p>Although <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a> reported this outcome for 15 days only, we considered it eligible and clinically reasonable for pooling since all study participants were discharged alive until day 15. In contrast, <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> with the same follow‐up for this outcome, was not eligible for meta‐analysis, since several patients were still in hospital at 15 days. </p> </section> <section id="CD015025-sec-0071"> <h6 class="title">Quality of life at longest follow‐up available</h6> <p>No study reported data for this outcome.</p> </section> <section id="CD015025-sec-0072"> <h6 class="title">Serious adverse events during the study period, defined as number of participants with any event </h6> <p>Four studies with moderately to severely ill inpatients recorded any serious adverse events during the study period comparing azithromycin to standard of care alone (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>) or placebo (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>). <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> included severely ill participants and the remaining three studies investigated moderate COVID‐19. Azithromycin probably has little or no effect on serious adverse events during the study period (RR 1.11; 95% CI 0.89 to 1.40; 794 participants; 4 studies; <a href="./references#CD015025-fig-0005" title="">Analysis 1.4</a>). The 95% prediction interval ranges from 0.67 to 1.83. We downgraded the certainty of the evidence one level for serious risk of bias. We performed two sensitivity analysis. Firstly, we excluded the only study with a mixed population regarding RT‐PCR results (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; 11% participants with negative RT‐PCR), which increased the imprecision of the estimated effect (RR 0.98; 95% CI 0.26 to 3.60; 355 participants; 3 studies). The certainty of evidence was not downgraded due to indirectness, as the same study was already the reason for the downgrading due to risk of bias. The second sensitivity analysis included peer‐reviewed publications only with a comparable result (RR 1.12; 95% CI 0.89 to 1.41; 770 participants; 2 studies) (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>). </p> <p><a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> reported data on serious adverse reaction to the study drug only, which did not fulfil the definition and criteria for assessment of any serious adverse events. Similarly, <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported the additional outcome ‘serious adverse events suspected to be related to study drug’ (azithromycin group: 12/241 versus control group: 8/198), which we did not pool in the meta‐analysis for the same reason. </p> </section> <section id="CD015025-sec-0073"> <h6 class="title">Adverse events (any grade) during the study period, defined as number of participants with any event </h6> <p>Three studies with RT‐PCR confirmed moderate COVID‐19 inpatients comparing azithromycin to standard of care alone (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>) or placebo (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>) recorded any adverse events during the study period. Azithromycin may increase any adverse events slightly during the study period (RR 1.20; 95% CI 0.92 to 1.57; 355 participants; 3 studies; <a href="./references#CD015025-fig-0006" title="">Analysis 1.5</a>). The certainty of the evidence for this outcome was low due to serious risk of bias and serious imprecision because the effect estimate is based on few studies with small sample sizes. Only the largest of the three studies was published in a peer‐reviewed journal, resulting in a marginally deviating sensitivity analysis (RR 1.19; 95% CI 0.89 to 1.57; 331 participants; 1 study) (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>). </p> </section> <section id="CD015025-sec-0074"> <h6 class="title">Cardiac arrhythmias during the study period</h6> <p>Four studies including moderately to severely ill patients provided data for this outcome, with varying outcome definitions between studies (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). We considered all definitions as clinically relevant and overall similar. Meta‐analysis indicated that azithromycin probably has little or no effect on cardiac arrhythmias (RR 0.92; 95% CI 0.73 to 1.15; 7865 participants; 4 studies; <a href="./references#CD015025-fig-0007" title="">Analysis 1.6</a>). The 95% prediction interval ranges from 0.22 to 3.92. We downgraded the level of evidence for serious indirectness due to the effect estimate based mainly (weight 99.1%) on two studies with mixed populations (8.5% and 11% participants with unknown or negative RT‐PCR) (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). Sensitivity analysis including only RT‐PCR confirmed COVID‐19 diagnosis increased the imprecision of the effect estimate (RR 0.46; 95% CI 0.04 to 5.05; 442 participants; 2 studies) (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). All studies were published in peer‐reviewed journals and used standard of care alone as comparator.  </p> <p>QT‐prolongation during the study period was reported by several studies. <a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a> did not report on overall cardiac arrhythmias, but on the incidence of prolonged QT interval, in RT‐PCR positive and moderately ill participants. This outcome was reported for one of seven participants in the azithromycin group and none of seven participants in the placebo control group within 15 days. Three studies comparing azithromycin to standard of care alone reported a prolonged QT interval in addition to any cardiac arrhythmias. <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported 47 of 241 (intervention group) versus 42 of 198 participants (control group) with prolonged QT interval within 29 days. <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> recorded this outcome up to seven days only, registering 14 of 85 (intervention group) versus 11 of 77 (control group) affected participants, while <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a> registered zero events in either group during hospital stay. </p> </section> </section> <section id="CD015025-sec-0075"> <h5 class="title">Secondary outcomes</h5> <p>For inpatients, we defined a set of secondary outcomes of inferior clinical relevance compared to our primary outcome set. Therefore, we did not assess risk of bias or quality of the evidence for that data. For transparency and completeness, we extracted the available data from the eligible study pool and presented their overall effect estimates in the following and further details are listed in <a href="#CD015025-tbl-0003">Table 1</a>. </p> <p>No studies were found that reported any or conclusive data on our secondary outcomes: clinical worsening at day 28 assessed as ‘new need for oxygen by mask or nasal prongs’, clinical improvement assessed as ‘duration to liberation from invasive mechanical ventilation’ or ‘duration to liberation from supplemental oxygen’, and ‘viral clearance at up to 3 or 14 days’. </p> <section id="CD015025-sec-0076"> <h6 class="title">New need for invasive mechanical ventilation at day 28</h6> <p>Two studies reported this outcome including hospitalised participants with RT‐PCR confirmed moderate disease (<a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>) or with mixed RT‐PCR test results and moderate to severe disease (<a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; 8.5% participants with negative or unknown RT‐PCR). Due to a wide confidence interval, the effect of azithromycin compared to standard of care alone for the new need of invasive mechanical ventilation remained unclear (RR 0.65; 95% CI 0.16 to 2.71; 7422 participants; 2 studies; <a href="#CD015025-tbl-0003">Table 1</a>), statistical heterogeneity was minor (I² = 36%). Both studies were published in peer‐reviewed journals. </p> <p><a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported the number of participants on invasive mechanical ventilation at day 29, however the study included intubated participants at baseline. Therefore, these data cannot be classified as ‘new need’ or generally worsening of clinical status. <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> reported this outcome for 15 days, which was too short, while <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a> followed participants up for 46 days which was not clinically useful for pooling in the analysis of this outcome. </p> </section> <section id="CD015025-sec-0077"> <h6 class="title">Ventilator‐free days</h6> <p><a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>, a journal publication, reported this outcome investigating RT‐PCR confirmed moderate disease and did not show any relevant differences between the azithromycin and the standard of care group in the days free from ventilator (MD ‐0.10; 95% CI ‐1.16 to 0.96; 331 participants; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>). <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> provided asymmetrical median data, that were not eligible for meta‐analysis. </p> </section> <section id="CD015025-sec-0078"> <h6 class="title">New need for non‐invasive mechanical ventilation or high flow at day 28</h6> <p><a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> provided data for this outcome in an inpatient population with mixed RT‐PCR test results (8.5% participants with negative or unknown RT‐PCR) and moderate to severe disease. Azithromycin showed no clinically relevant effect compared to standard of care alone (RR 0.91; 95% CI 0.78 to 1.05; 4073 participants; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>). The study was published in a peer‐reviewed journal. </p> <p><a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported the number of participants on non‐invasive mechanical ventilation or high flow at day 29, however the study included participants on all kinds of respiratory support at baseline. Therefore, these data cannot be classified as ‘new need’ or generally worsening of clinical status. <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> reported this outcome for 15 days, which was too short as follow‐up and not clinically useful to pool with the eligible time points. </p> </section> <section id="CD015025-sec-0079"> <h6 class="title">Weaning or liberation from invasive mechanical ventilation in surviving patients at day 28 </h6> <p><a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> provided data for this outcome in an inpatient population with mixed RT‐PCR test results (8.5% participants with negative or unknown RT‐PCR). The outcome was consequentially reported for intubated patients at baseline only. Azithromycin showed no clinically relevant effect compared to standard of care alone (RR 1.11; 95% CI 0.85 to 1.45; 452 participants; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>). The study was published in a peer‐reviewed journal. </p> <p><a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> reported the number of participants on less extensive respiratory support than invasive mechanical ventilation at day 29, however the study included participants at equal or milder stages of the disease at baseline. Therefore, these data cannot be classified as either improvement or worsening of clinical status. </p> </section> <section id="CD015025-sec-0080"> <h6 class="title">Liberation from supplemental oxygen in surviving patients at day 28</h6> <p>This outcome was reported by <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> for moderately to severely ill inpatients with RT‐PCR confirmed diagnosis (RR 0.85; 95% CI 0.67 to 1.08; 395; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>). Azithromycin showed no clinically relevant effect compared to standard of care alone. The study was published in a peer‐reviewed journal. </p> <p><a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> reported number of patients without oxygen support, but the study also included participants without any oxygen need at baseline. Therefore, these data cannot be classified as either improvement or worsening of clinical status. Further it was reported for 15 days only, which was not an eligible time point for the inpatient setting. </p> </section> <section id="CD015025-sec-0081"> <h6 class="title">Need for dialysis at up to 28 days</h6> <p>The two largest studies, published in a journal, and investigated moderate to severely ill patients reported results regarding need for dialysis at up to 28 days (<a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>). The meta‐analysis revealed no difference between azithromycin and standard of care alone (RR 1.03; 95% CI 0.85 to 1.25; 8052 participants; 2 studies; <a href="#CD015025-tbl-0003">Table 1</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> included 8.5% participants with negative or unknown RT‐PCR), with minor statistical heterogeneity (I² = 21%). </p> </section> <section id="CD015025-sec-0082"> <h6 class="title">Admission to the intensive care unit (ICU) at day 28</h6> <p>One small study reported this outcome for moderately ill patients with RT‐PCR confirmed diagnosis in a journal publication (RR 0.28; 95% CI 0.06 to 1.29; 111 participants; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>) (<a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). Due to the wide confidence interval, the effect of azithromycin compared to standard of care alone remained unclear.  </p> </section> <section id="CD015025-sec-0083"> <h6 class="title">Duration of hospitalisation</h6> <p>Three studies provided data for duration of hospitalisation for moderately ill inpatients with confirmed diagnosis (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). The meta‐analysis revealed no clinically relevant difference between the azithromycin and the standard of care group (MD 0.61; 95% ‐2.58 to 1.37; 448 participants; 3 studies; <a href="#CD015025-tbl-0003">Table 1</a>) with substantial statistical heterogeneity (I² = 63%). <a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a> and <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a> published their results in peer‐reviewed journals, while <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a> posted its results in a trial registry. <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> and <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a> provided asymmetrical median values with interquartile range, that were not eligible for meta‐analysis. </p> </section> <section id="CD015025-sec-0084"> <h6 class="title">Viral clearance up to seven days</h6> <p>One study on moderately ill inpatients with confirmed COVID‐19 diagnosis reported on viral clearance at day 6 (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>). The effect of azithromycin compared to placebo remained unclear due to a wide confidence interval (RR 1.50; 95% CI 0.35 to 6.40; 14 participants; 1 study; <a href="#CD015025-tbl-0003">Table 1</a>).   </p> </section> <section id="CD015025-sec-0085"> <h6 class="title">Hospital‐acquired infections at up to 28 days</h6> <p>This outcome was reported by <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a> for moderately to severely ill inpatients with RT‐PCR confirmed diagnosis (RR 1.16; 95% CI 0.90 to 1.49; 395 participants; 3 studies). Azithromycin showed no clinically relevant effect compared to standard of care alone. The study was published in a peer‐reviewed journal. </p> </section> </section> </section> <section id="CD015025-sec-0086"> <h4 class="title">Azithromycin compared to placebo or standard of care alone for outpatients with asymptomatic or mild COVID‐19 </h4> <section id="CD015025-sec-0087"> <h5 class="title">Primary outcomes</h5> <section id="CD015025-sec-0088"> <h6 class="title">All‐cause mortality at day 28</h6> <p>Azithromycin may have little or no effect on all‐cause mortality at day 28 based on three studies comparing azithromycin with placebo (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) or standard of care alone (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>) that reported outcome data in the outpatient setting including only RT‐PCR confirmed and mild COVID‐19 diagnosis (RR 1.00 ; 95% CI 0.06 to 15.59; 876 participants; 3 studies; <a href="./references#CD015025-fig-0008" title="">Analysis 2.1</a>). <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> included asymptomatic participants for this outcome. We downgraded certainty of the evidence one level due for serious risk of bias and one level for serious imprecision caused by the wide confidence interval and few events (only one death in either group). Sensitivity analysis with only peer‐reviewed journal publications resulted in a non‐estimable effect estimate due to zero events in all arms of the remaining studies (RR not estimable; 726 participants; 2 studies) (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>).  </p> </section> <section id="CD015025-sec-0089"> <h6 class="title">Admission to hospital or death within 28 days</h6> <p>Three studies comparing azithromycin with placebo (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) or standard of care alone (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>) reported data on admission to hospital or death within 28 days in participants with mild disease confirmed by RT‐PCR. <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> included asymptomatic participants for this outcome. Azithromycin may have little or no effect on admission to hospital or death within 28 days (RR 0.94 ; 95% CI 0.57 to 1.56; 876 participants; 3 studies; <a href="./references#CD015025-fig-0009" title="">Analysis 2.2</a>). We downgraded certainty of the evidence two levels for serious risk of bias and serious imprecision due to the wide confidence interval. Sensitivity analysis with only peer‐reviewed journal publications does not result in a different judgement (RR 0.90; 95% CI 0.47 to 1.74; 726 participants; 2 studies) (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). </p> </section> <section id="CD015025-sec-0090"> <h6 class="title">All initial symptoms resolved (asymptomatic) at day 14</h6> <p>One study comparing azithromycin to placebo reported data on resolution of all initial symptoms at day 14 in participants with mild disease confirmed by RT‐PCR (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). Azithromycin may have little or no effect on symptom resolution at day 14 (RR 1.03; 95% CI 0.95 to 1.12; 138 participants; 1 study; <a href="./references#CD015025-fig-0010" title="">Analysis 2.3</a>). The certainty of the evidence is low due to very serious imprecision because the effect estimate is based on one small study. The study was published as a peer‐reviewed journal article. </p> </section> <section id="CD015025-sec-0091"> <h6 class="title">All initial symptoms resolved (asymptomatic) at day 28</h6> <p>Two studies comparing azithromycin to placebo (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) or standard of care alone (<a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>) provided data for resolution of all initial symptoms at day 28 in the outpatient setting. The effect estimate of the meta‐analysis showed no clinically relevant difference in this outcome between groups (RR 0.95; 95% CI 0.79 to 1.15; 549 participants; 2 studies; <a href="./references#CD015025-fig-0011" title="">Analysis 2.4</a>). Both studies included RT‐PCR positive, mildly ill patients only and were published in a peer‐reviewed journal. </p> </section> <section id="CD015025-sec-0092"> <h6 class="title">Duration to symptom resolution</h6> <p>No study reported eligible data for this outcome. <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a> reported data as median with interquartile range which were not eligible for meta‐analysis. </p> </section> <section id="CD015025-sec-0093"> <h6 class="title">Quality of life at longest follow‐up available</h6> <p>No study reported data for this outcome.</p> </section> <section id="CD015025-sec-0094"> <h6 class="title">Serious adverse events during the study period, defined as number of participants with any event </h6> <p>Two studies comparing azithromycinwith standard of care alone (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>) or placebo (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>) assessed serious adverse events during the study period in the outpatient setting, but none of the participants in either study were affected. We downgraded certainty of the evidence by one level for serious risk of bias and two levels for very serious imprecision due to zero events in all arms of both studies. Hence, there were too few participants who experienced serious adverse events to determine whether azithromycin made a difference (RR not estimable; 454 participants; 2 studies; <a href="./references#CD015025-fig-0012" title="">Analysis 2.5</a>). Sensitivity analysis with exclusion of the preprint‐article (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>) was not meaningful (RR not estimable; 304 participants; 1 study). All included participants were diagnosed by an RT‐PCR test and were mildly ill or even asymptomatic (see <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). </p> </section> <section id="CD015025-sec-0095"> <h6 class="title">Adverse events (any grade) during the study period, defined as number of participants with any event </h6> <p>No study reported data for this outcome. <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a> and <a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a> reported on drug specific side effects and specific adverse events in their publications, therefore did not fulfil the definition and criteria for assessment of any adverse events. </p> </section> <section id="CD015025-sec-0096"> <h6 class="title">Cardiac arrhythmias during the study period</h6> <p>No study provided data for this outcome. However, QT‐prolongation during the study period was reported in one study with 5 of 152 affected participants in the azithromycin group versus 4 of 152 in the placebo group within 21 days (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). </p> </section> </section> <section id="CD015025-sec-0097"> <h5 class="title">Secondary outcomes</h5> <p>For outpatients, we defined a set of secondary outcomes of inferior clinical relevance compared to our primary outcome set. Therefore, we did not assess risk of bias or quality of the evidence for that data. For transparency and completeness, we extracted the available data from the eligible study pool and present their overall effect estimates in the following, further details are listed in <a href="#CD015025-tbl-0004">Table 2</a>. </p> <p>No studies were found that reported any or conclusive data on our secondary outcomes: clinical worsening at day 28 assessed as ‘need for non‐invasive mechanical ventilation or high flow’ or ‘need for hospitalisation without oxygen therapy’, ‘hospital‐acquired infections at up to 28 days’, and ‘viral clearance at up to 3 or 14 days’. </p> <section id="CD015025-sec-0098"> <h6 class="title">Need for invasive mechanical ventilation at day 28</h6> <p>One study comparing azithromycin to standard of care alone reported the need for invasive mechanical ventilation in RT‐PCR positive, mildly ill outpatients at day 28 (<a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). The study was published in a peer‐reviewed journal. The effect of azithromycin compared to standard of care alone remained unclear due to a wide confidence interval (RR 0.61, 95% CI 0.11 to 3.27; 405 participants; 1 study; <a href="#CD015025-tbl-0004">Table 2</a>). </p> </section> <section id="CD015025-sec-0099"> <h6 class="title">Need for hospitalisation with need for oxygen by mask or nasal prongs at day 28</h6> <p>One study reported the number of RT‐PCR positive outpatients with need for hospitalisation and with need for oxygen by mask or nasal prongs at day 28 (<a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). The effect of azithromycin compared to standard of care alone remained unclear due to a wide confidence interval (RR 0.80, 95% CI 0.29 to 2.22; 406 participants; 1 study; <a href="#CD015025-tbl-0004">Table 2</a>).  </p> </section> <section id="CD015025-sec-0100"> <h6 class="title">Viral clearance up to day 7</h6> <p>One outpatient study reported viral clearance at up to 7 days for previously RT‐PCR positive participants with mild or no symptoms and was published in a peer‐reviewed journal (<a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>). The effect of azithromycin compared to standard of care alone remained unclear due to a wide confidence interval (RR 0.83, 95% CI 0.44 to 1.54; 301 participants; 1 study; <a href="#CD015025-tbl-0004">Table 2</a>).  </p> <p>For other time points, there was no conclusive data available within the study pool. Although <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a> reported data for this outcome at day 14, we could not determine whether patients with initial viral clearance at day 6 were counted twice.  </p> </section> </section> </section> <section id="CD015025-sec-0101"> <h4 class="title">Azithromycin compared to other antibiotics for inpatients with moderate to severe COVID‐19 </h4> <section id="CD015025-sec-0102"> <h5 class="title">Primary outcomes</h5> <p>No study reported data for any primary outcome of this comparison.</p> </section> <section id="CD015025-sec-0103"> <h5 class="title">Secondary outcomes</h5> <section id="CD015025-sec-0104"> <h6 class="title">Viral clearance up to day 7</h6> <p>One peer‐reviewed publication compared azithromycin to lincomycin, another antibiotic, in moderately ill inpatients with confirmed COVID‐19 diagnosis and reported on viral clearance at day 6 (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>). The study revealed a reduced viral clearance for azithromycin compared to lincomycin (RR 0.40; 95% CI 0.17 to 0.93; 24 participants; 1 study; <a href="#CD015025-tbl-0005">Table 3</a>). </p> <div class="table" id="CD015025-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcomes for azithromycin compared to other antibiotics for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of heterogeneity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.40</b><br/>(0.17 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> </div> </section> </section> </section> <section id="CD015025-sec-0105"> <h4 class="title">Azithromycin compared to other antibiotics for outpatients COVID‐19 with asymptomatic or mild COVID‐19 </h4> <p>One preprint article was included that compared azithromycin to clarithromycin in outpatients with confirmed COVID‐19 diagnosis comparing azithromycin to clarithromycin, another antibiotic (<a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). The study did not report any outcome relevant for this review. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015025-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015025-sec-0106"></div> <section id="CD015025-sec-0107"> <h3 class="title" id="CD015025-sec-0107">Summary of main results</h3> <p>This review included 11 studies with 11281 participants investigating azithromycin compared to placebo, standard of care alone or another antibiotic.  The main findings of this review are summarised in the <a href="./full#CD015025-tbl-0001">summary of findings Table 1</a> (azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19) and <a href="./full#CD015025-tbl-0002">summary of findings Table 2</a> (azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19). </p> <p>Azithromycin has no effect on all‐cause mortality at 28 days, the most important patient‐relevant outcome during this pandemic, neither in the inpatient (4 studies with 8600 participants) nor the outpatient setting (3 studies with 876 participants). The certainty for this finding was high for inpatients, and low for outpatients due to concerns of risk of bias and very few events of deaths in this setting. </p> <p>For the inpatient setting, azithromycin probably has little or no effect on worsening of clinical status assessed by new need for invasive mechanical ventilation or death at day 28 or on improvement of clinical status assessed as participants discharged alive at day 28.  Regarding safety outcomes, azithromycin probably has little or no effect on cardiac arrhythmias and serious adverse events during the study period, while azithromycin may increase any adverse events slightly during the study period. </p> <p>For the outpatient setting, azithromycin may have little or no effect on admission to hospital or death within 28 days and on resolution of all initial symptoms at day 14. The certainty of the evidence for these findings was low. Regarding safety outcomes, we are uncertain whether azithromycin increases or reduces serious adverse events compared to placebo or standard of care alone, since no participant experienced serious adverse events in the studies. No study provided data for any adverse events or cardiac arrhythmias. </p> </section> <section id="CD015025-sec-0108"> <h3 class="title" id="CD015025-sec-0108">Overall completeness and applicability of evidence</h3> <p>The evidence summarised in this review applies to azithromycin for COVID‐19, but as yet no other antibiotic. Only two included studies investigated another antibiotic than azithromycin. However, those trials did not provide relevant data for this review nor for clinical practice (<a href="./references#CD015025-bbs2-0004" title="GuvenmezO , KeskinH , AyB , BirinciS , KancaMF . The comparison of the effectiveness of lincocin and azitro in the treatment of covid-19-associated pneumonia: a prospective study. Journal of Population Therapeutics and Clinical Pharmacology2020;27(SP1):e5-e10. [DOI: https://doi.org/10.15586/jptcp.v27iSP1.684]">Guvenmez 2020</a>; <a href="./references#CD015025-bbs2-0009" title="NCT04622891. Clarithromycin versus azithromycin in treatment of mild COVID-19 Infection. clinicaltrials.gov/ct2/show/results/NCT04622891?view=results (first received 10 November 2020). RashadA , NafadyA , HassanMH , MansourH , TayaU , BazeedSE , et al. Therapeutic efficacy of macrolides in management of patients with mild COVID-19. researchsquare.com/article/rs-181996/v1 (first posted 1 February 2021). [DOI: https://doi.org/10.21203/rs.3.rs-181996/v1]">Rashad 2021</a>). There are four ongoing trials with between 94 and 330 participants evaluating other antibiotics such as doxycycline (<a href="./references#CD015025-bbs2-0106" title="NCT04371952. DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19). clinicaltrials.gov/ct2/show/NCT04371952 (first received 1 May 2020). ">NCT04371952</a>; <a href="./references#CD015025-bbs2-0109" title="NCT04729140. An outpatientc linical trial using ivermectin and doxycycline in COVID-19 positive patients at high risk to prevent COVID-19 related hospitalization. clinicaltrials.gov/ct2/show/NCT04729140 (first received 28 January 2021). ">NCT04729140</a>) and cotrimoxazol (<a href="./references#CD015025-bbs2-0094" title="CTRI/2020/10/028297. Cotrimoxazole in hospitalised patients with moderate to early-severe COVID-19 infection. ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=48268&amp;EncHid=&amp;modid=&amp;compid=%27,%2748268det%27 (first received 8 October 2020). ">CTRI/2020/10/028297</a>; <a href="./references#CD015025-bbs2-0108" title="NCT04470531. Role of co-trimoxazole in severe COVID-19 patients. clinicaltrials.gov/ct2/show/NCT04470531 (first received 14 July 2020). ">NCT04470531</a>). Four completed studies with results publication pending investigate clarithromycin (<a href="./references#CD015025-bbs2-0085" title="IRCT20200718048129N1. Evaluation of the effectiveness of Hydroxychloroquine and Clarithromycin in dyspnea and caugh caused by COVID-19 in recovery phase. en.irct.ir/trial/49729 (first received 11 August 2020). ">IRCT20200718048129N1</a>), doxycycline (<a href="./references#CD015025-bbs2-0082" title="IRCT20191211045691N2. Evaluation of the efficacy and safety of doxycycline in combination with standard treatment in Covid-19 patients: a clinical trial. irct.ir/trial/51951 (first received 2 November 2020). ">IRCT20191211045691N2</a>; <a href="./references#CD015025-bbs2-0087" title="NCT04370782. Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting. clinicaltrials.gov/ct2/show/NCT04370782 (first received 1 May 2020). ">NCT04370782</a>) and metronidazol (<a href="./references#CD015025-bbs2-0084" title="IRCT20200608047686N1. Evaluation of therapeutic effects of metronidazole In inpatients with pneuomonia due to COVID-19. en.irct.ir/trial/48717 (first received 30 June 2020). ">IRCT20200608047686N1</a>). Except for the trial on doxycycline which evaluates overall 1490 patients, those studies are very small with trials sizes well below 100 participants. Therefore, we do not expect that publication of those trials alone will lead to reliable evidence. The ongoing platform trial REMAP‐CAP, evaluating 7100 participants, plans to investigate macrolides as well as flouroquinolones and ß‐lactam antibiotics, but it is unclear when those results will be available (<a href="./references#CD015025-bbs2-0092" title="AngusDC , BerryS , LewisRJ , Al-BeidhF , ArabiY , vanBentum-PuijkW , et al. The randomized embedded multifactorial adaptive platform for community-acquired pneumonia (REMAP-CAP) study: rationale and design. Annals of the American Thoracic Society2020;17(7):879-91. [DOI: 10.1513/AnnalsATS.202003-192SD]EUCTR-2015-002340-14. Adaptive trial in severe pneumonia (REMAP-CAP) - Version 23.0. www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14 (first received 13 July 2020). ISRCTN67000769. An international platform trial for severely ill patients with community-acquired pneumonia or COVID-19. isrctn.com/ISRCTN67000769 (first received 9 July 2020). NCT02735707. Randomized, Embedded, Multifactorial Adaptive Platform trial for community- Acquired Pneumonia (REMAP-CAP) with sub-platform REMAP-COVID. clinicaltrials.gov/ct2/show/NCT02735707 (protocol for sub-platform REMAP-COVID first received 25 March 2020). ">Angus 2020</a>). </p> <p>With seven out of 11 included studies, the majority of studies were conducted in inpatient settings. Those studies included participants with moderate as well as severe disease (WHO scale 4 to 7). Therefore, the findings of this review are transferable to inpatients with COVID‐19 at any stage. </p> <p>Four of the 11 included studies were conducted in outpatient settings with no, or mild COVID‐19 symptoms (WHO 1 to 3), of which three studies reported relevant outcomes. Due to the relatively small number of participants with confirmed COVID‐19 diagnosis, i.e. RT‐PCR test positives, and partially low number of events, certainty of the evidence is low for this particular population. However, as the inpatient studies included in this review show strong evidence for azithromycin’s futility for COVID‐19 treatment in inpatients who do not generally require medical support, applicability for the outpatient setting should be considered. </p> <p>The overall mean age of participants in all studies was 54 years with a mean range from 41 to 65 years and included patients affected by co‐morbidities, e.g. obesity, hypertension or diabetes. Considering age and pre‐existing conditions as the most important risk factors for developing severe COVID‐19, the current evidence is applicable to patients which are at most risk of death from COVID‐19. </p> <p>Three studies were conducted in the Middle East, three in Europe, two in the USA, two in South America, and one in Africa, covering states with high‐ and low‐healthcare expenditure. </p> <p>All outpatient studies administered azithromycin per mouth, while in the inpatient setting oral, intravenous and nasogastric application was used. With 500 mg daily for three to 14 days, seven of the 11 included studies exceeded usual dosage of azithromycin for bacterial infections which is described as 500 mg loading dose followed by 250 mg daily for four subsequent days. Too few studies were available to investigate dose effects by subgroup analyses. Overall, regimens were very similar. Considering the strong evidence on azithromycin's lack of benefit for COVID‐19 patients, a future subgroup analysis investigating different doses is unlikely to reveal relevant new information. Evidence on other antibiotics is lacking. </p> <p>A total of 19 studies are ongoing and 15 studies are awaiting classification pending publication of results or clarification of inconsistencies. It is questionable if ongoing studies investigating azithromycin will be completed due to the results of larger trials already available. Indeed, two of the 11 studies were already prematurely terminated due to results from large trials indicating no evidence of effect for azithromycin (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). It is not to be expected that including future publications of smaller or lower quality randomised controlled trials(RCTs) would change this review's conclusion on azithromycin. However, we will monitor preprints, ongoing studies and those awaiting classification for potentially relevant results that require updating this review. </p> <p>For other antibiotics than azithromycin, there is currently a complete lack of evidence. Well‐designed RCTs are required that may allow for a judgement of the effectiveness and the safety of other antibiotics for treatment of COVID‐19. However, as the emergence and spread of antimicrobial resistance has been considered as a global threat already before the pandemic, prudent use of antibiotics is of utmost importance. </p> <p>This review did not investigate antibiotic prophylaxis or preemptive therapy of bacterial infections in patients also infected with SARS‐CoV‐2, but focused on antibiotics used as COVID‐19 treatment only. Therefore, any conclusions drawn form our results are only valid for the latter rationale. There are no RCTs available on how to guide preemptive or prophylactic antibiotic prescription in COVID‐19 patients, which is an evidence gap to be filled urgently in the light of the global emergence of antimicrobial resistance as a major public health and development threat. </p> </section> <section id="CD015025-sec-0109"> <h3 class="title" id="CD015025-sec-0109">Quality of the evidence</h3> <p>The certainty of evidence for prioritised outcomes presented in the Summary of findings tables (<a href="./full#CD015025-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD015025-tbl-0002">summary of findings Table 2</a>) ranged from low to high for the inpatient setting and from very low to low for the outpatient setting. </p> <p>For the Summary of findings and assessment of the certainty of the evidence according to <a href="./references#CD015025-bbs2-0159" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Schünemann 2020</a>, we used the results from analysis of our primary outcomes. About half of the study results were assessed as overall low risk of bias. No respective study outcome was judged as high risk of bias, therefore, our meta‐analyses included only studies with low risk or some concerns of bias. Details of the risk of bias assessments per outcome are reported in <a href="#CD015025-sec-0060">Risk of bias in included studies</a>. </p> <p>Overall certainty of the evidence was higher for inpatients than for outpatients due to studies with larger size and low risk of bias. We are very certain that azithromycin has little or no effect on all‐cause mortality at day 28 in inpatients compared to standard of care alone. Most of the other findings for inpatients were assessed as moderate certainty of evidence. The certainty of evidence for the outcomes ‘worsening of clinical status or death at day 28’ and ‘cardiac arrhythmias during the study period’ was downgraded due to indirectness. The effect estimates of both outcomes were mainly based on one study that included about 10% of participants with negative or unknown RT‐PCR results. We did not downgrade ‘all‐cause mortality at day 28’ and ‘improvement of clinical status at day 28’ for indirectness, because the result did not change in a sensitivity analysis excluding studies with mixed populations. Inconsistency was the reason for downgrading the certainty of evidence for ‘improvement of clinical status at day 28’, because three studies contributed heterogenous results (I<sup>2</sup> = 49%). One study favoured standard of care alone and the other two showed no difference between study arms. Adverse events was the only outcome in the inpatient setting with low certainty of the evidence. The certainty of evidence was downgraded due to serious risk of bias because study results that contributed to the outcome were assessed as some concerns of bias and serious imprecision due to inclusion of few small studies. </p> <p>Small studies with few events causing serious imprecision were the main reason for downgrading certainty of the evidence in the outpatient setting. Certainty of the evidence was downgraded one level if studies with some concerns for risk of bias contributed to the according outcome. Therefore, all but one result was not downgraded for risk of bias because there was always at least one study contributing results assessed as some concerns of bias. </p> <p>In the current phase of the pandemic, it is impossible to reliably assess the risk of publication bias. Many of the registered studies are still ongoing or, in the case of a completed study status, their results have not yet been published. We will follow the publication and trial history of each ongoing study and study awaiting classification. Currently, we did not suspect publication bias for any outcome included in this review. However, this may change in future updates of this review. </p> </section> <section id="CD015025-sec-0110"> <h3 class="title" id="CD015025-sec-0110">Potential biases in the review process</h3> <p>To avoid potential bias in the review process, we were committed at all times to conduct a systematic review that followed published guidance provided by the <i>Cochrane Handbook for Systematic Reviews of Interventions (</i><a href="./references#CD015025-bbs2-0129" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook.">Higgins 2020a</a>). </p> <p>The review team is part of the German research project “CEOsys” (COVID‐19 Evidence‐Ecosystem). CEOsys is a consortium of clinical and methodologic experts supported by the German Federal Ministry of Education and Research to synthesise clinical evidence during this global pandemic. The involved medical information specialists of this consortium carried out a rigorous search of electronic databases including preprint servers and clinical trial registries to identify the complete extent of published and ongoing trials on this topic. The sensitive search included relevant electronic databases as well as clinical trial registries. As a supplement, we screened reference lists of included studies and compared our search results with those from the living network meta‐analysis (<a href="./references#CD015025-bbs2-0120" title="Van NguyenT , FerrandG , Cohen-BoulakiaS , MartinezR , KappP , CoqueryE , et al for the COVID-NMA consortium. RCT studies on preventive measures and treatments for COVID-19. covid-nma.com (accessed prior to 15 July 2019).">COVID‐NMA</a>). Therefore, we are confident that we identified all relevant studies and will monitor ongoing studies as well as full publication of preprints closely after the publication of this review. </p> <p>This review is part of a Cochrane Living Systematic Reviews Series on different interventions for treatment of COVID‐19 (<a href="./references#CD015025-bbs2-0111" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir to treat people with COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; Kreuzberger 2021b; <a href="./references#CD015025-bbs2-0154" title="PoppM , StegemannM , Metzendorf M-I, GouldS , KrankeP , Meybohm P et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021</a>; <a href="./references#CD015025-bbs2-0167" title="Stroehlein  JK, Wallqvist  J, Iannizzi  C, Mikolajewska  A, Metzendorf  M-I, Benstoem  C, et al. Vitamin D supplementation for the treatment of COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>; <a href="./references#CD015025-bbs2-0171" title="Wagner  C, Griesel  M, Mikolajewska  A, Mueller  A, Nothacker  M, Kley  K, et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>) established and performed by the CEOsys consortium. Initially, a common core outcome set was established for all reviews in accordance with the Core Outcome Measures in Effectiveness Trials (COMET) Initiative for COVID‐19 patients (<a href="./references#CD015025-bbs2-0118" title="Core outcome set developers’ response to COVID-19. www.comet-initiative.org/Studies/Details/1538 (accessed 22 March 2021).">COMET 2020</a>; <a href="./references#CD015025-bbs2-0143" title="MarshallJC , MurthyS , DiazJ , AdhikariNK , AngusDC , ArabiYM , et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infectious Diseases2020;20(8):e192-7. [DOI: 10.1016/S1473-3099(20)30483-7]">Marshall 2020</a>), and additional outcomes that have been prioritised by consumer representatives and the German guideline panel for inpatient therapy of people with COVID‐19. Prespecified outcomes in the protocol template and previous reviews (<a href="./references#CD015025-bbs2-0111" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir to treat people with COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; Kreuzberger 2021b; <a href="./references#CD015025-bbs2-0154" title="PoppM , StegemannM , Metzendorf M-I, GouldS , KrankeP , Meybohm P et al. Ivermectin for preventing and treating COVID-19. Cochrane Database of Systematic Reviews2021, Issue 7. Art. No: CD015017. [DOI: 10.1002/14651858.CD015017.pub2]">Popp 2021</a>; <a href="./references#CD015025-bbs2-0167" title="Stroehlein  JK, Wallqvist  J, Iannizzi  C, Mikolajewska  A, Metzendorf  M-I, Benstoem  C, et al. Vitamin D supplementation for the treatment of COVID‐19: a living systematic review. Cochrane Database of Systematic Reviews2021, Issue 5. Art. No: CD015043. [DOI: 10.1002/14651858.CD015043]">Stroehlein 2021</a>; <a href="./references#CD015025-bbs2-0171" title="Wagner  C, Griesel  M, Mikolajewska  A, Mueller  A, Nothacker  M, Kley  K, et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>) have been changed to address issues of competing risks associated with certain outcomes describing the clinical status of COVID‐19 patients. These issues are extensively discussed in previous reviews (<a href="./references#CD015025-bbs2-0111" title="AnsemsK , GrundeisF , DahmsK , MikolajewskaA , ThiemeV , PiechottaV , et al. Remdesivir to treat people with COVID-19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014962. [DOI: 10.1002/14651858.CD014962]">Ansems 2021</a>; <a href="./references#CD015025-bbs2-0171" title="Wagner  C, Griesel  M, Mikolajewska  A, Mueller  A, Nothacker  M, Kley  K, et al. Systemic corticosteroids for the treatment of COVID‐19. Cochrane Database of Systematic Reviews2021, Issue 8. Art. No: CD014963. [DOI: 10.1002/14651858.CD014963]">Wagner 2021</a>). To overcome competing risks, we added outcomes for hospitalised and ambulatory managed patients that aim to simultaneously capture all participants of the population with clinical worsening and all participants with clinical improvement. This was possible by using composite outcomes, e.g. combining new need for invasive mechanical ventilation and death as clinical worsening for hospitalised individuals, and combining admission to hospital and death for outpatients. Clinical improvement for inpatients was represented by the number of participants discharged alive within the same time period used for clinical worsening, and for outpatients as complete resolution of initial symptoms. All previous outcomes defined in the protocol on clinical status assessed by need for respiratory support were analysed as secondary outcomes. </p> <p>Two included studies were published as preprint articles and two other ones posted data in their registry entry. We are aware that articles may change following peer‐review. Nevertheless, we are convinced that including all eligible data in a highly dynamic situation such as the COVID‐19 pandemic is crucial to be up‐to‐date and to provide timely information on potentially promising treatment options. Journal publications and corresponding preprint articles were compared in terms of consistency and all study results were assessed for their risk of bias. Study authors were contacted if the publication included unclear or missing information. Unfortunately, not all attempts of gathering additional data were successful. Details of the communication with authors are provided in the <a href="./references#CD015025-sec-0129" title="">Characteristics of included studies</a>. </p> <p>For two studies that had already published results, we could not finally judge eligibility due to insufficient description of their randomisation method and inconsistent information on analysed participants (<a href="./references#CD015025-bbs2-0088" title="Purwati, Budiono, RachmanBE , Yulistiani, MiatmokoA , Nasronudin, et al. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Mo. Biochemistry Research International2021;2021:6685921. [DOI: 10.1155/2021/6685921]">Purwati 2021</a>; <a href="./references#CD015025-bbs2-0089" title="SayedAM , KhalafAM , AbdelrahimMEA , ElgendyMO . Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation. International Journal of Clinical Practice 17 December 2020 [Epub ahead of print]. [DOI: 10.1111/ijcp.13877]">Sayed 2020</a>). We tried to outreach to the corresponding authors to clarify those questions, though we have not received any satisfying response at the time of review publication. Further, nine trials classified as awaiting classification have completed recruitment, but publication of results is still pending. Those trials will be closely monitored for publication in the near future. </p> <p>None of the members of the review author team has any affiliation with any stakeholder group who favours or disapproves of any antibiotic or the comparators used in relevant studies. </p> </section> <section id="CD015025-sec-0111"> <h3 class="title" id="CD015025-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>The findings of our review on azithromycin as a treatment for COVID‐19, is similar to findings of the rapid guideline released by NICE 2020 and last updated in June 2021 (<a href="./references#CD015025-bbs2-0148" title="National Institute for Health and Care Excellence. COVID-19 rapid guideline: azithromycin. Available from www.nice.org.uk/guidance/ng191/evidence (accessed 19 July 2021).">NICE 2021</a>). The authors included four randomised controlled trials RCTs) on hospitalised patients, which were also identified in this review (<a href="./references#CD015025-bbs2-0001" title="CavalcantiAB , ZampieriFG , AzevedoLC , RosaRG , AvezumA , VeigaVC , et al. Hydroxychloroquine alone or in combination with azithromycin to prevent major clinical events in hospitalised patients with coronavirus infection (COVID-19): rationale and design of a randomised, controlled clinical trial. medrxiv.org/content/10.1101/2020.05.19.20106997v1 (first posted 26 May 2020). CavalcantiAB , ZampieriFG , Rosa RG, AzevedoLC , VeigaVC , AvezumA , et al.  Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New England Journal of Medicine 2020;383(21):2041-52. [DOI: https://doi.org/10.1056/nejmoa2019014]NCT04322123. Safety and efficacy of hydroxychloroquine associated WithaAzithromycin in SARS-Cov-2 Virus (COVID-19) (Coalition-I). clinicaltrials.gov/ct2/show/NCT04322123 (first received 26 March 2020). ">Cavalcanti 2020</a>; <a href="./references#CD015025-bbs2-0003" title="FurtadoRH , BerwangerO , FonsecaHA , CorrêaTD , FerrazLR , LapaMG , et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet2020;396(10256):959-67. [DOI: https://doi.org/10.1016/S0140-6736(20)31862-6]NCT04321278. Safety and efficacy of hydroxychloroquine associated with azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II). clinicaltrials.gov/ct2/show/NCT04321278 (first received 25 March 2020). ">Furtado 2020</a>; <a href="./references#CD015025-bbs2-0010" title="EUCTR-2020-001113-21/GB. Randomised Evaluation of COVID-19 Therapy (RECOVERY). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001113-21/GB (first received 19 March 2020). HorbyPW , RoddickA , SpataE , StaplinN , EmbersonJR , Pessoa-AmorimG , et al. Azithromycin in hospitalised patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medrxiv.org/content/10.1101/2020.12.10.20245944v1 (first posted 14 December 2020) . [DOI: https://doi.org/10.1101/2020.12.10.20245944v1]ISRCTN50189673. A randomised trial of treatments to prevent death in patients hospitalised with COVID-19 (coronavirus). www.isrctn.com/ISRCTN50189673 (first received 2 April 2020). NCT04381936. Randomised evaluation of COVID-19 therapy (RECOVERY). clinicaltrials.gov/ct2/show/NCT04381936 (first received 11 May 2020). Recovery Collaborative Group . Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet2021;397(10274):605-12. [DOI: https://doi.org/10.1016/S0140-6736(21)00149-5]">RECOVERY 2021</a>; <a href="./references#CD015025-bbs2-0011" title="IRCT20200415047092N1. Safety and effectiveness of azithromycin in patients with COVID-19 referred to Zeiaeian hospital: a clinical trial study. en.irct.ir/trial/47244 (first received 20 April 2020). SekhavatiE , JafariF , SeyedAlinaghiS , JamalimoghadamsiahkaliS , SadrS , TabarestaniM , et al. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomized trial. International Journal of Antimicrobial Agents2020;56(4):106143. [DOI: https://doi.org/10.1016/j.ijantimicag.2020.106143]">Sekhavati 2020</a>). The additional two studies in our review were not included in the NICE guideline presumably due to the date of publication (<a href="./references#CD015025-bbs2-0002" title="CJWT629A12301. Hydroxychloroquine monotherapy and in combination with azithromycin in patients with moderate and severe COVID-19 disease. clinicaltrials.gov/ct2/show/results/NCT04358081?view=results (results first posted 17 March 2021). ">CJWT629A12301</a>; <a href="./references#CD015025-bbs2-0006" title="NCT04335552. Pragmatic factorial trial of hydroxychloroquine, azithromycin, or both for treatment of severe SARS-CoV-2 infection. clinicaltrials.gov/ct2/show/NCT04335552 (results first posted 12 May 2021). ">NCT04335552</a>). For azithromycin in ambulatory settings, the evidence syntheses include the same study pool as this review (<a href="./references#CD015025-bbs2-0005" title="EUCTR-2020-001740-26/GB. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID-19 (ATOMIC2). www.clinicaltrialsregister.eu/ctr-search/trial/2020-001740-26/GB (first received 24 April 2020). HinksTS , BarberVS , BlackJ , DuttonSJ , JabeenM , MelhornJ , et al. A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. Trials2020;21(1):718. [DOI: https://doi.org/10.1186/s13063-020-04593-8]HinksTS , CuretonL , KnightR , WangA , CaneJL , BarberVS , et al. A randomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial. medrxiv.org/content/10.1101/2021.04.21.21255807v1 (first posted 27 April 2021). [DOI: https://doi.org/10.1101/2021.04.21.21255807]NCT04381962. A multicentre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care In ambulatory COVID19 (ATOMIC2). clinicaltrials.gov/ct2/show/NCT04381962 (first received 11 May 2020). ">Hinks 2020</a>; <a href="./references#CD015025-bbs2-0007" title="NCT04349592. Hydroxychloroquine with or without azithromycin for virologic cure of COVID-19. clinicaltrials.gov/ct2/show/NCT04349592 (first received 16 April 2020). OmraniAS , PathanSA , ThomasSA , HarrisTR , CoylePV , ThomasCE , et al. Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. EClinicalMedicine2020;29:100645. [DOI: https://doi.org/10.1016/j.eclinm.2020.100645]">Omrani 2020</a>; <a href="./references#CD015025-bbs2-0008" title="EUCTR-2020-001209-22/GB. Platform Randomised trial of INterventions against COVID-19 In older peoPLE. www.clinicaltrialsregister.eu/ctr-search/trial/2020-001209-22/GB (first received 25 March 2020). ISRCTN86534580. PRINCIPLE: A clinical trial evaluating treatments for suspected and confirmed COVID-19 for recovery at home. www.isrctn.com/ISRCTN86534580 (first received 22 March 2020). Principle Trial Collaborative Group. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet2021;397(10279):1063-74. [DOI: https://doi.org/10.1016/S0140-6736(21)00461-X]">PRINCIPLE 2021</a>). In agreement with our results, the guideline authors claimed that azithromycin does not reduce mortality in out‐ or inpatients, and there is a lack of benefit for azithromycin regarding discharge from hospital for inpatients or clinical recovery for outpatients, as well as adverse and serious adverse events in both settings. Certainty of the evidence for these outcomes ranged from very low to moderate.  </p> <p><a href="./references#CD015025-bbs2-0135" title="KamelAM , MonemMSA , SharafNA , MagdyN , FaridSR . Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Reviews in Medical Virology 2 June 2021 [Epub ahead of print]. [DOI: 10.1002/rmv.2258]">Kamel 2021</a>, a very up to date meta‐analysis investigating azithromycin as COVID‐19 treatment, included the same studies as <a href="./references#CD015025-bbs2-0148" title="National Institute for Health and Care Excellence. COVID-19 rapid guideline: azithromycin. Available from www.nice.org.uk/guidance/ng191/evidence (accessed 19 July 2021).">NICE 2021</a>, and draw the same conclusion on azithromycin to treat COVID‐19, correspondingly. Based on three studies identical to our review, they also report no relevant influence of azithromycin on cardiac arrhythmias, an additional safety outcome of high clinical relevance. Our work differs from this review in its methods as in <a href="./references#CD015025-bbs2-0135" title="KamelAM , MonemMSA , SharafNA , MagdyN , FaridSR . Efficacy and safety of azithromycin in Covid-19 patients: a systematic review and meta-analysis of randomized clinical trials. Reviews in Medical Virology 2 June 2021 [Epub ahead of print]. [DOI: 10.1002/rmv.2258]">Kamel 2021</a> different health care settings were pooled in some of their analyses, suspected COVID‐19 was accepted, and they did not use GRADE to rate the certainty of evidence. </p> <p>To the best of our knowledge, there is currently no systematic review available that investigates antibiotics other than azithromycin as anti‐viral or anti‐inflammatory treatment of COVID‐19. <a href="./references#CD015025-bbs2-0160" title="SharmaS , SinghA , BanerjeeT . Antibacterial agents used in COVID-19: A systematic review and meta-analysis. Environmental Sustainability 7 June 2021 [Epub ahead of print]. [DOI: 10.1007/s42398-021-00194-6]">Sharma 2021</a> includes non‐RCTs and RCTs in their meta‐analysis on different antibiotics, but focused on the prevalence of each antibiotic in COVID‐19 studies instead of their efficacy and safety. </p> <p>Currently, there are few RCT‐ investigating the effectiveness and safety of antibiotics other than azithromycin used for COVID‐19 treatment. It is not well. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015025-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD015025-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 1: All‐cause mortality at day 28" data-id="CD015025-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 1: All‐cause mortality at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 2: Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28" data-id="CD015025-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 2: Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 3: Improvement of clinical status: participants discharged alive at day 28" data-id="CD015025-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 3: Improvement of clinical status: participants discharged alive at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 4: Serious adverse events during the study period, defined as number of participants with any event" data-id="CD015025-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 4: Serious adverse events during the study period, defined as number of participants with any event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 5: Adverse events (any grade) during the study period, defined as number of participants with any event" data-id="CD015025-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 5: Adverse events (any grade) during the study period, defined as number of participants with any event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 6: Cardiac arrhythmias during the study period" data-id="CD015025-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19, Outcome 6: Cardiac arrhythmias during the study period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 1: All‐cause mortality at day 28" data-id="CD015025-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 1: All‐cause mortality at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 2: Admission to hospital or death within 28 days" data-id="CD015025-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 2: Admission to hospital or death within 28 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 3: All initial symptoms resolved (asymptomatic) at day 14" data-id="CD015025-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 3: All initial symptoms resolved (asymptomatic) at day 14 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 4: All initial symptoms resolved (asymptomatic) at day 28" data-id="CD015025-fig-0011" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 4: All initial symptoms resolved (asymptomatic) at day 28 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015025-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/urn:x-wiley:14651858:media:CD015025:CD015025-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 5: Serious adverse events during the study period, defined as number of participants with any event" data-id="CD015025-fig-0012" src="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_t/tCD015025-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19, Outcome 5: Serious adverse events during the study period, defined as number of participants with any event </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015025/media/CDSR/CD015025/image_n/nCD015025-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015025-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with moderate to severe disease (WHO scale 4 to 9)  </p> <p><b>Setting:</b> inpatient  </p> <p><b>Intervention:</b> azithromycin<b> </b> </p> <p><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo or standard of care<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>223 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>219 per 1000 </b> </p> <p>(201 to 236)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.98</b> (0.90 to 1.06) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8600</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊕</p> <p>High<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin has little or no effect on all‐cause mortality at day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>261 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b> 248 per 1000</b> </p> <p>(227 to 269)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.95</b> (0.87 to 1.03) </p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7311 </p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on worsening of clinical status or death at day 28 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement of clinical status: participants discharged alive at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>672 per 1000<br/>  </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>645 per 1000 </b> </p> <p>(564 to 746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.96</b> </p> <p>(0.84 to 1.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 8172</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on improvement of clinical status at day 28 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at longest follow‐up available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>214 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>238 per 1000 </b> </p> <p>(190 to 300)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.11</b> </p> <p>(0.89 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>794</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on serious adverse events during the study period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>333 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>400 per 1000</b> </p> <p>(306 to 523)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.20</b> </p> <p>(0.92 to 1.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>355</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>e</sup><br/><i> </i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may increase any adverse events slightly during the study period</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrhythmias during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>45 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b> 41 per 1000 </b> </p> <p>(33 to 52)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.92</b> </p> <p>(0.73 to 1.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7865</p> <p>(4 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊖</p> <p>Moderate<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin probably has little or no effect on cardiac arrhythmias during the study period </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>No change of result in sensitivity analysis (RR 1.04; 95% CI 0.82 to 1.31; 837 participants; 3 studies) excluding studies with mixed populations (negative or unknown RT‐PCR). Therefore, no downgrading of evidence for indirectness.<br/><sup>b</sup>Downgrade by one level for serious indirectness due to the effect estimate based on only one study with a mixed population (8.5% participants with negative or unknown RT‐PCR).<br/><sup>c</sup>Downgrade by one level for serious heterogeneity (I<sup>2</sup> = 49%). No change of result in sensitivity analysis (RR 0.89; 95% CI 0.65 to 1.21; 402 participants; 2 studies) excluding studies with mixed populations (negative or unknown RT‐PCR). Therefore, no downgrading of evidence for indirectness.<br/><sup>d</sup>Downgrade by one level for serious risk of bias due to an as‐treated analysis in the study with the highest weight (97.0%). The certainty of evidence was not downgraded due to indirectness, even if the imprecision of the effect estimate had increased in the sensitivity analysis excluding the study with a mixed population (RR 0.98; 95% CI 0.26 to 3.60; 355 participants; 3 studies), as the same study was already the reason for downgrading due to risk of bias.<br/><sup>e</sup>Downgrade by one level for serious risk of bias due to non‐blinded outcome assessment in the study with the highest weight (87.7%), and one level for serious imprecision due to few small studies.<br/><sup>f</sup>Downgrade by one level for serious indirectness due to the effect estimate based mainly (weight 99.1%) on two studies with mixed populations (8.5% and 11% participants with negative or unknown RT‐PCR). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD015025-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with mild disease (WHO scale 1 to 3)  </p> <p><b>Setting:</b> outpatient  </p> <p><b>Intervention:</b> azithromycin<b> </b> </p> <p><b>Comparison:</b> placebo or standard of care </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign=""> <p><b> </b> </p> <p><b>Anticipated absolute effects* (95% CI)</b> </p> <p><b> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Certainty in the evidence (GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>Comment</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with placebo or standard of care<br/> </b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Risk with azithromycin</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality at day 28</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>2 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>2 per 1000 </b> </p> <p>(0 to 31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.00</b> </p> <p>(0.06 to 15.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on all‐cause mortality at day 28</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to hospital or death within 28 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>67 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>63 per 1000</b> </p> <p>(38 to 105)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.94</b> </p> <p>(0.57 to 1.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>876</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>b</sup>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on admission to hospital or death within 28 days </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All initial symptoms resolved (asymptomatic) at day 14</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>927 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>955 per 1000 </b> </p> <p>(881 to 1038)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.03</b> </p> <p>(0.95 to 1.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> 138</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊖⊖</p> <p>Low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Azithromycin may have little or no effect on symptom resolution (all initial symptoms resolved) at day 14 </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration to symptom resolution</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at duration to symptom resolution.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life at longest follow‐up available</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at quality of life.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at any adverse events during the study period.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Two studies assessed serious adverse events during the study period, but none of the participants in either group were affected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not estimable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>454</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊖⊖⊖</p> <p>Very low<sup>d</sup><br/>  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>We are uncertain whether azithromycin increases or reduces serious adverse events.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac arrhythmias during the study period</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(0 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No study was found that looked at cardiac arrhythmias during the study period</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk on the comparison group and the <b>relative effect</b> of the intervention (and its 95% confidence interval). </p> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect. </p> <p><b>Moderate certainty:</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is the possibility that it is substantially different. </p> <p><b>Low certainty: </b>Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> <p><b>Very low certainty:</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in that study contributing events to the analysis; and by one level for serious imprecision due to a wide confidence interval and few events.<br/><sup>b</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in one study and lack of registering the outcome in another study; and by one level for serious imprecision due to a wide confidence interval.<br/><sup>c</sup>Downgrade by two levels for very serious imprecision due to the effect estimate based on one small study.<br/><sup>d</sup>Downgrade by one level for serious risk of bias due to possible trial context related deviations from the intended interventions in one study and lack of registering the outcome in the other study; and by two levels for very serious imprecision due to zero events in both studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015025-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measures of heterogeneity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New need for invasive mechanical ventilation at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.65 </b><br/>(0.16 to 2.71) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7422</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 0.64; Chi² = 1.57, df = 1 (P = 0.21); I² = 36%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ventilator‐free days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.10</b><br/>(‐1.16 to 0.96) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>331</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>New need for non‐invasive mechanical ventilation or high flow at day 28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.91</b><br/>(0.78 to 1.05) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4073</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weaning or liberation from invasive mechanical ventilation in surviving patients at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.11</b><br/>(0.85 to 1.45) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>452</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Liberation from supplemental oxygen in surviving patients at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.85</b><br/>(0.67 to 1.08) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for dialysis at up to 28 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.03</b><br/>(0.85 to 1.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8052</p> <p>(2 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 0.00; Chi² = 1.27, df = 1 (P = 0.26); I² = 21%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Admission to the intensive care unit (ICU) at day 28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.28 </b><br/>(0.06 to 1.29 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>111</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Duration of hospitalisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MD ‐0.61</b> <br/>(‐2.58 to 1.37) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>448</p> <p>(3 RCTs)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tau² = 1.61; Chi² = 5.37, df = 2 (P = 0.07); I² = 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.50</b><br/>(0.35 to 6.40) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hospital‐acquired infections at up to 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.16 </b><br/>(0.90 to 1.49) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>395</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>MD:</b> mean difference <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for inpatients with confirmed moderate to severe COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015025-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Measures of heterogeneity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for invasive mechanical ventilation at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.61 </b><br/>(0.11 to 3.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>405</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Need for hospitalisation with need for oxygen by mask or nasal prongs at 28 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.80</b><br/>(0.29 to 2.22) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>406</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.83 </b><br/>(0.44 to 1.54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>301</p> <p>(1 RCT)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>CI:</b> confidence interval; <b>NA:</b> not applicable; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Secondary outcomes for azithromycin compared to placebo or standard of care alone for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015025-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcomes for azithromycin compared to other antibiotics for inpatients with confirmed moderate to severe COVID‐19</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Relative effect (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>N° of participants (studies)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Measures of heterogeneity</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral clearance up to 7 days </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 0.40</b><br/>(0.17 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> <p>(1 RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Secondary outcomes for azithromycin compared to other antibiotics for inpatients with confirmed moderate to severe COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/full#CD015025-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015025-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Moderate disease (WHO 4 to 5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.21, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Moderate to severe disease (WHO 4 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.90, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Moderate to severe disease (WHO 4‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7311</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.87, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Improvement of clinical status: participants discharged alive at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.84, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Moderate disease (WHO 4‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.78, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Moderate to severe disease (WHO 4‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.72, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Serious adverse events during the study period, defined as number of participants with any event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.89, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 Moderate disease (WHO 4‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.26, 3.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 Moderate to severe disease (WHO 4‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.89, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events (any grade) during the study period, defined as number of participants with any event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.92, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 Moderate disease (WHO 4‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.92, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Cardiac arrhythmias during the study period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.73, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Moderate disease (WHO 4‐5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>442</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.04, 5.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 Moderate to severe disease (WHO 4‐9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7423</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.92 [0.74, 1.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Azithromycin compared to placebo or standard of care for inpatients with confirmed moderate to severe COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015025-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.06, 15.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Admission to hospital or death within 28 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>876</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.57, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 All initial symptoms resolved (asymptomatic) at day 14 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.95, 1.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 All initial symptoms resolved (asymptomatic) at day 28 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>549</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Serious adverse events during the study period, defined as number of participants with any event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Not estimable</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Azithromycin compared to placebo or standard of care for outpatients with confirmed asymptomatic or mild COVID‐19</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#CD015025-tbl-0007">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-1"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.1 Moderate disease (WHO 4 to 5)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Sekhavati 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Insufficient information on allocation concealment. Sparsely reported baseline details. <br/>  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. None of the participants withdrew or discontinued the assigned intervention.No information provided on relevant co‐interventions.The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not registered, but clinically relevant and seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sparsely reported baseline details. Insufficient information on allocation concealment and lack blinding of participants and health care providers. </p> </td> </tr> <tr class="study-data"> <td> <p>Cavalcanti 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.1.2 Moderate to severe disease (WHO 4 to 9)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Furtado 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr class="study-data"> <td> <p>RECOVERY 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 16 (&lt; 1%) participants withdrew consent. 91% and 1% in the azithromycin and control group received azithromycin, respectively. Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.1 All‐cause mortality at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-1">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-2"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.2.1 Moderate to severe disease (WHO 4‐9)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>RECOVERY 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 16 (&lt; 1%) participants withdrew consent. 91% and 1% in the azithromycin and control group received azithromycin, respectively. Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis excluding those on any form of ventilation at randomisation. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants not on any form of invasive ventilation at randomisation. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not reported as registered, but seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.2 Worsening of clinical status: participants with clinical deterioration (new need for invasive mechanical ventilation) or death at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-2">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-3"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Improvement of clinical status: participants discharged alive at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.1 Moderate disease (WHO 4‐5)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CJWT629A12301</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study registry was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns. The study was terminated early due to poor recruitment.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.3.2 Moderate to severe disease (WHO 4‐9)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Furtado 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr class="study-data"> <td> <p>RECOVERY 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 16 (&lt; 1%) participants withdrew consent. 91% and 1% in the azithromycin and control group received azithromycin, respectively. Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not registered, but seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.3 Improvement of clinical status: participants discharged alive at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-3">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-4"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Serious adverse events during the study period, defined as number of participants with any event</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.1 Moderate disease (WHO 4‐5)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>CJWT629A12301</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study registry was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns. The study was terminated early due to poor recruitment.</p> </td> </tr> <tr class="study-data"> <td> <p>NCT04335552</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sparsely reported baseline details. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. One participant in the control group withdrew. None of the participants discontinued the assigned intervention. No information provided on relevant co‐interventions. The primary analysis was an intention‐to‐treat analysis (one withrawal was not included). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study register was not reported as registered, but seem not to be selected based on the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to insufficient information provided on baseline details and lack of blinding of participants and health care providers. The protocol was prospectively registered and the outcome in the study register was not reported as registered, but seem not to be selected based on the results. The trial was terminated early, strong evidence from larger trials of no therapeutic effect. </p> </td> </tr> <tr class="study-data"> <td> <p>Cavalcanti 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was prespecified in the study protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.4.2 Moderate to severe disease (WHO 4‐9)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Furtado 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Safety analyses were done in all patients who received at least one dose of study treatment. 2% of participants were not analysed in the group to which they were randomized (as treated analysis). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (safety population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome in the journal publication was reported as prespecified. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was analysed in an as‐treated analysis (safety population). </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.4 Serious adverse events during the study period, defined as number of participants with any event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-4">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-5"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Adverse events (any grade) during the study period, defined as number of participants with any event</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.5.1 Moderate disease (WHO 4‐5)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>NCT04335552</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sparsely reported baseline details. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. One participant in the control group withdrew. None of the participants discontinued the assigned intervention. No information provided on relevant co‐interventions. The primary analysis was an intention‐to‐treat analysis (one withrawal was not included). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of intervention status could have influenced outcome assessment but there is no reason to believe that it did. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study register was not reported as registered, but seem not to be selected based on the results. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to insufficient information provided on baseline details and lack of blinding of participants and health care providers. The protocol was prospectively registered and the outcome in the study register was not reported as registered, but seem not to be selected based on the results. The trial was terminated early, strong evidence from larger trials of no therapeutic effect. </p> </td> </tr> <tr class="study-data"> <td> <p>CJWT629A12301</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study registry was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns. The study was terminated early due to poor recruitment.</p> </td> </tr> <tr class="study-data"> <td> <p>Cavalcanti 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of intervention status could have influenced outcome assessment but there is no reason to believe that it did. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was prespecified in the study protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not blinded and knowledge of intervention status could have influenced outcome assessment but there is no reason to believe that it did. </p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.5 Adverse events (any grade) during the study period, defined as number of participants with any event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-5">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-6"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Cardiac arrhythmias during the study period</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.1 Moderate disease (WHO 4‐5)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Sekhavati 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-some col2" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Insufficient information on allocation concealment. Sparsely reported baseline details. <br/>  </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. None of the participants withdrew or discontinued the assigned intervention.No information provided on relevant co‐interventions.The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not registered, but clinically relevant and seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Sparsely reported baseline details. Insufficient information on allocation concealment and lack blinding of participants and health care providers. </p> </td> </tr> <tr class="study-data"> <td> <p>Cavalcanti 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Few (&lt; 1%) participants withdrew consent. 2% and 1% in the azithromycin and control group did not receive the assigned treatment.  Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an modified intention‐to‐treat analysis. RT‐PCR negative participants were excluded. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (mITT population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was prespecified in the study protocol. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr> <td bgcolor="#ffffff" colspan="13"> <p><b>Subgroup 1.6.2 Moderate to severe disease (WHO 4‐9)</b> </p> </td> </tr> <tr class="study-data"> <td> <p>Furtado 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. Safety analyses were done in all patients who received at least one dose of study treatment. 2% of participants were not analysed in the group to which they were randomized (as treated analysis). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all participants (safety population). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome in the journal publication was not registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The outcome was analysed in an as‐treated analysis (safety population). </p> </td> </tr> <tr class="study-data"> <td> <p>RECOVERY 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a computer‐based program. Allocation was concealed until after randomisation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 16 (&lt; 1%) participants withdrew consent. 91% and 1% in the azithromycin and control group received azithromycin, respectively. Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants with complete follow‐up forms (10% missing data). </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not registered, but clinically relevant and seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 1.6 Cardiac arrhythmias during the study period</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-6">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-7"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Omrani 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study used a computer‐based randomization and a central allocation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The primary analysis was an intention‐to‐treat analysis.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was not registered, but clinically relevant and seems not to be selected based on the result. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr class="study-data"> <td> <p>PRINCIPLE 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 18 (1%) participants withdrew consent with comparable distribution between groups. 87% in the azithromycin received at least one dose azithromycin. Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. RT‐PCR negative participants were excluded in a mITT analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> <tr class="study-data"> <td> <p>Hinks 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received. The reason for complete withdrawals/withdrawal are consistent with routine care and equal between groups. Non‐compliance with experimental intervention (AZT) is major and reasons for non‐compliance not described, therefore it cannot be judged if those deviations were due to the trial context (open‐label). However, the analysis was appropriate in this context (mITT). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of the intervention received could not have affected outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to possible trial context related deviations from the intended interventions.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.1 All‐cause mortality at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-7">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-8"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Admission to hospital or death within 28 days</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Omrani 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study used a computer‐based randomization and a central allocation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The primary analysis was an intention‐to‐treat analysis.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received by the participants.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome in the journal publication was not registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to lack of registering the outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Hinks 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received. The reason for complete withdrawals/withdrawal are consistent with routine care and equal between groups. Non‐compliance with experimental intervention (AZT) is major and reasons for non‐compliance not described, therefore it cannot be judged if those deviations were due to the trial context (open‐label). However, the analysis was appropriate in this context (mITT). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome was registered differently than reported, but results and reason for outcome modification were in reported full detail in the publication. Due to relevance of this outcome data in this context of this trial we did not assume that the results have have been selected. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to possible trial context related deviations from the intended interventions.</p> </td> </tr> <tr class="study-data"> <td> <p>PRINCIPLE 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 18 (1%) participants withdrew consent with comparable distribution between groups. 87% in the azithromycin received at least one dose azithromycin.   Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. RT‐PCR negative participants were excluded in a mITT analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.2 Admission to hospital or death within 28 days</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-8">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-9"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 All initial symptoms resolved (asymptomatic) at day 14</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Omrani 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study used a computer‐based randomization and a central allocation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The primary analysis was an intention‐to‐treat analysis.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for &gt; 90% of randomized participants. Missing data were equally distributed between groups and reasons were described. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received by the participants.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.3 All initial symptoms resolved (asymptomatic) at day 14</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-9">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-10"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 All initial symptoms resolved (asymptomatic) at day 28</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>PRINCIPLE 2021</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col8" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of the intervention received. 18 (1%) participants withdrew consent with comparable distribution between groups. 87% in the azithromycin received at least one dose azithromycin.   Changes from assigned interventions are consistent with what would occur outside the trial context. The primary analysis was an intention‐to‐treat analysis. RT‐PCR negative participants were excluded in a mITT analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. Knowledge of intervention status could have influenced outcome assessment but there is no reason to believe that it did. </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome on symptom recovery was added during the study due to lower hospitalistion rates than originally expected.  </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to lack of blinding of outcome assessors.</p> </td> </tr> <tr class="study-data"> <td> <p>Omrani 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col12" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study used a computer‐based randomization and a central allocation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The primary analysis was an intention‐to‐treat analysis. </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for &gt; 90% of randomized participants. Missing data were equally distributed between groups and reasons were described. </p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received by the participants.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the journal publication was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>No concerns.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.4 All initial symptoms resolved (asymptomatic) at day 28</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-10">Navigate to table in review</a></div> </div> <div class="table riskOfBias2"> <table data-id="riskOfBias2Table-11"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Serious adverse events during the study period, defined as number of participants with any event</span></div> <tr> <th align="center" class="headercell" colspan="13" rowspan="1" scope="col" valign=""> <p><b>Bias</b></p> </th> </tr> <tr> <th class="headercell"> <p><b>Study</b></p> </th> <th class="rob-col-trigger" colspan="2" data-index="0"> <p><b>Randomisation process</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="1"> <p><b>Deviations from intended interventions</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="2"> <p><b>Missing outcome data</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="3"> <p><b>Measurement of the outcome</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="4"> <p><b>Selection of the reported results</b> </p> </th> <th class="rob-col-trigger" colspan="2" data-index="5"> <p><b>Overall</b> </p> </th> </tr> <tr class="study-data"> <td> <p>Omrani 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col4" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col10" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The study used a computer‐based randomization and a central allocation. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were not aware of the intervention received. The primary analysis was an intention‐to‐treat analysis.  </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were not aware of the intervention received by the participants.</p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered. The outcome in the journal publication was not registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to lack of registering the outcome.</p> </td> </tr> <tr class="study-data"> <td> <p>Hinks 2020</p> </td> <td bgcolor="#ffffff" class="rob-trigger rob-low col2" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col4" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col6" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col8" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-low col10" colspan="2"><img alt="Low risk of bias" src="/cochrane-theme/images/low.png" title="Low risk of bias"/></td> <td bgcolor="#ffffff" class="rob-trigger rob-some col12" colspan="2"><img alt="Some concerns" src="/cochrane-theme/images/some_concerns.png" title="Some concerns"/></td> </tr> <tr class="indicator-row col3"> <td colspan="1"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Random sequence was generated using a web‐based system. The trial team was masked to the randomisation ratios and allocation was concealed. There were no baseline imbalances that would suggest a problem with randomisation. </p> </td> </tr> <tr class="indicator-row col5"> <td colspan="3"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Both participants and those delivering the intervention were aware of intervention received. The reason for complete withdrawals/withdrawal are consistent with routine care and equal between groups. Non‐compliance with experimental intervention (AZT) is major and reasons for non‐compliance not described, therefore it cannot be judged if those deviations were due to the trial context (open‐label). However, the analysis was appropriate in this context (mITT). </p> </td> </tr> <tr class="indicator-row col7"> <td colspan="5"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Data were available for nearly all randomized participants.</p> </td> </tr> <tr class="indicator-row col9"> <td colspan="7"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Outcome assessors were aware of the intervention received. By following a clinical protocol, knowledge of the intervention received could only minimally affect the outcome measurement.  </p> </td> </tr> <tr class="indicator-row col11"> <td colspan="9"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>The protocol was prospectively registered and the outcome in the study register was reported as registered. </p> </td> </tr> <tr class="indicator-row col13"> <td colspan="11"></td> <td class="indicator" colspan="2"></td> </tr> <tr class="support"> <td></td> <td colspan="12"> <p>Due to possible trial context related deviations from the intended interventions.</p> </td> </tr> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label"></span><span class="table-title">Risk of bias for analysis 2.5 Serious adverse events during the study period, defined as number of participants with any event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015025/references#riskOfBias2Table-11">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015025&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD015025-note-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD015025-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015025-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015025-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD015025-note-0011">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD015025-note-0017">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD015025-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD015025-note-0019">Polski</a> </li> <li class="section-language"> <a class="" href="pt#CD015025-note-0009">Português</a> </li> <li class="section-language"> <a class="" href="ru#CD015025-note-0008">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD015025-note-0016">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015025-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015025-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015025"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015025"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015025"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015025\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015025\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015025"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=0TJL4CWK&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015025&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015025';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015025/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015025/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015025%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718160627"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015025/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718160631"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015025/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc98b38a4f3fd',t:'MTc0MDcxODE2MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 